



Experimental models to study intestinal microbes–mucus interactions in health and disease

Lucie Etienne-Mesmin, Benoit Chassaing, Mickaël Desvaux, Kim De paepe, Raphaële Gresse, Thomas Sauvaitre, Evelyne Forano, Tom Van De wiele, Stephanie Schüller, Nathalie Juge, et al.

► To cite this version:

Lucie Etienne-Mesmin, Benoit Chassaing, Mickaël Desvaux, Kim De paepe, Raphaële Gresse, et al.. Experimental models to study intestinal microbes–mucus interactions in health and disease. FEMS Microbiology Reviews, 2019, 43 (5), pp.457-489. 10.1093/femsre/fuz013 . hal-02335708


HAL Id: hal-02335708

<https://hal.science/hal-02335708>


Submitted on 1 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



In vitro mucus/mucin binding assays





Intestinal organoids




In vivo animal models



Ex-vivo organ cultures



In vivo digestive models with mucosal phase



Experimental models to study intestinal microbes-mucus interactions in health and disease

Sentence summary: The review summarises the state of the art for studying gut microbes-mucus interactions using *in vitro*, *ex vivo* and *in vivo* experimental models.

Lucie Etienne-Mesmin¹, Benoit Chassaing^{2,3}, Mickaël Desvaux¹, Kim De Paepe⁴, Raphaële Gresse¹, Thomas Sauvatre¹, Evelyne Forano¹, Tom Van de Wiele⁴, Stephanie Schüller^{5,6}, Nathalie Juge^{6#*} and Stéphanie Blanquet-Diot^{1#*}

¹ Université Clermont Auvergne, INRA, MEDIS, Clermont-Ferrand, France.

² Neuroscience Institute, Georgia State University, Atlanta, GA, USA.

³ Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.

⁴ Center for Microbial Ecology and Technology (CMET), Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.

⁵ Norwich Medical School, University of East Anglia, Norwich, United Kingdom.

⁶ Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom.

These authors contributed equally to this work

20 **Corresponding authors:*
21 Stéphanie Blanquet-Diot (stephanie.blanquet@uca.fr)
22 28 place Henri Dunant
23 63000 Clermont-Ferrand, FRANCE
24 +33473178390
25
26 Nathalie Juge (nathalie.juge@quadram.ac.uk)
27 Gut Microbes and Health Institute Strategic Programme
28 Quadram Institute Bioscience
29 Norwich Research Park
30 NR4 7UA
31 Norwich, UK
32 +441603255068

ABSTRACT

A close symbiotic relationship exists between the intestinal microbiota and its host. A critical component of gut homeostasis is the presence of a mucus layer covering the gastrointestinal tract. Mucus is a viscoelastic gel at the interface between the luminal content and the host tissue that provides a habitat to the gut microbiota and protects the intestinal epithelium. The review starts by setting up the biological context underpinning the need for experimental models to study gut bacteria-mucus interactions in the digestive environment. We provide an overview of the structure and function of intestinal mucus and mucins, their interactions with intestinal bacteria (including commensal, probiotics and pathogenic microorganisms) and their role in modulating health and disease states. We then describe the characteristics and potentials of experimental models currently available to study the mechanisms underpinning the interaction of mucus with gut microbes, including *in vitro*, *ex vivo* and *in vivo* models. We then discuss the limitations and challenges facing this field of research.

Keywords: intestinal mucus, gut microbiota, experimental models, mucin O-glycosylation

INTRODUCTION

The human gastrointestinal (GI) tract harbours a complex and diverse community of microbes, including 10 trillion of microorganisms, collectively referred to as the gut microbiota (Sender *et al.*, 2016). Several regulatory mechanisms cooperate to maintain intestinal homeostasis and a disturbance of the relationship between the gut microbiota and the host can result in several disorders including chronic inflammatory diseases and metabolic syndromes (Rooks & Garrett, 2016). While the intestinal microbiota provides important benefits to the host, such as calorie extraction and immune system maturation, it also holds the power to activate various innate and adaptive immune signalling which can lead to uncontrolled and deleterious intestinal inflammation (Pickard *et al.*, 2017). A key component in maintaining a beneficial relationship between the commensal microbes inhabiting the intestine and the host is the presence of an appropriate barrier that prevents bacteria to reach and persist on the epithelial surface (Johansson & Hansson, 2016, Sicard *et al.*, 2017, Bretin *et al.*, 2018). It is well acknowledged that intestinal epithelial cells (IECs) provide a physical and biochemical barrier that prevents the translocation of commensal bacteria to the underlying host tissue. In addition, there is an emerging paradigm that the mucus layer is an important modulator of human health in mediating the homeostatic relationship between the gut microbiota and the host. On the luminal side, the mucus layer provides the first physical, chemical, and biological line of defence against large particles, including commensal bacteria and invading pathogens, segregating them from IECs (Turner, 2009, Peterson & Artis, 2014). Furthermore, mucus provides a biological niche for a microbial community, referred to as mucus-associated microbiota, which is likely to have a major influence on human health (Martens *et al.*, 2018). However, advances in this field of research have been hampered by the lack of suitable model systems recapitulating all the interactions occurring at the mucosal interface. This review provides an overview of currently

76 available experimental models to study the interplay between gut bacteria and intestinal
77 mucus at a mechanistic level, and summarizes their main applications and the challenges
78 remaining in this field of research.

79

PRE-PRINT

1. Overview of mucus structure and function in the gastrointestinal (GI) tract

1.1. Mucus structural organisation

Mucus structure. Mucus is a highly hydrated gel made up of more than 98% water that makes it totally transparent, microscopically invisible and difficult to study. This aqueous viscoelastic secretion also contains electrolytes, lipids and various proteins (Bansil & Turner, 2018). Mucus is found throughout the entire GI tract from the stomach to the large intestine, with its thickness and structure varying depending on the location, reflecting its various protective functions.

The mucus in the small intestine consists of one layer, while the stomach and colon have a bi-layered mucus. In human stomach, the mucus is about 200–400 μm in thickness and consists of an inner layer loosely attached to the epithelial surface, keeping the surface neutral (pH 7) while the gastric lumen pH is acidic (pH 2), and an outer layer which is mobile on the luminal side. Only few bacteria have evolved strategies to colonise the stomach, among which *Helicobacter pylori* is a specialist (Atuma *et al.*, 2001, Juge, 2012). In the small intestine, mucus fills up the space between the villi but is not attached to the epithelium and is somewhat permeable to bacteria (Atuma *et al.*, 2001). In the colon, the two layers mediate opposite interactions with the microbiota; whereas the outer layer (up to 800 μm) is densely colonised by an important microbial biomass, the inner layer (>200 μm in humans) is virtually devoid of bacteria leaving a space virtually free of microbes (commensals and or pathogens) leaving a space virtually free of microbes above the epithelium (Johansson *et al.*, 2013). However, single-cell imaging at tissue scale in mice revealed the presence of bacteria in close proximity of the epithelium (Earle *et al.*, 2015). Among commensal microorganisms, Segmented Filamentous Bacteria (SFB) are immunomodulatory commensals with the ability

to adhere to IECs and to invade this mucus layer without invading the host (Hedblom *et al.*, 2018, Ladinsky *et al.*, 2019). Of note, a recent study revealed differences in mucus organization between the proximal and distal colon of rodents (Kamphuis *et al.*, 2017): in the later, the mucus layer is attached to the faecal pellet and absent from the surface of the epithelium (Kamphuis *et al.*, 2017).

Other studies demonstrated that the mucus thickens as the microbiota become more diverse, as particularly evident in the colon (Jakobsson *et al.*, 2015). This is also supported by studies using germ free mice showing an impairment in mucus structure (Johansson *et al.*, 2008, Johansson *et al.*, 2013, Jakobsson *et al.*, 2015). Gnotobiotic mice colonized with human faecal microbiota present a mucus layer structure resembling that of conventional mice by day 7 post-colonization (Hayes *et al.*, 2018). Animals housed in distinct rooms of the same animal facility exhibit distinct microbiota profiles that are associated with large differences in the inner colon mucus layer, thereby affecting mucus barrier properties (Jakobsson *et al.*, 2015). Also, it has been demonstrated in mice that mucus becomes thinner with age (Elderman *et al.*, 2017). Variations in the mucus thickness and spatial organisation of the gut microbiota in mice were also found to be dependent of the diet (Earle *et al.*, 2015). Interestingly, the thickness of the mucus layer has been shown to undergo circadian fluctuations, with highest microbial proximity to the mucosal surface during the dark phase (Thaiss *et al.*, 2016).

Mucus secretion. The mucus is produced and secreted by specialized cells namely goblet cells located in the crypt in the small intestine and in higher numbers in the upper crypt in the colon (Johansson & Hansson, 2013, Johansson & Hansson, 2016, Sicard *et al.*, 2017). Before secretion in the gut lumen, mucin polymers are stored in mucin granulae within the goblet cells (Johansson *et al.*, 2011, Johansson *et al.*, 2013). The function of goblet cells varies depending on their localisation in the small intestinal or colonic crypts (Pelaseyed *et al.*,

2014). Apart from their role in secreting mucus, small intestinal goblet cells can play a role in delivering luminal material to the immune system (Pelaseyed *et al.*, 2014). Interestingly, a study from Gunnar Hanson's laboratory identified a subpopulation of goblet cells called "sentinels" goblet cells (Birchenough *et al.*, 2016). These cells are able to sense Toll-like receptor (TLR) microbial ligands at the entrance of colonic crypts and trigger the activation of NLRP6 inflammasome, leading to mucus secretion from neighbouring goblet cells to defend the colon against bacterial invasion (Birchenough *et al.*, 2016).

Renewal of the mucus is an important factor to preserve epithelial damage and bacterial exposure. The colonic mucus has a rapid turnover, since the inner mucus layer is renewed within 1 hour (Johansson, 2012), while the gut epithelium renewal takes around 4-5 days (De Weirdt & Van de Wiele, 2015).

Gastro-intestinal mucins. The main structural components of mucus are large glycoproteins called mucins. The protein sequences of mucin domains share a common core structure rich in the amino acids proline (P), threonine (T) and serine (S) called the PTS domain. These domains are then decorated by *O*-linked glycans made up of *N* acetylgalactosamine (GalNAc), *N*-acetylglucosamine (GlcNAc), galactose (Gal) and usually terminated by sialic acid and fucose (Juge, 2012, Johansson & Hansson, 2016, Sicard *et al.*, 2017). These *O*-glycans render the mucin domains highly resistant to protease degradation and confer mucins their high-water binding capacity.

Mucins are produced as transmembrane mucins or secreted gel forming mucins (Juge, 2012, Johansson *et al.*, 2013). In the stomach, MUC1 and MUC5AC are produced by the superficial epithelium, while MUC6 are secreted by the stomach glands (Johansson *et al.*, 2013, Johansson & Hansson, 2016). In the small intestine and colon, mucus is structurally built around the mucin-2 glycoprotein (MUC2). The folding and dimerization of MUC2 is a

demanding process owing to the large number of disulfide bonds, and a defect during this process may affect the structure and function of intestinal mucus (Johansson *et al.*, 2011). Proteolytic cleavages of MUC2 catalysed by the host as well as bacteria enzymes favour the transition from firm to loose layer form and allow bacteria to penetrate into the mucin net-like structure of the outer mucus layer (Johansson *et al.*, 2008). In addition to this proteolytic activity, the degradation of mucin glycan chains by bacterial glycosidases contribute to the establishment of a microbial community in the outer mucus layer (Johansson *et al.*, 2008, Pelaseyed *et al.*, 2014).

Mucin glycosylation. Glycosylation is the most frequent post-translational modification of proteins and can occur in *N*-linked and *O*-linked form, and *O*-glycosylation is the main modification of mucins (Arike & Hansson, 2016). Mucin-type *O*-glycans are built from eight core structures, with core 1, core 2, core 3 and core 4 glycans most commonly found in intestinal mucins (Brockhausen *et al.*, 2009). *O*-glycosylation is initiated in the Golgi apparatus by the addition of a GalNAc residue to the hydroxyl group of serine and threonine of the mucin backbone. Further elongation and branching of the *O*-glycan chains is governed by a large family of glycosyltransferase enzymes (Bennett *et al.*, 2012). The oligosaccharides can be further modified by addition of histo-blood group antigens (ABO, Lewis), secretor (H) epitopes and sialic acids and sulfate (Rossez *et al.*, 2012, Bansil & Turner, 2018). Mucin glycosylation varies along the GI tract (Robbe *et al.*, 2003, Robbe *et al.*, 2004, Holmen Larsson *et al.*, 2013) and is linked to microbial colonization (Juge, 2012, Bergstrom & Xia, 2013, Tailford *et al.*, 2015, Arike *et al.*, 2017). Mounting evidence suggests that mucin glycosylation is critical to the biological and physical role played by mucus in the gut by influencing the physico-chemical properties and penetrability of mucus and by modulating the composition of the associated mucus-associated microbiota (see section 1.3). Not

surprisingly, an alteration of mucin *O*-glycosylation profile has been reported in intestinal diseases associated with an impaired gut barrier function such as inflammatory bowel disease (IBD) and colorectal cancer (Larsson *et al.*, 2011, Theodoratou *et al.*, 2014) as also supported by work in animal models (Bergstrom *et al.*, 2017) (see also section 4.5).

1.2. Mucus function in the gut

For decades, mucus has been considered to act as a simple physical barrier protecting the host, but mounting evidence suggests that mucus plays additional biological and immunological roles in maintaining gut homeostasis. The coating gel of mucus is acting, in concert with the immune system, the intestinal epithelium and the gut microbiota, to provide a physical, biological, and chemical line of defence against potentially harmful invaders while harbouring a distinct microbial community having a major influence on host health.

Throughout the gut, the viscous mucus secretion acts as a lubricant that helps the progress of digestive matter along the GI tract and protects the underlying epithelium from excessive mechanical or chemical stresses. In the stomach, the mucus coating creates a pH gradient that protects the epithelium against the crude acidic gastric environment. Mucus acts as a size exclusion filter for larger compounds while selectively allowing transport of small molecules such as gases, ions, nutrients, and many proteins to reach the enterocytes (De Weirdt & Van de Wiele, 2015), but the mucus lining would prevent digestive enzymes from attacking these cells.

In the colon, the outer mucus layer serves as a biological habitat for various microorganisms. Indeed, the glycan structures in the mucus provide potential binding sites and constitute a carbon and energy source to support the growth of commensal but also pathogenic bacteria (Tailford *et al.*, 2015) (see sections 2.1 and 2.2). It is believed that the

mucin glycosylation patterns along the GI tract contribute to the microbial tropism of certain taxa in the mucus (Tailford *et al.*, 2015).

The mucus layer also helps in the protection of the epithelium and, in association with the immune system, plays a crucial role in intestinal homeostasis. This gel is an important retention matrix for non-mucin proteins with immune regulatory molecules such as antimicrobial molecules (e.g. bactericidal RegIII γ , α -defensins, secretory immunoglobulins IgAs, etc), therefore limiting the number of bacteria that can reach the epithelium and the underlying immune system (Peterson & Artis, 2014, Johansson & Hansson, 2016). This physical and biological barrier helps to keep the tremendous amount of bacteria that reside in the lumen as well as enteric pathogens at a safe distance from the epithelium (Chassaing *et al.*, 2014, Johansson *et al.*, 2014, Chassaing *et al.*, 2015). However, this system can be subverted and invading pathogens or pathobionts have evolved strategies to circumvent this barrier by e.g. degrading mucins and/or influencing mucin secretion (Rolhion & Chassaing, 2016). In summary, mucus has a dual role in relation to the gut microbiota, it is an ecological niche for bacteria by providing adhesion sites and nutrients, while protecting the underlying epithelium from microbial aggressors that can breach this barrier.

1.3. The mucus-associated microbiota

The gut microbiota composition is known to differ along the longitudinal axis of the GI tract but it also varies transversally from the lumen to the mucosa due differences in key physiological parameters such as nutrient availability or oxygen gradient. The colonic epithelium is made of crypts with specific oxygen conditions and various concentrations of glycans that is a niche for mucin- degrading bacteria such as *Bacteroides fragilis* (Pereira & Berry, 2017). The use of Carnoy fixative to preserve the mucus layer has been a crucial step

for the detection of bacteria in the mucosal environment (Johansson *et al.*, 2008). It is now well appreciated that the faecal microbiota community differs from the luminal, mucosa- or mucus-associated bacterial communities (Swidsinski *et al.*, 2005, Li *et al.*, 2015).

Studies in humans demonstrated that the abundance of Bacteroidetes appears to be higher in faecal/luminal samples than in the mucosa (Eckburg *et al.*, 2005). Members of Firmicutes phylum and in particular *Clostridium* cluster XIVa are significantly enriched in the mucus layer compared to the lumen (Van den Abbeele *et al.*, 2013). Analysis of human colonic biopsies have also shown a distinct mucosal community enriched in Actinobacteria and Proteobacteria compared to the luminal community (Albenberg *et al.*, 2014). Certain species such as *Bacteroides acidifaciens*, *B. fragilis*, and *Akkermansia muciniphila* are enriched in the outer layer of colon mucus (Derrien *et al.*, 2004, Donaldson *et al.*, 2016).

Similar findings have been observed in animals. Indeed, mice studies have shown that Firmicutes were enriched in the mucosa-associated microbiota, especially members of the Lachnospiraceae and Ruminococcaceae families (Tailford *et al.*, 2015). Bacterial species such as *Bacteroides thetaiotaomicron* or *Escherichia coli* display specific genomic repertoires to persist in the outer mucus layer compared with the same species in the intestinal lumen (Li *et al.*, 2015). This spatial localisation may be reflective of the radial oxygen gradient that shapes the mucus-associated and faecal microbiota, since oxygen can favour or impede certain microorganisms (Albenberg *et al.*, 2014). Moreover, laser capture microdissection (LCM) in combination with metagenomics studies provided new insights into the composition of the mucus-associated microbiota (Wang *et al.*, 2010). The use of LCM in mouse models revealed that this microbial community is especially dominated by *Acinetobacter* in the colonic crypts (Pedron *et al.*, 2012). Using LCM coupled to DNA sequencing-based analysis, Chassaing and Gewirtz recently reported profound differences at the phyla level between the inner mucus

communities comprising 20%–60% Proteobacteria and a concomitantly marked reduction in Bacteroidetes as compared to faecal microbiota (Chassaing & Gewirtz, 2019).

Due to a high polysaccharide content (up to 80% of the mucin biomass), mucus provides an ecological niche for the intestinal microbiota. Mucus-associated bacteria are able to use oligosaccharides from mucins as binding sites through specific bacterial adhesins that promote their colonisation (Section 2.1) or as an energy source to support their growth (Section 2.2). Robbe and colleagues first suggested that the important repertoire of potential ligands and/or carbon sources in mucins could explain the pattern of bacterial colonisation in the different gut regions (Robbe *et al.* 2004). Mucin degradation has been extensively studied in pathogenic bacteria and more recently investigated in commensal bacteria including *A. muciniphila*, *Bacteroides* spp., Bifidobacteria and *Ruminococcus* spp. (Derrien *et al.*, 2004, De Weirdt & Van de Wiele, 2015). A disproportion of bacterial taxa able to invade mucus could further play a role in the development of the dysbiotic microbiota associated with the onset of various intestinal diseases (see section 3).

2. Mucin-bacteria interactions

2.1. Mechanisms of mucin binding by commensal and pathogenic microorganisms in the gut

Cell-surface proteins of pathogens and probiotics/commensal strains have been implicated in mediating the binding of microbes to intestinal mucus (Fig. 1). These include (i) specialized cell-surface adhesins or lectins, (ii) appendages such as pili and flagella or (iii) moonlighting proteins (see (Juge, 2012) for a review). In particular, a considerable amount of

research has been devoted to the characterization of these adhesins in *Lactobacillus* species (as extensively reviewed in (Van Tassell & Miller, 2011, Nishiyama *et al.*, 2016)).

Mucus binding proteins. Mucus-binding proteins (MUBs) containing a variable number of Mub repeats are unique to gut inhabiting Lactobacilli and these proteins have been thoroughly characterised in *Lactobacillus reuteri*, a gram-positive bacterial species inhabiting the GI tract widely used as a probiotic (Frese *et al.*, 2011). MUB from *L. reuteri* ATCC 53608 is one of the best studied examples of mucus adhesins in commensal bacteria. It is a large protein consisting of six type 1 repeats (Mub1) and eight type 2 repeats (Mub2) with each repeat divided into a mucin binding (MucBP) domain and an immunoglobulin binding protein domain (Kuznetsova, 1990, MacKenzie *et al.*, 2009, Etzold *et al.*, 2014). The Mub repeats mediate binding to mucin glycans, through interactions with terminal sialic acid (Etzold *et al.*, 2014, Gunning *et al.*, 2016), and Igs (MacKenzie *et al.*, 2009). MUB has the shape of a long, fibre-like structure, of around 180 nm in length (Etzold *et al.*, 2014), and forms appendices reminiscent to pili found in pathogenic and, more rarely, other commensal bacterial species. However, in contrast to pathogenic pili which adhesin is restricted to the N-terminal tip, MUB interactions with mucin glycans occur through its long and linear multi-repeat structure, as shown by atomic force spectroscopy (Gunning *et al.*, 2016). This multivalent binding would restrict penetration through mucus and limit access of the bacteria to the epithelium surface. In addition, MUB from *L. reuteri* ATCC 53608 was recently shown to modulate inflammatory responses in human monocyte-derived dendritic cells *via* interaction with DC-SIGN (Bene *et al.*, 2017). The presence of mucus adhesins was also shown to mediate the binding of *L. reuteri* strains to both HT-29 and mucus-producing LS174T cells. The binding of *L. reuteri* to mucus led to a decreased enteropathogenic *E. coli* (EPEC) adherence to small intestinal biopsy epithelium (Walsham *et al.*, 2016). Recombinant Mub proteins containing

Mubs5s6 domains from Lp-1643 protein of *L. plantarum* Lp9 have been shown to adhere to human intestinal tissue sections (Singh *et al.*, 2017) and inhibited the adhesion of enterotoxigenic *E. coli* (ETEC) to cultured intestinal HT-29 and Caco-2 cell lines, probably through the recognition of cell-surface mucins (Singh *et al.*, 2018). Together, these findings show that the nature and function of these adhesins are strain-specific with the potential to target either the epithelium or the mucus layer and compete with pathogens.

Flagella. Several microorganisms have evolved strategies, in particular extracellular appendages such as flagella, pili and fimbriae, to attach to and to penetrate the mucus layer (Juge, 2012). Pili and flagella are large polymeric proteins that form long surface structures involved in bacterial adhesion. Flagella are composed of several thousand copies of flagellin subunits and have been extensively studied in EPEC and enterohemorrhagic *E. coli* (EHEC) for their role in virulence and motility, but their role in mucus binding remains unclear. The adhesive properties of bacterial flagella to mucus were previously reported for *Clostridium difficile* where crude flagella, recombinant flagellar FliC and FliD proteins were shown to bind to murine mucus (Tasteyre *et al.*, 2001). In pathogenic *E. coli* strains, the H6 and H7 flagella EPEC E2348/69 and EHEC EDL933 and their flagellin monomers were shown to bind to mucins and to bovine mucus (Erdem *et al.*, 2007). Further studies then showed that EPEC and EHEC O157:H7 adherence to HT-29 cells is related to mucin-type core 2 O-glycan, facilitating invasion into host cells (Ye *et al.*, 2015, Ye *et al.*, 2015). However, flagella are involved in the ability of these pathogenic strains to cross the mucus layer, conferring a selective advantage in penetrating the mucus layers and reaching the epithelial surface, as demonstrated with Adherent-Invasive *E. coli* (AIEC) LF82 (Khodzhakuliev & Ovezova, 1986). It is therefore tempting to speculate that in EPEC and EHEC, the flagella have a preference for cell-surface mucins rather than secreted mucus, in line with their ability

to penetrate the mucus layer and attach onto the cell surface before invasion. In the probiotic *E. coli* strain Nissle 1917, a direct interaction was observed between isolated flagella from EcN and porcine MUC2 and human mucus but not murine mucus. The mucus component gluconate was identified as one receptor for the binding of EcN flagella (Troge *et al.*, 2012). EcN was therefore proposed to confer the probiotic strain the ability to compete for binding sites on host tissue with bacterial pathogens.

Pili. Pili have been identified in *Lactobacillus rhamnosus* GG where they confer binding to mucus (Kankainen *et al.*, 2009, von Ossowski *et al.*, 2011) and are predicted to exist in other *Lactobacillus* species including *L. casei* and *L. paracasei*, based on genomics analyses (Douillard *et al.*, 2013, Aleksandrzak-Piekarczyk *et al.*, 2015, Nissila *et al.*, 2017). In *L. rhamnosus* GG, these are composed of a three-protein complex SpaCBA, which has been involved in adhesion to mucus, IECs, and immunomodulatory interactions with IEC (Lebeer *et al.*, 2012, von Ossowski *et al.*, 2013, Ganguli *et al.*, 2015, Vargas Garcia *et al.*, 2015, Bene *et al.*, 2017). The mucus-binding pili of *L. rhamnosus* GG shares immunological and functional similarities with those of the clinical *Enterococcus faecium* strain E1165. The binding of *E. faecium* E1165 to mucus could be prevented by the addition of the mucus-binding SpaC protein or antibodies against *L. rhamnosus* GG (Tytgat *et al.*, 2016). Collectively, these studies show the potential of using mucus adhesins from probiotic strains to prevent the binding of enteric pathogens to the host.

Although not a resident member of the gut microbiota, several *Lactococcus lactis* strains have also been shown to exhibit mucus-binding properties through bacterial surface proteins such as mucin-binding proteins and pili (as recently reviewed in (Mercier-Bonin & Chapot-Chartier, 2017)). The mechanisms of adhesion have been extensively studied by atomic force spectroscopy demonstrating a comparable role played by these two surface

proteinaceous components in adhesion of *L. lactis* TIL448 to pig gastric mucin (PGM) neutral oligosaccharides under static conditions, whereas a more important contribution of the MUBs than the pili one was observed under shear flow (Le *et al.*, 2013).

Other cell surface proteins. Other cell surface proteins implicated in the binding of commensal bacteria to mucin include aggregation-promoting factors (APFs) from *L. plantarum* NCIMB 8826 (Bolonkin, 1990) or *L. lactis* (Lukic *et al.*, 2012, Lukic *et al.*, 2014), mucus-binding protein A (CmbA) from *L. reuteri* ATCC PTA 6475 (Etzold *et al.*, 2014, Jensen *et al.*, 2014), Lam29 from *L. mucosae* ME-340 (Watanabe *et al.*, 2010), mucus adhesion-promoting protein (MapA) from *L. fermentum/reuteri* 104R (Rojas *et al.*, 2002), a mucus-binding factor (MBF) from *L. rhamnosus* GG (von Ossowski *et al.*, 2011, Nishiyama *et al.*, 2015), a MucBP-containing mannose-specific adhesin protein (Msa) from *L. plantarum* WCFS-1 (Pretzer *et al.*, 2005), a 32-Mmubp from *L. fermentum* BCS87 (Macias-Rodriguez *et al.*, 2009), an extracellular transaldolase (Tal) from *Bifidobacterium bifidum* DSM20456 (Gonzalez-Rodriguez *et al.*, 2012) and a recently-characterised serine rich repeat protein (SRRP) from *L. reuteri* ATCC 53608 (Sequeira *et al.*, 2018). It is expected that adhesion of these commensal or probiotic bacteria to mucus may favour their persistence within the gut in order to exert their beneficial effects to the host. Furthermore, it was recently suggested that carbohydrate binding modules (CBMs) appended to glycoside hydrolases could contribute to the tropism of gut bacteria to glycan-rich area of mucins in the colon, as shown for *Ruminococcus gnavus* sialic-acid-specific CBM40 (Owen *et al.*, 2017).

Blood group binding adhesins. In addition, several human enteric pathogens bind to human histo-blood group antigens (HBGAs) expressed on the gut mucosa, including *Campylobacter jejuni*, *Norwalk virus* and *H. pylori*. The role of HBGA recognition to mucin binding has been

extensively studied in the gastric pathogen *H. pylori* where *Helicobacter* adhesins have been reported to play a critical role in the attachment of the pathogen to both the glycosylated gastric epithelial cell surface and to glycosylated mucins. The binding of *H. pylori* to gastric mucins through blood group binding adhesin (BabA) and sialic acid-binding adhesin (SabA) revealed a complex charge/low pH-dependent mechanism involving four modes of *H. pylori* adhesion to MUC5B, MUC7, and MUC5AC mucins (Linden *et al.*, 2008, Skoog *et al.*, 2017). More recently, a novel outer membrane protein adhesin named LabA has been identified in *H. pylori* and shown to bind to LacdiNAc, a structure, which is also expressed on MUC5AC (Rossez *et al.*, 2014). Binding of *H. pylori* to gastric mucins therefore is determined both by the mucin glycosylation and also by the adhesins expressed by individual strains. A chitin-binding protein GbpA from *Vibrio cholerae* shown to bind to N-acetyl-D-glucosamine residues of intestinal mucin has been proposed as an important factor mediating intestinal colonisation and pathogenesis by *V. cholerae* (Bhowmick *et al.*, 2008, Wong *et al.*, 2012).

Moonlighting proteins. Unexpectedly, several primarily cytoplasmic proteins have been reported to play a role in mucin binding. Due to their dual function, these proteins are referred to as moonlighting proteins (Henderson & Martin, 2011, Henderson & Martin, 2013, Henderson, 2014). In *L. acidophilus*, *L. plantarum* and *Mycoplasma genitalium* for instance, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was clearly demonstrated to play a role in bacterial adhesion and bind mucins (Alvarez *et al.*, 2003, Kinoshita *et al.*, 2008, Patel *et al.*, 2016). While the exact domain responsible for mucin binding remains to be elucidated, GAPDH is suggested to play a similar role in other commensal or pathogenic microorganisms (Kinoshita *et al.*, 2013). In *L. reuteri*, elongation factor-Tu (EF-Tu) was found to bind the PGM when exposed at the bacterial cell surface (Nishiyama *et al.*, 2013). Here, the sulfated carbohydrate moieties of mucins were demonstrated to play a significant role in EF-Tu-

mediated bacterial adhesion to PGM and mucosal surfaces (Nishiyama *et al.*, 2013). Proteosurfaceome analyses in a range of microorganisms have revealed a large repertoire of cytoplasmic proteins present at the bacterial cell surface but their implications in binding to various extracellular matrix (ECM) proteins, including mucins, remain to be more systematically investigated (Chagnot *et al.*, 2012, Desvaux *et al.*, 2018).

2.2. Mechanisms of mucin degradation by commensal and pathogenic microorganisms in the gut

Several enzymatic activities are required for the degradation of mucins by pathogens or commensal bacteria including glycoside hydrolases (GHs), sulfatases, or proteases (Fig. 1) as described below.

Glycoside hydrolases. Mucin glycan degradation in bacteria relies on the expression of GHs such as sialidases (GH33), α -fucosidases (GH29, GH95), exo- and endo- β -N-acetylglucosaminidases (GH84 and GH85), β -galactosidases (GH2, GH20, GH42), α -N-acetylglucosaminidases (GH89), endo- β 1,4-galactosidases (GH98) and α -N-acetylgalactosaminidases (GH101, GH129) (www.cazy.org). These enzymes have been functionally characterised in resident members of the gut microbiota able to forage on mucins, including *A. muciniphila*, *B. thetaiotaomicron*, *B. bifidum*, *B. fragilis*, and *R. gnavus*, as recently reviewed (Tailford *et al.*, 2015, Ndeh & Gilbert, 2018). The released mono- or oligosaccharides derived from mucus degradation by these commensal bacteria can be utilised by the bacteria itself or scavenged by other bacteria inhabiting the mucus niche including pathogenic species such as *Salmonella* species, *C. difficile*, diarrhoeagenic *E. coli*, or *Vibrio cholerae* through cross-feeding interactions (Fabich *et al.*, 2008, Abyzov *et al.*, 2012, Ng *et*

al., 2013). In addition, some of these pathogens have the glycolytic potential to release mucus-derived sugars for their own consumption (Mondal *et al.*, 2014, Arabyan *et al.*, 2016).

Sulfatases. Sulfatases are being increasingly investigated for their role in modulating the gut microbial ecosystem in health and disease. Some members of the gut microbiota such as *B. thetaiotaomicron*, *Bacteroides ovatus*, and Prevotella sp. strain RS2 *Bifidobacterium breve* UCC2003, or *B. fragilis* possess mucin- desulfating sulfatases or glycosulfatases (Salyers *et al.*, 1977, Berteau *et al.*, 2006, Benjdia *et al.*, 2011, Egan *et al.*, 2016, Praharaj *et al.*, 2018). Mucin sulfatase activity of these species may provide them a competitive advantage in the infant gut and/or the adult gut. The mucin- desulfating sulfatases that have been characterised so far include sulfatases specific for the - D- galactopyranosyl 3- sulfate, - Dgalactopyranosyl6- sulfate, and 2- acetamido- 2- deoxy- D- glucopyranosyl6- sulfate (6- SO₃- GlcNAc) building blocks of the oligosaccharide chains. GlcNAc-6-S can be found in terminal or branched positions of mucin oligosaccharide. The desulfation of mucin by bacterial sulfatases may be a rate-limiting step in mucin degradation mechanism, allowing glycosidases to access and act on the mucins by other members of the gut microbiota. The release of sulfate from mucins may also contribute to the expansion of Sulfate-reducing bacteria (SRB) in the gut (Rey *et al.*, 2013). SRB are able to produce hydrogen sulfide (H₂S) which can reduce disulfide bonds present in the mucus network, leading to mucus erosion and access of bacteria to the epithelium, therefore contributing to epithelial damage and inflammation. This mechanism has been proposed to be involved in the aetiology and/or severity of IBD (Ijssennagger *et al.*, 2016). In addition, Hickey and colleagues showed that sulfatases of *B. thetaiotaomicron* are required for its outer membrane vesicles to transit to underlying host immune cells and cause colitis (Chatzidaki-Livanis & Comstock, 2015). Together these data highlight the complex role of bacterial sulfatases in the gut.

453

454 **Proteases.** Bacterial proteases from commensal or pathogenic *E. coli* have also been
455 implicated in the recognition and degradation of mucins. In EHEC, StcE (secreted protease of
456 C1 esterase inhibitor from EHEC) was originally described as specifically cleaving C1
457 esterase inhibitor (C1-INH) (Lathem *et al.*, 2002, Grys *et al.*, 2006) but later showed to be
458 even more active against MUC7 (Lathem *et al.*, 2002). This soluble enzyme is important in
459 reducing mucin levels. StcE has been suggested to have a dual role during human infection,
460 (i) by promoting the penetration of bacterial cells through the mucus barrier lining the GI tract
461 and thus facilitating the intimate EHEC adherence to IECs, which is an essential step in
462 colonisation (Hews *et al.*, 2017), and (ii) by acting as an anti-inflammatory agent protecting
463 bacterial and host cell surfaces from complement-mediated lysis (Grys *et al.*, 2005, Abreu &
464 Barbosa, 2017). StcE is secreted by a Type II, subtype a, secretion system (T2aSS) (Monteiro
465 *et al.*, 2016, Hay *et al.*, 2018). This mucinase is a metalloprotease belonging to the peptidase
466 M66 family (IPR019503) carrying one zinc atom per protein but no structural calcium, which
467 is a reported feature of metalloproteases (Yu *et al.*, 2012). Recently, EHEC StcE
468 metalloprotease was shown to reduce the inner mucus layer in human colonic mucosal
469 biopsies and the MUC2 glycoprotein levels in mucin-producing LS174T colon carcinoma
470 cells (Hews *et al.*, 2017).

471 Pic (protein involved in intestinal colonisation), also previously known as Shmu
472 (*Shigella* mucinase), is a secreted protease identified in *Shigella flexneri* and
473 enteroaggregative *E. coli* (EAEC) (Henderson *et al.*, 1999). Pic is secreted by a Type V,
474 subtype a, secretion system (T5aSS) and belongs to the subfamily of serine protease
475 autotransporters (SPATEs), with a catalytic domain corresponding to the peptidase S6 family
476 (IPR030396). This enzyme was reported to display proteolytic activity against gelatin as well

as bovine and murine mucin but not hog gastric mucin (Henderson *et al.*, 1999). PicU was also shown to exhibit mucinolytic activity in uropathogenic *E. coli* (Parham *et al.*, 2004).

Hbp (hemoglobin-binding protease), also previously known as Tsh (temperature-sensitive haem-agglutinin), is capable of cleaving bovine submaxillary mucin but not hog gastric mucin, which so far would appear as a feature of mucinolytic serine protease autotransporter of Enterobacteriaceae (SPATE) of the peptidase S6 family (Dutta *et al.*, 2002). In some EHEC strains, a SPATE of the peptidase S6 family exhibiting mucinolytic activity was identified on plasmid pO113, namely EpeA (EHEC plasmid-encoded autotransporter) (Leyton *et al.*, 2003). In AIEC, a Vat (vacuolating autotransporter) homologue belonging to the SPATE of the peptidase S6 family was demonstrated to exhibit a mucinolytic activity (Gibold *et al.*, 2016). Vat-AIEC appears to significantly contribute to the colonisation ability of AIEC by decreasing mucus viscosity as well as enhancing bacterial penetration in mucus and access to IECs (Gibold *et al.*, 2016).

In some non-O157 EHEC strains, a subtilase cytotoxin (SubAB) was identified (Paton *et al.*, 2006, Wang *et al.*, 2007) and appeared to contribute to mucin depletion as shown with a Shiga-toxin encoding *E. coli* (STEC) O113:H21 strain (Gerhardt *et al.*, 2013). While the A subunit harbours the enzymatic activity with a subtilase-like serine protease domain belonging to the peptidase S8/S53 family (IPR000209), the mucinolytic activity of SubAB remains to be clearly established.

Other proteins have been described in *V. cholerae*. Among them, TagA is a secreted protease of *V. cholerae* that specifically cleaves mucin glycoproteins (Szabady *et al.*, 2011). The *V. cholerae* extracellular chitinase ChiA2 secreted in the intestine hydrolyzes intestinal mucin to release GlcNAc, and the released sugar is successfully utilized by *V. cholerae* for growth and survival in the host intestine (Mondal *et al.*, 2014).

SslE (secreted and surface associated lipoprotein), previously known as YghJ, is a secreted and cell-surface lipoprotein degrading the major mucins in the small intestine, namely MUC2 and MUC3, thus facilitating bacterial penetration of the mucus layer and ultimately adhesion to host cells (Luo *et al.*, 2014, Valeri *et al.*, 2015, Tapader *et al.*, 2017). SslE is secreted via a T2aSS and appears inactive against the mucin-like CD43, bovine submaxillary mucin, gelatin, or IgG (Luo *et al.*, 2014). This Zn-metalloprotease, belonging to the peptidase M60 family (IPR031161), is found in pathogenic and commensal *E. coli*, including ETEC, EHEC O104:H4, *E. coli* SE-11 or Nissle 1917 strains. AcfD (accessory colonisation factor D) from *V. cholerae* is homologous to SslE but its putative mucinolytic activity remains to be investigated (Peterson & Mekalanos, 1988). Of note, SslE is also considered as a relevant target for the development of vaccines against intestinal pathogenic *E. coli* (Nesta *et al.*, 2014, Naili *et al.*, 2016, Naili *et al.*, 2017).

3. *Importance of mucus-bacteria interactions in health and disease*

In the colon, the outer mucus layer offers a niche to commensal bacteria by providing preferential binding sites (Section 2.1) and nutrients (Section 2.2). Due to its proximity to host cells and the immune system, the mucus-associated microbiota, sometimes also referred to as the mucobiome (Belzer *et al.*, 2017), has been proposed as an important modulator of health. The integrity of the mucosa relies on a combination of factors including the gut microbiota composition, the diet and host genetic factors (Fig. 2) (Martens *et al.*, 2018). The mucus and mucus-associated bacterial community play a key role in limiting access of invading pathogens to the underlying epithelial cells and in limiting the progression of intestinal and extra-intestinal diseases (Donaldson *et al.*, 2016).

Effect of bacteria and bacterial products on mucus production. A number of animal studies (using antibiotic-treated, germ-free or gnotobiotic mice) suggest that the presence of bacteria triggers the development of the protective mucus layer. Mice treated with the antibiotic metronidazole, but not streptomycin, display an altered goblet cell function and thinning of the inner mucus layer (Wlodarska *et al.*, 2011). However, another study reported that depletion of the intestinal microbiota following a three week-antibiotic period (cocktail of four antibiotics) did not modify mucus penetrability (Johansson *et al.*, 2015).

Compared to conventionally housed animals, germ-free mice have fewer goblet cells, which are smaller in size (Kandori *et al.*, 1996) and harbour an impaired mucus layer, indicating that the formation of the protective mucus layer depends upon the presence of bacteria (Rodriguez-Pineiro & Johansson, 2015). Johansson and colleagues demonstrated that the mucus of germ-free mice displayed a significant decrease in Muc2 level and was more penetrable to bacterium-size fluorescent beads as compared to conventionally raised mice (Johansson *et al.*, 2015). The gut microbiota composition of germ free animals is normalized two weeks after colonisation in terms of microbiota composition, but up to 8 weeks are needed to reach a normalized mucus phenotype (Johansson *et al.*, 2015, Hayes *et al.*, 2018). In support of this, fortification of the mucus layer and increased diversity of mucin glycosylation was observed within 48 hours of human intestinal organoid colonization with human-derived, non-pathogenic *E. coli* (Hill *et al.*, 2017). Some bacteria, in particular Anaerostipes, have been shown to display mucus-stimulating properties (Jakobsson *et al.*, 2015). *Lactobacillus* species can also stimulate MUC2 production and secretion by the goblet cells in the human gut (Sicard *et al.*, 2017). Representative members of the two main phyla of the gut microbiota, *B. thetaiotaomicron* and *Faecalibacterium prauznitzii* can modulate goblet cell differentiation and thus mucus production (Wrzosek *et al.*, 2013). A recent study showed that *Streptococcus thermophilus*, a transient food-borne bacterium, was able to induce mucus

pathway in gnotobiotic rodents despite its poor capacity for mucus adhesion and mucin glycan degradation *in vitro* (Fernandez *et al.*, 2018). Some of the mechanisms mediating mucin production and secretion by gut bacteria have been elucidated as described below.

Pathogen associated molecular patterns such as lipopolysaccharide (LPS) or peptidoglycan are known to induce mucus production (Petersson *et al.*, 2011). LPS and flagellin purified from Gram-negative bacteria as well as lipoteichoic acid from Gram-positive bacteria have been shown to induce mucin upregulation via the Ras-signalling pathway (McNamara & Basbaum, 2001). LPS also increases the production of interleukin (IL)-8 by goblet cells, which further promotes mucin secretion (Smirnova *et al.*, 2003). TLR family members play an important role in mucus formation. Mice lacking the TLR adaptor protein MyD88 show a decreased production of mucus (Bhinder *et al.*, 2014). Mice engineered to lack the flagellin receptor, TLR5 deficient mice, have a disorganised mucus layer and lack a well-defined inner layer when compared to wild type animals with an increase abundance of Proteobacteria in close contact with the epithelial surfaces (Carvalho *et al.*, 2012, Chassaing *et al.*, 2014, Chassaing *et al.*, 2015). Lastly, it has been shown *in vitro* using various human-derived cell lines that bacterial metabolites such as short-chain fatty acids (SCFA) and especially butyrate can stimulate MUC2 production in the absence of other energy sources (Willemsen *et al.*, 2003, Gaudier *et al.*, 2004). The effect of butyrate on MUC2 gene expression is mediated by epigenetic modifications (acetylation/methylation of histones) on the MUC2 promoter as demonstrated *in vitro* using human goblet cell-like LS174T cells (Burger-van Paassen *et al.*, 2009). Fernandez and colleagues suggested that lactate produced by *S. thermophilus* in the GI tract could stimulate mucus production via a signalling pathway dependent of KLF4, a transcription factor involved in the differentiation of goblet cells (Fernandez *et al.*, 2018). Some other bacterial effectors have been identified to

mediate mucin expression and glycosylation such as small peptides from *R. gnavus* and *B. thetaiotaomicron* (see section 2).

Interactions of pathogens with mucus. The mucus barrier provides a bulwark against intestinal pathogens (Johansson *et al.*, 2013, Sicard *et al.*, 2017, Martens *et al.*, 2018). The importance of intestinal mucus in controlling enteric infection has been widely documented in *Muc2* knockout mice (*Muc2*^{-/-} mice) (see section 4.5), which do not produce mucus in the small and large intestine, thus leading to a close contact between bacteria and the epithelium. Bergstrom and colleagues reported that *Muc2*^{-/-} mice exhibit an increase susceptibility to murine bacterial pathogen *Citrobacter rodentium* (Bergstrom *et al.*, 2010). Likewise, *Muc2* plays a crucial role in controlling *Salmonella* infection (Zarepour *et al.*, 2013). In a similar way, *H. pylori* has evolved mechanisms allowing its residence in the gastric mucus layer (Moore *et al.*, 2011). As previously described for bacteria, *Muc2*^{-/-} mice are also more susceptible to enteric parasitic infection with *Trichuris muris* since they exhibit a delayed expulsion of the parasite compared to wild type animals (Hasnain *et al.*, 2010). Clearance of parasitic infection is associated with exclusion of helminths via a TH2 cell-mediated goblet cell increase and mucus release (Artis & Grencis, 2008). *Entamoeba histolytica* also possesses lectins binding to mucins and secretes proteases responsible for the cleavage of *Muc2*, allowing the protozoan to invade the underlying epithelium (Lidell *et al.*, 2006). Recently, a detailed investigation of the cooperative roles for colonic microbiota and *Muc2* in mediating innate host defence against *E. histolytica* was carried out using *Muc2*^{-/-} mice, germ free mice and mucus-secreting LS174T cells, demonstrating that mucus secretion and pro-inflammatory responses were microbiota-specific (Leon-Coria *et al.*, 2018). Lastly, as shown with *S. flexneri* and *H. pylori*, some pathogenic bacteria are able to reshape mucin structures

by remodelling their glycosylation pattern in a type III secretion system-dependent manner (Sperandio *et al.*, 2013, Magalhaes *et al.*, 2015).

Emerging data suggest that pathogenic bacteria can benefit from the capacity of commensal microorganisms to release mucin degradation products that can be used to support their proliferation within the mucus niche. For example, *B. thetaiotaomicron* can release free sialic acid from colonic mucus glycans that can be utilized by *C. difficile* and *Salmonella* Typhimurium to promote their own colonisation and persistence in the gut (Ng *et al.*, 2013). Another study indicates that EHEC bacteria colonise the mucus layer within the cooperation of local bacterial communities including *B. thetaiotaomicron* and other anaerobes which are able to cleave host glycan- derived sugar and produce fucose (Pacheco *et al.*, 2012). EHEC then senses fucose produced by *B. thetaiotaomicron* to control expression of its type III secretion system (Pacheco *et al.*, 2012, Cameron *et al.*, 2018).

Mucus-pathogen interactions have also been evidenced in the extra-digestive area. *Pseudomonas aeruginosa*, a Gram-negative flagellated pathogen, is the main causal agent for the development of pneumonia in immunocompromised patients and patients with cystic fibrosis (CF). This infection is associated with a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride and bicarbonate ion channel protein with a key role in protecting the small intestine from bacterial invasion. CF conducts to blockage airway, mucus hypersecretion leading to chronic bacterial lung infections and inflammation. It has been shown that *P. aeruginosa*, via LPS, upregulate MUC2 and MUC5AC gene expression contributing to the excessive mucus production and airway blockage seen in CF (Bellu *et al.*, 2013).

Effect of diet on mucus. Recent evidences have demonstrated that the diet can influence the properties of colonic mucus and thereafter interfere with the gut microbiota.

Fibres. Living in symbiosis with the host, the gut microbiota depends mostly on non-digestible fibres and polysaccharides as energy source. In the absence of fibres in the diet, the gut microbiota shifts towards the utilisation of host glycans such as those provided by mucins, resulting in a thinner protective colonic mucus (Sonnenburg & Sonnenburg, 2014, Earle *et al.*, 2015). Accordingly, Desai and colleagues demonstrated that a low-fibre diet promotes the enrichment of mucin-degrading bacteria and the overexpression of carbohydrate-active enzymes (CAZymes) that degrade the colonic mucus barrier (Desai *et al.*, 2016, Martens *et al.*, 2018). In these mice fed with a deprived-fibre diet, infection with *C. rodentium* promotes greater epithelial access and lethal colitis (Desai *et al.*, 2016).

A lack of fermentable fibres in the diet also leads to a reduction in epithelial cell proliferation resulting in a thin mucosa with encroached bacteria (Chassaing *et al.*, 2015). Further studies in mice reported that inulin supplementation increases the number of colonic goblet cells, which correlates with a thicker mucus layer and an increase proportion of the *Akkermansia* genus (Kleessen *et al.*, 2003, Everard *et al.*, 2013). Similarly, studies in mice showed that a diet enriched in inulin fibre prevents mucus deterioration (Schroeder *et al.*, 2018). It was recently showed that inulin but not cellulose protects against diet-induced obesity by reducing microbiota encroachment in a cytokine IL-22-dependent manner (Zou *et al.*, 2018), demonstrating the importance of dietary factors, especially soluble fibre, in the homeostasis of host-microbiota relationship. Considering the increased mucus foraging activity occurring when mice are fed with a low-fibre diet, a recent study showed that supplementation with probiotic bifidobacteria (*B. longum*) or prebiotic fibre (inulin) could reduce such mucus defect. Notably, administration with *B. longum* was sufficient to restore mucus growth, while administration with inulin could prevent the increase of mucus penetrability in mice fed a western style diet (WSD) (Schroeder *et al.*, 2018).

Western diet and food additives. Besides fibres, other nutrients within a WSD can modulate intestinal barrier function. A WSD is rich in saturated fats and simple carbohydrates but depleted in dietary fibres. As a result, a diet-induced obesity in mice leads to colon mucosal barrier dysfunction with a thinner mucus layer (as described above) and treatment with *A. muciniphila* appears to counteract this effect by improving mucus thickness (Everard *et al.*, 2013). Similarly, mice fed a high-fat and high-sugar diet exhibit an increased abundance of mucin-degrading species leading to a decrease in mucus thickness (Martinez-Medina *et al.*, 2014). The diet of modern societies has dramatically changed as evidenced by a steady increase in the consumption of processed foods concomitantly with an increase in the use of food additives (Chassaing *et al.*, 2015). Mice treated with dietary emulsifiers (polysorbate 80 or carboxymethylcellulose) show a reduced mucus thickness and increased gut permeability. In these animals, some bacteria appear in close contact with the epithelium. Emulsifier-treated mice have an altered microbial composition associated with increased levels of mucolytic bacteria including *R. gnavus* and a marked reduction in microbial diversity, with a bloom in *Verrucomicrobia* phyla, especially *A. muciniphila* (Chassaing *et al.*, 2015). This may further contribute to the intestinal passage of bacterial constituents such as LPS and flagellin, which participates in the development of low-grade inflammation and metabolic disorders in wild type mice and of colitis in susceptible host animals (Chassaing *et al.*, 2014, Chassaing *et al.*, 2015, Chassaing *et al.*, 2017). Mice fed with diets enriched in maltodextrin, a filler and thickener used in food processing, show a reduction of *Muc2* expression, making the host more sensitive to low-grade inflammation but with no significant change in mucosa-associated microbiota (Laudisi *et al.*, 2018).

Effect of food contaminants on mucus. The intestinal mucosa is increasingly appreciated as a key player in the emerging field of gut toxicology of environmental pollutants, as recently

reviewed (Gillois *et al.*, 2018). Human contamination mainly occurs via the oral route through consumption of food but also through polluted water and soil exposure.

Nanomaterials. The use of nanotechnology in many common consumer products, especially in food products, is growing. Scarce studies have evaluated the interactions of food nanoparticles with the microbiota and mucus (Mercier-Bonin *et al.*, 2018). It was shown *in vitro* that common nanoparticles of Titanium dioxide (TiO₂) are trapped into mucus, leading to areas with a high local concentration (Talbot *et al.*, 2018). Silver nanoparticles are widely used in food industry to colour the surface of confectionary and pastries. Rats fed with these particles exhibit higher numbers of goblet cells and a modification of the glycosylation pattern of mucins with a decreased proportion of sulfated mucins and an increased proportion of sialylated mucins (Jeong *et al.*, 2010). Repeated silver nanoparticle-exposure may therefore produce pathological regions in the lamina propria (Jeong *et al.*, 2010).

Persistent Organic Pollutants. A recent study showed that mice chronically exposed to benzo[a]pyrene (BaP) which is the most toxic member of the polycyclic aromatic hydrocarbons family display significant shifts in the composition and relative abundance of stool and mucosa-associated bacterial communities (decrease of *Verrucomicrobiaceae*, represented by *A. muciniphila*) (Ribiere *et al.*, 2016). Furthermore, exposure to perfluorooctane sulfonate (PFOS, environmental contaminant used as a surfactant and repellent) in a mouse model of *C. rodentium* infection led to a significant reduction in mucin gene expression and a failure to clear the bacterial infection (Suo *et al.*, 2017). Smoke exposure also significantly affects the mucosa-associated bacterial community and alters the expression of mucins in the murine gut (Allais *et al.*, 2016).

Mucus and inflammatory related diseases.

Inflammatory bowel diseases (IBD). Barrier disturbances including alterations in the thickness or composition of the intestinal mucus layer are recognized to play a crucial role in the onset of GI disorders such as Crohn disease (CD) or ulcerative colitis (UC). The mucus layer in UC patients is thinner and has an altered glycosylation profile making it more penetrable to bacteria (Johansson *et al.*, 2014). To better understand the onset of IBD, several murine models of intestinal inflammation (genetically or chemically induced) have been established. The most common experimental model of colitis relies on the administration of Dextran Sodium Sulfate (DSS) in the drinking water. Mice orally administered with DSS display an inner mucus layer which is more penetrable by bacteria within 12 hours (Johansson *et al.*, 2010). Similarly, *IL-10*^{-/-} and *TLR5*^{-/-} mice that develop spontaneous colitis have a thicker mucus layer and more penetrable inner mucus layer when compared to wild type animals (Johansson *et al.*, 2014). *Muc2*^{-/-} mice develop intestinal inflammation with diarrhoea, rectal bleeding and prolapse (Johansson *et al.*, 2008) and are more susceptible to DSS-induced colitis; these animals exhibit a massive number of bacteria in close contact with host tissues, further promoting inflammation (Van der Sluis *et al.*, 2006). Moreover, abnormal mucin *O*-glycosylation has been associated with an increased inflammation, highlighting the importance of mucin glycans in the maintenance of gut homeostasis (Johansson *et al.*, 2014) (Bergstrom & Xia, 2013, Bergstrom *et al.*, 2016).

These changes in mucus composition were also mirrored by changes in the gut microbiota composition at the mucosal surface. IBD patients exhibit a disproportion of mucin-degrading (or mucinolytic) bacteria with an increased abundance of *Ruminococcus torques* and *R. gnavus*, but a decreased abundance of *A. muciniphila*. In addition, the expansion of certain pathobionts and in particular AIEC exhibiting mucinolytic activity has been reported to favour gut colonisation and further induce inflammation in CD (Palmela *et al.*, 2018). Taken together, these data suggest that mucus-bacteria interactions contribute to

the intestinal barrier dysfunction in IBD patients and future work is needed to better understand the influence or consequence of these interactions on the disease.

Obesity and metabolic-related disorders. A correlation between adiposity, dysglycemia and microbiota encroachment has been reported in a number of animal studies. *Muc2*^{-/-} mice fed a High Fat Diet (HFD) are protected from diet-induced weight gain, fatty liver, and insulin resistance as they displayed less inflammation and increased systemic levels of IL-22 (Hartmann *et al.*, 2016). This study supports a role of Muc2 during obesity and highlights the importance of the crosstalk between microbiota, mucus and immune mediators. In mice fed a HFD, mucus secretion is altered in the ileum but not in the duodenum and jejunum, largely in response to an alteration of PPAR- γ signalling. In these mice, Muc2 accumulates at the apical side of goblet cells, leading to a reduction in the expansion capacity of the mucins, thus strongly altering the phenotype of the mucus layer (Tomas *et al.*, 2016). Studies by Chassaing and colleagues in different mouse models of metabolic syndrome and in humans demonstrated that bacteria have the ability to infiltrate the mucus layer and reach the epithelium (Chassaing *et al.*, 2014, Chassaing *et al.*, 2015, Chassaing *et al.*, 2017). Further, measurement of bacterial-epithelial distance reveals that microbiota encroachment is a feature of insulin resistance-associated dysglycemia in humans that may promote inflammation (Chassaing *et al.*, 2017). Several studies demonstrated that *A. muciniphila* is less abundant in the intestinal microbiota of both genetic and diet-induced obese and diabetic mice, as well as in individuals with obesity, when compared to the faecal microbial population of healthy individuals (Everard *et al.*, 2013, Shin *et al.*, 2014). *A. muciniphila* treatment has been shown to reverse fat gain, serum LPS levels, gut barrier function, and insulin resistance. In addition, oral administration of an outer-membrane protein from *A. muciniphila* led to reduced fat mass and metabolic syndrome in mice fed an obesity induced diet (Plovier *et al.*, 2017).

Conversely, anti-diabetic treatments such as metformin administration led to an increase in the *Akkermansia* spp. population (Shin *et al.*, 2014).

Human studies have shown that alcohol abuse induced alcoholic liver diseases (ALD) are associated with an increase in intestinal mucus thickness in patients, using wheat germ agglutinin staining on duodenal biopsies (Hartmann *et al.*, 2013). Animal studies demonstrated that when compared to wild type animals, *Muc-2*^{-/-} mice are protected from alcoholic steatohepatitis in an experimental alcohol-induced liver disease model (Hartmann *et al.*, 2013). In addition, *Muc-2*^{-/-} mice are protected from Non Alcoholic Fatty Liver Disease (NAFLD) when fed a high-fat diet inducing liver steatosis (Hartmann *et al.*, 2016). Altogether, these data highlight the role of mucus and mucins in the gut-liver axis.

Cancer. The role of mucins in cancer progression has been extensively reviewed (Hollingsworth & Swanson, 2004, Kufe, 2009). *Muc2*^{-/-} mice displayed spontaneous development of adenomas in the small intestine that progressed to invasive adenocarcinoma, as well as rectal tumours (Velcich *et al.*, 2002). In humans, high levels of expression of MUC2 by pancreatic and biliary tumours has been associated with a low degree of invasiveness, malignancy and a better prognosis as compared to tumours not expressing MUC2 (Hollingsworth & Swanson, 2004). An abnormal mucin *O*-glycosylation has been associated with an increased inflammation that could contribute to the development of colitis-associated colon cancer in mice (Bergstrom & Xia, 2013, Bergstrom *et al.*, 2016). Together these studies support the role of MUC2 as a tumour suppressor.

4. Potential of experimental models to study mucus/mucin interactions with gut microbes

As mounting evidences highlight the importance of mucus in the cross-talk between the gut microbiota and the host, a wide range of experimental models has been developed to study mucus-bacteria interactions (Table 1). These include the use of purified mucins, mucin-secreting cells or tissues, or mucin-containing fermentation models, as described below.

4.1. *In vitro* mucus/mucin binding assays

Microplate assays. Several microtiter plate assays have been developed for testing bacterial adhesion to mucus and/or mucin (McNamara *et al.*, 2000, Gusils *et al.*, 2004). These generally rely on the immobilisation of mucins or mucus to the wells of microtiter plates following incubation overnight at 4°C or at room temperature in buffers such as PBS (pH 7-7.5), HBSS (pH 7-7.5) or carbonate buffer (pH 9.6) (Gusils *et al.*, 2004, Dague *et al.*, 2010, Mackenzie *et al.*, 2010, Chagnot *et al.*, 2013). BSA (bovine serum albumin) is generally used as a negative control for assessing the specificity of the binding to mucus and/or mucin. Binding assays are usually performed at 37°C and the contact time with bacterial cells generally ranges between 30 min to 3 hours before washing to remove non-adhered bacteria. Antibiotic at growth inhibiting concentration, such as chloramphenicol, or sometimes thermic treatment can be applied to prevent the growth of microorganisms in the course of the adhesion assay. Binding can be determined using crystal violet staining of the adhered microbial biomass (Azeredo *et al.*, 2017) or by Enzyme-linked Immunosorbent Assay (ELISA) when specific antibodies against bacteria are available (Skoog *et al.*, 2012), by measurement of viable counts after plating of the cells (McNamara *et al.*, 2000) or by quantitative PCR (Skoog *et al.*, 2012). Alternatively, bacteria can be labelled with a radioactive probe or a fluorescent dye before inoculation and the binding quantified using a scintillation counter or a fluorometer, respectively (Gusils *et al.*, 2004, Mackenzie *et al.*,

2010). Microbial cells can also be labelled by biotinylation and further assayed using streptavidin-HRP by ELISA (Sheng *et al.*, 2012). Quantification of microbial binding to mucin can also be performed by flow cytometry, where microbial cells are put in contact with mucin labelled with a fluorescent tag (de Repentigny *et al.*, 2000).

Dot blot assay. More recently, a dot-blot method was developed for the sensitive and rapid detection of microorganisms able to bind to mucins (Ringot-Destrez *et al.*, 2018). In brief, purified mucins were spotted on a nitrocellulose membrane, whereas the bacterial cells were labelled using a fluorescent dye, such as 4',6-diamidino-2-phenylindole (DAPI), Syto9 or Fluorescein isothiocyanate (FITC), before being overlaid (Ringot-Destrez *et al.*, 2018). The adhesion capacities of the microorganisms tested differed depending on the nature of the mucins including purified GI tract mucins, PGM and mucins from the mucus-secreting cell line such as HT29-MTX (see detailed description of this cell line in Section 4.2) (Ringot-Destrez *et al.*, 2018).

Mucin microarrays. The carbohydrate microarray technology offers a powerful platform where natural or synthetic glycans are immobilized onto a solid support. (Poole *et al.*, 2018). . Microarrays incorporating mucins from various sources onto different chips surfaces provide a high-throughput approach to screen bacteria-mucin interactions as well as identify glycan-binding proteins and glycan epitopes involved in this interaction (Clyne *et al.*, 2017). For example, the use of mucin microarrays revealed that *C. jejuni* and *H. pylori* recognised distinct mucin receptors despite being closely related phylogenetically (Naughton *et al.*, 2013). Recently, *H. pylori* was shown to interact with trefoil factor family (TFF) protein TFF1 (Reeves *et al.*, 2008), and that TFF1 specifically interacts with human gastric mucin but not with human colonic mucins nor mucins from other animal sources as shown using mucin

microarrays (Dunne *et al.*, 2018). This indicates that TFF1 may play an important role in the development of gastric cancer in *H. pylori* infections (Reeves *et al.*, 2008, Dunne *et al.*, 2018). Mucin microarrays were also used to identify the interactions of commensal strains with mucus (*Lactobacillus salivarius* AH102 and *Bifidobacteria longum* AH1205), highlighting the importance of mucin glycans in the preference of the two bacteria to mucins (Naughton *et al.*, 2013, Flannery *et al.*, 2015).

Binding assays in flow chamber. As a consequence of fluid shear gradient in the gut, the bacteria located in the outer mucus layer are exposed to a more turbulent flow compared to those that reside between the microvilli of the epithelial cells and therefore less exposed to physical perturbation (De Weirde & Van de Wiele, 2015). While the assays described above correspond to adhesion under static conditions, experiments can also be performed in dynamic conditions using flow chamber, where the shear force can be controlled (Le *et al.*, 2013). Low-fluid shear environments and high shear rates are known to provide laminar pattern. Over time and with different laminar flow rates, the surface coverage of microbial cells to coupons coated with mucin provides an estimate detachment profile as a function of the shear stress.

Biophysical assays. In order to gain further molecular insights into the interactions of microbial cells with mucin, various biophysical techniques have been developed and applied over the years. Optical biosensors based on resonant mirrors have been used to determine the binding kinetics of *H. pylori* cells to mucin (Hirno *et al.*, 1999). Following competition binding assays, the recognition of sialylated and sulphated moieties of mucin by *H. pylori* was demonstrated. Surface plasmon resonance (SPR) has been used to evaluate the adhesion abilities of a range of *Lactobacillus* species (Uchida *et al.*, 2004, Kinoshita *et al.*, 2007). In

these studies, human colonic mucin (HCM) was immobilised on the sensor chip whereas bacterial cells were eluted as analytes. Using sialidase or sulfatase, it was further possible to discriminate some strains of lactobacilli and bifidobacteria that could specifically bind to the sialic acid or sulphate residues of HCM respectively (Huang *et al.*, 2013). Single-cell force spectroscopy (SFCS) has been used to quantify the adhesion forces of *L. rhamnosus* with mucin at a single-cell level, pinpointing heterogeneities in the bacterial population (Sullan *et al.*, 2014). More recently, further molecular details of mucin-bacteria interactions were investigated using atomic force microscopy (AFM). Such an approach was used for the first time to accurately quantify the force of adhesion of *L. lactis* cells immobilised on the AFM tip to PGM at nanoscale level (Dague *et al.*, 2010). Surprisingly, it was found that PGM coating strongly reduced the bacterial adhesion force compared to bare polystyrene, highlighting the interplay between electrostatic, hydrophilic and steric repulsions, and that both specific and non-specific interactions need to be considered (Dague *et al.*, 2010). These results were consistent with a previous investigation of the muco-adhesive properties of *L. lactis* using quartz crystal microbalance with dissipation monitoring (Le *et al.*, 2012). Using bacteria mutant strains, AFM was also used to provide molecular insights into the respective role and contribution of mucus-binding proteins and surface organelles (pili or flagella) in muco-adhesion (Le *et al.*, 2013). Interactions at the protein-protein level were further investigated by AFM to study the adhesive properties of *L. reuteri* Mub with mucins (Gunning *et al.*, 2016).

4.2. *In vitro* mucin-secreting cell models

Monoculture models. While many colon carcinoma cell lines express mRNAs encoding surface-associated and/or secreted intestinal mucins (Deplancke & Gaskins, 2001), few of

873 them secrete MUC2 or form a mucus layer (Linden *et al.*, 2007, Navabi *et al.*, 2013, Hews *et*
874 *al.*, 2017). Most mucus-secreting cell lines are derived from the heterogeneous
875 adenocarcinoma cell line HT-29 which can be differentiated into a mucus-secreting phenotype
876 by growth under metabolic stress conditions. After an initial phase of cell mortality, adapted
877 subpopulations of highly differentiated cells emerge (Lievin-Le Moal & Servin, 2013). HT29-
878 18N2 cells are often used as a model system for goblet cell differentiation and mucin
879 secretion; these cells have been established by growth under glucose deprivation in galactose-
880 containing culture medium (Phillips *et al.*, 1988). In contrast, HT29-MTX cells and their
881 clonal derivatives have been obtained by sequential adaptation to increasing concentrations of
882 methotrexate (Lesuffleur *et al.*, 1990). When grown on Transwell filter supports, some HT-29
883 MTX clones (e.g. MTX-D1 and MTX-E12) form polarised monolayers mostly constituted of
884 mature goblet cells secreting an adherent mucus layer of 50-150 μ m thickness as revealed by
885 Alcian Blue staining (Behrens *et al.*, 2001). In addition, the mucin-secreting clonal cell line
886 HT-29.cl16E emerged from parental HT-29 cells after subculture in sodium butyrate whilst
887 HT29-FU cells were established by treatment with 5-fluorouracil (Lesuffleur *et al.*, 1991).

888 These mucus-producing HT-29 derivatives have been widely used to investigate the
889 adherence of commensal and pathogenic bacteria to host cells (Coconnier *et al.*, 1992, Bernet
890 *et al.*, 1993, Eveillard *et al.*, 1993, Bernet *et al.*, 1994, Kerneis *et al.*, 1994, Favre-Bonte *et al.*,
891 1999, Gopal *et al.*, 2001, Schild *et al.*, 2005, Barketi-Klai *et al.*, 2011, Dolan *et al.*, 2012,
892 Gagnon *et al.*, 2013, Naughton *et al.*, 2013, Martins *et al.*, 2015, Martins *et al.*, 2016) and/or
893 evaluate the effect of commensal bacteria on infection with enteropathogens (Bernet *et al.*,
894 1993, Bernet *et al.*, 1994, Coconnier *et al.*, 1998, Gopal *et al.*, 2001, Alemka *et al.*, 2010,
895 Zihler *et al.*, 2011, Zivkovic *et al.*, 2015, Vazquez-Gutierrez *et al.*, 2016). Some studies
896 investigated the direct effect of commensal or pathogenic bacteria on host cell mucin
897 synthesis and/or composition of the mucus layer. Infection with atypical EPEC increased

expression of secreted MUC2 and MUC5AC as well as membrane-bound MUC3 and MUC4 in HT29-MTX cells, thereby enhancing bacterial growth by providing nutrients for adherent bacteria (Vieira *et al.*, 2010). Another study showed that apical infection with *Listeria monocytogenes* stimulated mucus secretion by polarised HT29-MTX cells. This effect was mediated by binding of the toxin listeriolysin O to a receptor on the epithelial brush border (Coconnier *et al.*, 1998) and reduced bacterial invasion and colonisation of the host epithelium (Lievin-Le Moal *et al.*, 2005). Interestingly, probiotic *Lactobacillus* strains which adhering to mucus-producing HT-29 cells upregulated the transcription and secretion of MUC3 which reduced adherence of EPEC in co-incubation experiments (Mack *et al.*, 2003). Modulation of mucus production and mucin glycosylation by commensal bacteria can also occur independently of adhesion. For example, a small soluble peptide of the gut commensal *R. gnavus* E1 strain has been shown to increase HT-29 MTX cell glycosylation via enhanced transcription of glycosyltransferases and MUC2-encoding genes (Graziani *et al.*, 2016). Similarly, a soluble low molecular weight compound from *B. thetaiotaomicron* has been reported to enhance galactosylation in HT29-MTX cells. While no change in transcription was detected, galactosyltransferase activity was increased in HT29-MTX cells treated with soluble bacterial extract suggesting post-translational mechanisms of regulation (Miguel *et al.*, 2001).

In addition to HT-29 cell derivatives, mucus-producing LS174T colon carcinoma cells have been used to study host-bacteria interactions. LS174T cells secrete mature MUC2, MUC5AC and human gallbladder mucin (van Klinken *et al.*, 1996) but do not produce an organised adherent mucus layer (Navabi *et al.*, 2013). Recent studies using this cell line showed that the secreted metalloprotease StcE reduced MUC2 levels during infection with EHEC and thereby facilitated bacterial adherence to the intestinal epithelium (Hews *et al.*, 2017). In addition, the soluble protein p40 from *L. rhamnosus* GG stimulated MUC2 mRNA

and protein expression in LS174T cells, and this effect was dependent on the epidermal growth factor receptor (Wang *et al.*, 2014). Furthermore, treatment with butyrate, a product of bacteria fermentation, increased mucin production in LS174T cells (Burger-van Paassen *et al.*, 2009, Jung *et al.*, 2015). Recently, LS174T cells were used to decipher *E. histolytica*-elicited suppressed goblet cell transcription (Leon-Coria *et al.*, 2018).

Co-culture models. To model human intestinal epithelia, mixed cultures of enterocyte-like Caco-2 cells and mucus-producing HT29-MTX cells have been widely used in drug absorption and permeability studies (Hilgendorf *et al.*, 2000, Lozoya-Agullo *et al.*, 2017). Co-cultures prepared with different ratios of Caco-2 and HT29-MTX cells seeded out on Transwell inserts formed a continuous mucus layer similar to cultures of HT-29-MTX cells grown alone (Poquet *et al.*, 2008, Beduneau *et al.*, 2014). Notably, the probiotic strains *L. rhamnosus* GG or bifidobacteria as well as pathogenic strains of *E. coli* or *L. monocytogenes* adhered better to mucus-deficient Caco-2 cells than to mucus-producing HT-29MTX cells or Caco-2/HT-29 co-cultures (Laparra & Sanz, 2009). Considering the “closed” oxygen-restricted environment in the human gut, Chen and colleagues developed a 3D porous silk scaffolding in the shape of a hollow tube. While the inner tube wall was coated with Caco-2/HT29-MTX epithelia, primary human intestinal myofibroblasts were grown in the tube scaffold space underneath to support epithelial growth and differentiation. Notably, epithelia grown on 3D scaffolds demonstrated increased MUC2 production compared to Transwell cultures resulting in the formation of a mucus layer of 11-17 μm thickness (Chen *et al.*, 2015).

Organ-on-a-chip. Another approach to simulate a mucin-producing human intestinal epithelium is the ‘Gut-on-a-Chip’ system, where Caco-2 cells are grown on a porous membrane support in a microfluidic device. While the cell membrane support is maintained

under cyclic strain mimicking peristaltic motion, the chambers above and below the cell membrane are constantly perfused with medium, thereby generating low shear stress. This environment stimulates the formation of 3D intestinal villi similar to those found in the small intestine (Kim *et al.*, 2012), and the differentiation of Caco-2 cell into absorptive enterocytes, and also includes enteroendocrine cells, Paneth cells and mucus-producing goblet cells (Kim & Ingber, 2013). In addition, Caco-2 epithelium grown in the Gut-on-a-Chip model display enhanced barrier function and mucus production as compared to static Caco-2 cell cultures (Kim & Ingber, 2013). This system has recently been developed further to allow co- culture with strict anaerobes (Shin *et al.*, 2019). Although the Gut-on-a-Chip devices have been mostly used for long-term co-culture of IECs with commensal microbes under healthy conditions, they are now being employed to model intestinal inflammation (Kim *et al.*, 2016). Using a Gut-on-a-Chip model, the pathophysiological manifestation and dysregulated barrier function observed during inflammation could be recapitulated which may help to gain insights into disease mechanisms and assess potential therapeutic strategies (Shin & Kim, 2018). Notably, probiotic VSL#3 targeted restoration of the mucosal barrier did not effectively control the local inflammation nor improve mucus production (Shin & Kim, 2018). The HuMix (Human Microbial Cross-talk) model is another microfluidic device enabling the co-culture of Caco-2 cell monolayers with commensal bacteria under anaerobic conditions. In contrast to the Gut-on-a-Chip system, the epithelial cells which do not produce mucus are separated from the bacteria by a membrane coated with porcine gastric mucin (Shah *et al.*, 2016).

4.3. *Ex vivo organ cultures*

As described above, traditional culture of human cells represents a valuable predictor of human physiology, pathology, and therapeutic responses but is limited by the absence of the tissue microenvironment. Culture approaches using human intestinal biopsy samples therefore represent an upscale platform to investigate the involvement of the mucus layer in healthy conditions or in the onset of various diseases.

In vitro organ culture (IVOC). In 1969, Browning and Trier were the first to establish a technique to culture human mucosal biopsies *ex vivo*. By using a specific culture medium and incubation of the samples in 95% O₂, 5% CO₂ at 37°C, mucosal biopsies from the duodeno-jejunal junction were kept alive for up to 24 hours demonstrating epithelial cell proliferation, fat absorption and active mucus secretion by goblet cells (Browning & Trier, 1969). The advantages of IVOC of intestinal biopsies versus cell line culture models include the presence of healthy non-transformed cells including all major IEC types (enterocytes, goblet cells, Paneth cells and neuroendocrine cells), underlying basement membrane and mucosal tissue, and the production of mucus. While it is problematic to maintain the loose outer mucus layer of colonic biopsies during sampling, the inner colonic and small intestinal mucus layers are generally well preserved as evidenced by microscopy (Haque *et al.*, 2004, Walsham *et al.*, 2016, Hews *et al.*, 2017). IVOC of biopsy samples has been used to investigate adherence of pathogenic bacteria such as EPEC (Knutton *et al.*, 1987, Schüller *et al.*, 2007), EHEC (Phillips *et al.*, 2000, Fitzhenry *et al.*, 2002, Lewis *et al.*, 2015), ETEC (Knutton *et al.*, 1989, Baker *et al.*, 1997) and *C. jejuni* (Grant *et al.*, 2006) to human intestinal mucosa. In addition, IVOC demonstrated cytotoxic effects of bacterial toxins, such as Pet toxin from EAEC (Henderson *et al.*, 1999), Shiga toxin from EHEC (Schüller *et al.*, 2004) and *C. difficile* toxin A (Mahida *et al.*, 1996) on intestinal epithelium or mucosa. Interactions of enteropathogenic bacteria with mucus production were observed in small intestinal and colonic biopsy tissue

infected with EAEC where bacteria were predominantly associated with a thick mucus layer above the epithelium, which was not present in non-infected control samples (Hicks *et al.*, 1996, Andrade *et al.*, 2011). This suggests that EAEC stimulates mucus secretion which agrees with the production of mucoid stools during EAEC diarrhoea (Croxen *et al.*, 2013). Similarly, stimulation of mucus secretion and bacterial binding to the mucus layer were observed in biopsy samples from the terminal ileum infected with *S. Typhimurium*. This was followed by *Salmonella* adherence and invasion of the epithelium accompanied by ruffling of the host cell membrane (Haque *et al.*, 2004). Recently, the IVOC system was used to show that the metalloprotease StcE diminishes the inner mucus layer and enhances EHEC adherence to human colonic biopsy epithelium (Hews *et al.*, 2017).

Polarised IVOC (pIVOC). While the traditional IVOC system allows bacterial access to the mucosal and submucosal side of the biopsy, polarised organ culture models have been developed which limit bacterial contact to the mucosal side of the tissue. This is particularly relevant when studying host responses to bacterial infections where artificial interactions with immune cells in the lamina propria might confound experimental readouts. Using a pIVOC approach by mounting colonic tissue explants between two Perspex disks in a Snapwell plate, Raffatellu and colleagues demonstrated that *Salmonella* Typhi reduced mucosal expression of the pro-inflammatory cytokine interleukin (IL)-8 by production of a capsule which masked pathogen-associated molecular patterns such as LPS and flagellin (Raffatellu *et al.*, 2005). In addition, pIVOC showed that apical exposure to EPEC or purified H6 flagellin induced IL-8 expression in duodenal biopsies (Schüller *et al.*, 2009). Furthermore, infection with *C. jejuni* stimulated the production of reactive oxygen species (ROS) in duodenal and colonic mucosa (Corcionivoschi *et al.*, 2012). The pIVOC system has also been used to study the interaction of probiotic bacteria with mucosal tissue, and incubation of duodenal explants with *L. reuteri*

demonstrated localisation of bacteria in the mucus layer but not in the epithelium. Nevertheless, pre-incubation with *L. reuteri* reduced EPEC adherence to the epithelium (Walsham *et al.*, 2016). A different approach to restrict bacterial access to the epithelial surface was developed by Tsilingiri and colleagues by gluing a perspex cylinder to the mucosal side of colonic resection tissue (Tsilingiri *et al.*, 2012). Surprisingly, apical incubation with probiotic *L. plantarum* resulted in degeneration of mucosal tissue from healthy donors, whilst all three strains studied (*L. paracasei*, *L. rhamnosus*, *L. plantarum*) caused tissue damage in resections from patients with IBD. In contrast, supernatants from *L. paracasei* reduced inflammation in *Salmonella*-infected and IBD tissue. As the maintenance of larger tissue samples requires incubation in high levels of oxygen (95-99%), the use of IVOC to study interactions of oxygen-sensitive bacteria with human intestinal mucosa remains problematic. However, a novel murine 3D-intestinal organ culture system was recently developed whereby an intact intestinal fragment was lumenally perfused with de-gassed medium containing anaerobic bacteria while the serosal side of the tissue was maintained under humidified oxygenated conditions. Whilst preserving gut tissue architecture, the system also supported the growth of commensal microbes (*Clostridium ramosum* and SFB) and allowed assessment of their impact on the immune and nervous system (Yissachar *et al.*, 2017).

Human enteroids/colonoids and intestinal organoids. New technologies have been developed which enable the generation of self-propagating spheres of primary intestinal epithelial cells (“mini-guts”). Enteroids or colonoids are derived from adult stem cells isolated from the crypts of human small intestinal or colonic tissue, respectively (Jung *et al.*, 2011, Sato *et al.*, 2011). In contrast, human intestinal organoids (HIOs) are established by differentiation of embryonic or, more often, induced pluripotent stem cells (genetically

reprogrammed adult stem cells) (Spence *et al.*, 2011). In comparison to enteroids, HIOs lack maturation and more closely resemble foetal than adult intestine. In addition, they are devoid of functional intestinal stem cells and surrounded by a mesenchyme which is absent in enteroids (Sinagoga & Wells, 2015, Leslie & Young, 2016). As the apical side of the epithelium is facing inwards, infection of spheroid enteroids/HIOs with bacteria requires microinjection. Studies on the anaerobic pathogen *C. difficile* showed that injected bacteria remained alive in HIOs for up to 12 hours and caused disruption of epithelial barrier function *via* secretion of the toxin TcdA. Interestingly, oxygen measurements indicated reduced oxygen levels in the lumen of HIOs (5 to 15%). Furthermore, infection with *C. difficile* resulted in reduced MUC2 and mucus production in HIOs (Engevik *et al.*, 2015). HIOs also supported growth of EHEC and commensal *E. coli*. Infection with EHEC induced ROS production and an inflammatory response associated with recruitment of external neutrophils into HIO spheres (Karve *et al.*, 2017). Interestingly, colonisation of HIOs with commensal *E. coli* (ECOR2) stimulated enterocyte maturation, antimicrobial peptide secretion, production of a MUC2-containing mucus layer, and increased epithelial barrier function, thereby indicating the establishment of stable host-microbe symbiosis (Hill *et al.*, 2017).

To facilitate incubations with bacteria, 2D enteroid systems have now been successfully developed where primary intestinal cells are grown as monolayers on permeable membrane supports. Previous studies showed that differentiated human enteroid and colonoid monolayers contained MUC2-producing goblet cells and formed a mucus layer of more than 25 μm thickness (VanDussen *et al.*, 2015, In *et al.*, 2016). Two-dimensional enteroids and colonoids supported binding of EAEC, EHEC and EPEC (VanDussen *et al.*, 2015). More specifically, apical EHEC infection of colonoids resulted in the formation of characteristic attaching and effacing lesions, mucus degradation and reduced expression of the microvillar protein protocadherin 24, which was mediated by the secreted serine protease EspP (In *et al.*,

2016). The 2D enteroid model was further refined by adding primary human macrophages to the basolateral side of the membrane support. Intriguingly, enteroid monolayers grown in the presence of macrophages exhibited increased cell height and barrier function. In addition, underlying macrophages were able to capture and kill EPEC and ETEC by extending projections across the epithelial monolayer (Noel *et al.*, 2017).

In another approach to mimic the gut environment more closely, cells from human small intestinal enteroids were seeded on tubular silk sponge scaffolds and supported by primary human intestinal myofibroblasts as described for Caco-2/HT29-MTX (Section 4.2). The resulting intestinal model epithelium contained all four major epithelial cell types and exhibited tight junction formation, microvillus polarisation, digestive enzyme secretion, and low oxygen tension in the lumen. Moreover, infection with a laboratory strain of *E. coli* resulted in a significant innate immune response (Chen *et al.*, 2017). Recently, a Gut-on-a-Chip model based on primary intestinal epithelial cells has been developed which also includes co-culture of an underlying endothelium. Human enteroids are cultured on a side of a porous membrane within a microfluidic device whereas the intestinal microvascular endothelium is established on the other side of the filter.. This device reproduces the epithelial cells proliferation and host defenses more accurately (Kasendra *et al.*, 2018). Kim and colleagues showed that a human Gut-on-a-Chip micro device colonized by non-pathogenic bacteria (commensal and probiotic bacteria) was able to induce production of a key set of pro-inflammatory cytokines. This device enabled high level of mucus production on micro engineered intestinal villi, therefore providing a protective barrier to maintain long-term stable host–microbe coexistence (Kim *et al.*, 2016).

4.4. *In vitro* human fermentation models involving a mucosal phase

As aforementioned, the spatial positioning of gut microorganisms in the mucus layer is important with respect to their functional role in the human gut ecosystem. The microbial community residing in the mucus layer across the length of the GI tract is, however, hard to study given the difficulty to sample this region *in vivo*, especially in human (Macfarlane *et al.*, 1997, Flint *et al.*, 2012, Donaldson *et al.*, 2016). *In vitro* colonic models involving a mucosal phase are a valuable alternative to study the fine-scale spatial organisation of the gut microbial ecosystem.

Multiple colon *in vitro* models have been developed over the years, ranging from simple, single stage batch incubations to more complex and representative three stage continuous and semi-continuous reactor models (Miller & Wolin, 1981, Gibson *et al.*, 1988, Allison *et al.*, 1989, Blanquet-Diot *et al.*, 2012, McDonald *et al.*, 2013, Van den Abbeele *et al.*, 2013). These continuous fermentation models, inoculated with faecal samples of donors, recapitulate the main biotic and abiotic parameters of the human colon, such as temperature, pH, residence time, supply of nutritive medium reproducing the composition of ileal effluents, therefore enabling the study of a complex and metabolically active gut microbiota under anaerobiosis conditions. In these fermentation models, the bioreactors can be inoculated with fresh or frozen stools provided by individual or pool of different donors being healthy human volunteers with no history of antibiotic treatment 2 to 6 months before the beginning of the study.

Introduction of mucus carriers in human in vitro colonic models. Mucins in solution have been frequently included in these colonic models to provide a nutrient source to the gut bacteria, but the study of mucus colonisation by gut bacteria in these systems has been revolutionized by the ability to simulate the viscoelastic gel-like nature of the mucus layer through the incorporation of mucus carriers (Gibson *et al.*, 1988, Macfarlane *et al.*, 1989,

Macfarlane *et al.*, 2005, Van Herreweghen *et al.*, 2017). MacFarlane first demonstrated a rapid colonisation of an agar-mucus layer during a 48-hour incubation in a two-stage continuous fermentor system by a mixture of *Bacteroides*, enterobacteria and facultative anaerobes (Macfarlane *et al.*, 2005). However, the use of glass tubes, containing this agar-mucus layer, in this set-up did not permit a practical long-term implementation (Van den Abbeele *et al.*, 2009). Mucus-coated beads (mixture of 5% porcine mucin type II and 1% agar) have since been identified as crucial platforms in sustaining microbial diversity by selectively enriching species, which are not thriving in the luminal environment. This mucus interphase was introduced in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME) resulting in the M-SHIME (Mucus SHIME) configuration (Van den Abbeele *et al.*, 2012). This system was first used to assess the fitness of potential probiotic lactobacilli, revealing a pronounced enrichment of *Lactobacillus mucosae* and *L. rhamnosus* GG in the mucus beads compared to the luminal environment, contributing to their long-term persistence in M-SHIME (Van den Abbeele *et al.*, 2012). The use of next-generation 16S rRNA gene amplicon sequencing methods and the incorporation of mucus beads in both proximal and distal colon conditions in the M-SHIME, further resulted in the detection of several additional mucus-associated species (De Paepe *et al.*, 2018). Besides *Roseburia faecis*/*Enterococcus rectale*, a strong enrichment of *Ruminococcus inulinivorans*, *Clostridium*, *Bilophila*, *Anaeroglobus* and *Veillonellaceae* species was observed in the proximal mucus layer compared to the lumen (De Paepe *et al.*, 2018). *A. muciniphila*, *Cloacibacillus evryensis*, *Pyramidobacter piscolens*, *Eubacterium contortum* and species belonging to *Odoribacter*, *Enterobacteriaceae* and *Desulfovibrio* were predominantly residing in the distal mucus layer (De Paepe *et al.*, 2018). It can be expected that the list of species inhabiting the mucus layer will continue to expand in the future M-SHIME experiments, by continuing to explore the inter-individual variability of faecal samples.

Another major advantage of *in vitro* fermentation models is the possibility to capture dynamics by time-resolved analyses. To minimize disturbance of the system during such analyses, the M-SHIME system was adapted to facilitate a rapid, anaerobic, frequent sampling by mounting sampling ports with an airlock system on top of the SHIME lids. These sampling ports moreover enable the anaerobic addition, transfer and sampling of any insoluble dietary substrate. The adapted model was correspondingly termed Dietary Particle-Mucosal-Simulator of the Human Intestinal Microbial Ecosystem (DP-M-SHIME). The DP-M-SHIME offers a closer proxy for the diversity of *in vivo* GI microenvironments, as aside from the mucus layer, insoluble dietary particles present an interesting additional niche for microorganisms to physically interact with and colonise (De Paepe *et al.* 2018).

In addition, these colonic *in vitro* fermentation models enable the study of severe gut microbiome perturbations such as antibiotic therapy or pathogen invasion, which cannot be performed in humans for obvious ethical reasons. Using M-SHIME, the mucus bead carriers were shown to confer resilience to lactobacilli species against a combined treatment of antibiotics including tetracycline, amoxicillin and ciprofloxacin (Van den Abbeele *et al.*, 2012). In addition, the M-SHIME model has been used to demonstrate the antagonistic effects of probiotics and prebiotics such as *L. reuteri*, long-chain arabinoxylans or inulin towards AIEC colonisation in the mucosal environment (Van den Abbeele *et al.*, 2016). Another study reported the importance of mucus for providing a protective environment to beneficial gut microbes, such as *L. reuteri*, to help them escape from stress induced by high loads of linoleic acid, the most common polyunsaturated fatty acid in a WSD (De Weirdt *et al.*, 2013). The M-SHIME model has also been shown to preserve disease signatures, as illustrated by a reduced luminal and mucosal *Clostridium* cluster XIVa colonisation in colon vessels inoculated with the faecal material of ulcerative colitis patients compared to healthy donors (Vermeiren *et al.*, 2012). The mucin-beads technology has recently been transferred into the Artificial Colon

(ARCOL), with adaptations to avoid flushing the bioreactor with nitrogen when mucin-coated beads are being renewed (Cordonnier *et al.*, 2015, Thevenot *et al.*, 2015) .

Combining colon fermentation models with in vitro cell culture. Recent advancements in the field of *in vitro* fermentation involve the combination of gut microbiota models with a host compartment to assess host-microbiota interactions (Bahrami *et al.*, 2011, Marzorati *et al.*, 2014, Defois *et al.*, 2018). The three-way interactions between host, microbiome and dietary interventions can be examined by applying the supernatants of colonic samples onto human cell lines or combinations thereof, such as co-cultures of enterocytes and immune cells, in Transwell systems (Marzorati *et al.*, 2014). Cytokine and TNF- α production are followed up as markers of intestinal inflammation, whereas the trans-epithelial electrical resistance (TEER) and Lucifer yellow translocation give an indication of epithelial barrier function (Geirnaert *et al.*, 2017). While typically, in human cell line experiments, the short-term effects of a single treatment application onto differentiated cells with a disrupted barrier are being evaluated, recently, a method was developed to test the effects of a probiotic treatment on the development of epithelial barrier integrity during cell differentiation, which is more representative of the *in vivo* situation (Geirnaert *et al.*, 2017). In order to further improve the *in vivo* relevance, a host module, such as the Host Microbiota Interaction (HMI) Module (Marzorati *et al.*, 2014), can be coupled to the colonic *in vitro* fermentation systems described above to directly and continuously recirculate the colonic microbial suspension over a mucus layer that is in indirect contact with enterocytes and/or immune cells.

4.5. In vivo animal models

As described above, *in vitro* mucin-secreting cell cultures, *ex-vivo* organ cultures as well as *in vitro* fermentation models have yielded fundamental insights into the role of mucins and mucus in bacterial interactions with the host. However, the use of *in vivo* models is necessary to study the biological roles of mucins under physiological or pathological conditions at the level of entire organism. Genetically modified mouse models with an impaired mucin production or glycosylation have been developed to assess the role of mucus in the interaction between gut bacteria and the host *in vivo*.

***Muc2*^{-/-} mouse model.** Many *in vivo* animal studies investigating the role of mucus in gut homeostasis have relied on the use of *Muc2*^{-/-} mice, lacking the major intestinal mucin Muc2. The first studies based on *Muc2*^{-/-} mice showed that these animals displayed an impaired epithelial barrier function characterised by aberrant intestinal crypt morphology and altered cell maturation and migration, and that the mice frequently developed adenomas in the small intestine, as well as rectal tumours (Velcich *et al.*, 2002). The microscopic analysis of the colon indicated mucosal thickening, increased proliferation and superficial erosions (Van der Sluis *et al.*, 2006). The development of spontaneous colitis in Muc2 deficient mice indicated that Muc2 is critical for colonic protection (Van der Sluis *et al.*, 2006). A gut microbiota dysbiosis was also observed in the *Muc2*^{-/-} mice which harbored a pro-inflammatory-like microbiota profile, characterized by an increase in *Clostridiales* and a decrease in *Lactobacillaceae* (Huang *et al.*, 2015). Furthermore, it was shown that the spatial compartmentalization of bacteria in the intestine of *Muc2*^{-/-} mice was compromised and transcriptomic analysis revealed a downregulation of TLR, immune and chemokine signaling pathways compared to wild type mice (Sovran *et al.*, 2015). Also, the expression of the network of IL-22-regulated defense genes was increased in *Muc2*^{-/-} mice (Sovran *et al.*, 2015). Recent work also confirmed a clear shift in the microbiota composition of *Muc2*^{-/-} mice, with

the Firmicutes phylum enriched and the Bacteroidetes phylum decreased, as well as an increase in genera considered as potential pathogens also (Wu *et al.*, 2018).

Muc2^{-/-} mice have been used to test the effect of the probiotic mixture VSL#3 on colonic inflammation and intestinal barrier function (Kumar *et al.*, 2017). This probiotic mixture contains eight strains belonging to *Lactobacillus*, *Bifidobacterium* and *Streptococcus* genera which are usually found in the human intestinal microbiota. In *Muc2*^{-/-} mice, VSL#3 reduced basal colonic proinflammatory cytokine levels and improved epithelial barrier function. In addition, VSL#3 reduced the level of proinflammatory chemokines and upregulated tissue regeneration growth factors leading to a faster resolution of colitis symptoms in *Muc2*^{-/-} mice with DSS-induced colitis. This was associated with the restoration of antimicrobial peptide gene expression in the small intestine, and an increased abundance of commensal bacteria in the gut. The authors proposed that these beneficial effects were mediated by acetate, produced by the gut bacteria (Kumar *et al.*, 2017). Treatment of *Muc2*^{-/-} mice with *Lactobacillus* spp. could ameliorate spontaneous colitis and led to an increased production of SCFA (Morampudi *et al.*, 2016).

Muc2^{-/-} mice have also been used to investigate the role of this mucin to prevent bacterial and parasite infection. Upon infection with *C. rodentium*, a murine pathogen related to diarrhoeagenic attaching-effacing *E. coli*, *Muc2*^{-/-} mice exhibited a rapid weight loss and up to 90% mortality (Bergstrom *et al.*, 2010). Mucin secretion was increased in wild type mice during infection as compared to the uninfected controls, suggesting that mucin production is critical to clear the mucosal surface from pathogenic bacteria. In *Muc2*^{-/-} mice, commensal bacteria were also found to interact with *C. rodentium* and host tissues, indicating that Muc2 regulates all forms of intestinal microbiota at the gut surface (Bergstrom *et al.*, 2010). When *Muc2*^{-/-} mice were infected with *Salmonella*, they showed a dramatic susceptibility to infection, carrying significantly higher caecal and liver pathogen burdens, and developing

1247 significantly higher barrier disruption and higher mortality rates than wild type mice
1248 (Zarepour *et al.*, 2013). Colonisation of *Muc2*^{-/-} mice by enterotoxigenic *B. fragilis*, a
1249 causative agent of acute diarrhoea in humans, led to lethal disease (Hecht *et al.*, 2017). The
1250 protective function of Muc2 was also demonstrated in models of *T. muris* parasitic infection
1251 (Hasnain *et al.*, 2010). *T. muris* is a murine infecting nematode which is used as model of *T.*
1252 *trichiura* infection in humans, a threat in developing countries. After infection, *Muc2*^{-/-} mice
1253 showed a delayed expulsion of the worms from the intestine compared to wild type mice. In
1254 addition, an increase in Muc2 production, observed exclusively in resistant mice, correlated
1255 with worm expulsion. The nematodes demonstrated a decrease in their energy status in wild
1256 type mice compared to the susceptible *Muc2*^{-/-} mice (Hasnain *et al.*, 2010). *E. histolytica* is a
1257 human parasite infecting the colon and responsible of amoebic dysentery and/or liver
1258 abscesses. *E. histolytica* specifically colonises the mucus layer by adhering to galactose and
1259 GalNAc residues present in Muc2 (Kissoon-Singh *et al.*, 2013). The parasite also induces
1260 potent hypersecretion from goblet cells. Kissoon-Singh and colleagues showed that *E.*
1261 *histolytica* induced a pronounced time-dependent secretory exudate with increased gross
1262 pathology scores and serum albumin leakage in *Muc2*^{-/-} mice. Colonic pathology, secretory
1263 responses, and increased pro-inflammatory cytokine secretions were also correlated with
1264 altered expression of tight junction proteins (Kissoon-Singh *et al.*, 2013). These results
1265 demonstrate that colonic mucins confer both luminal and epithelial barrier functions and that,
1266 in the absence of Muc2, mice are more susceptible to *E. histolytica*-induced secretory and
1267 pro-inflammatory responses. A recent study using antibiotic treated *Muc2*^{-/-} and *Muc2*^{+/+}
1268 littermates showed that *E. histolytica* elicited robust mucus and water secretions, enhanced
1269 pro-inflammatory cytokines and chemokine expression and higher pathology scores as
1270 compared to the modest response observed in non-antibiotic treated littermates. Host
1271 responses were microbiota specific as mucus secretion and pro-inflammatory responses were

attenuated following homologous faecal microbial transplants in antibiotic-treated *Muc2*^{+/+} quantified by secretion of ³H-glucosamine newly synthesized mucin, Muc2 mucin immunostaining and immunohistochemistry (Leon-Coria *et al.*, 2018). The mechanism controlling mucus release in the presence of *E. histolytica* was further studied by Cornick and colleagues who identified vesicle-associated membrane protein 8 (VAMP8) present on mucin granules as orchestrating regulated exocytosis in human goblet cells in response to the presence of *E. histolytica* (Cornick *et al.*, 2017). In *Vamp8*^{-/-} mice, *E. histolytica* induced enhanced killing of epithelial cells and aggressive proinflammatory response with elevated levels of IL-1 α , IL-1 β , and TNF- α secretion, highlighting the downstream consequences of improper mucin secretion in mucosal barrier defence. Taken together, these results demonstrate the critical involvement of Muc2 in host protection from nematode infection, by constituting an effective physical and biological barrier against pathogenic infection.

***Muc1*^{-/-} mouse model.** Mice impaired in the production of cell surface mucins have also been engineered. The *Muc1*^{-/-} mouse model revealed the role played by Muc1 in *H. pylori* infection, a pathogen involved in gastric ulcers and adenocarcinoma (McGuckin *et al.*, 2007, Linden *et al.*, 2009). *Muc1*^{-/-} mice displayed a 5-fold increase in *H. pylori* colonisation as compared to wild type mice (McGuckin *et al.*, 2007). This study further demonstrated the ability of *H. pylori* to bind to purified Muc1 *in vitro*, suggesting that Muc1 limits the access of *H. pylori* to the epithelial surface thereby providing protection from infection and proinflammatory bacterial products. Muc1 deficiency also resulted in increased epithelial cell apoptosis in *H. pylori* infected mice (Linden *et al.*, 2009). More recently, the long-term consequence of Muc1 deficiency on *H. pylori* pathogenesis was investigated in *Muc1*^{-/-} mice (Ng *et al.*, 2016). *Muc1*^{-/-} mice began to die 6 months after *H. pylori* challenge, indicating that a deficiency in Muc1 leads to lethal infection. This study also revealed that *Muc1* was an

important, previously unidentified negative regulator of the NLRP3 inflammasome, and loss of this regulation resulted in the development of severe pathology (Ng *et al.*, 2016). Consistent with these studies, *Muc1^{-/-}* mice have a higher rate of systemic infection in a murine *C. jejuni* model of gastroenteritis (McAuley *et al.*, 2007).

Muc13^{-/-} mouse model. The MUC13 transmembrane mucin is highly and constitutively expressed in the small and large intestines and MUC13 polymorphisms have been associated with human IBD and susceptibility to *E. coli* infection in pigs. While Muc13-deficient mice did not show intestinal pathology, they developed more severe acute colitis than wild type mice after DSS challenge, as reflected by increased weight loss, rectal bleeding, diarrhoea and histological colitis scores (Sheng *et al.*, 2011).

Mouse models with an altered mucin glycosylation. Loss of *O*-glycans impairs the expression and function of several intestinal mucins, thereafter causing more profound defects in the function of the intestinal barrier than a flaw caused by the deficiency of an individual mucin. A number of transgenic mouse models have been developed to decipher the mechanisms underpinning the role of mucin glycosylation in gut homeostasis. Mice lacking core 3–derived *O*-glycans (also known as *C3GnT^{-/-}* mice) display a substantial reduction of Muc2 protein and an increased susceptibility to DSS-induced colitis and accelerated colorectal tumorigenesis (An *et al.*, 2007). In addition, core 3 *O*-glycosylation was shown to play a major role in controlling Salmonella intestinal burdens in *C3GnT^{-/-}* mice (Zarepour *et al.*, 2013). Similarly, *C2GnT2^{-/-}* mice (mice lacking core 2-derived *O*-glycans) displayed an increased susceptibility to DSS-induced colitis but with no change in Muc2 expression (Stone *et al.*, 2009). Mice with intestinal epithelial cell–specific deficiency of core 1–derived *O*-glycans (IEC *C1galt1^{-/-}*) develop spontaneous colitis (Fu *et al.*, 2011). Mice lacking both core

1- and core 3–derived *O*-glycans (DKO mice) have an impaired mucus barrier function and develop colitis-associated colon cancer in which the dysbiotic microbiota promote inflammation and cancer (Bergstrom *et al.*, 2016). In a water avoidance model in rats, psychological stress lead to less-protective mucus layer. In particular, *O*-glycosylation of mucins was strongly affected and these changes were associated with flattening and loss of the mucus layer cohesive properties (Da Silva *et al.*, 2014). Altogether, these data suggest that the lack of a proper *O*-glycosylation impairs Muc2 expression or secretion and alters gut barrier function of the mucus layer.

In addition to modifications of mucin core glycans, mouse models have been developed targeting epitope modifications of the mucin glycans chains. Dawson and colleagues reported that deletion of the sulfate transporter NaS1 in mice (*Nas1*^{-/-} mice) resulting in a decrease in mucin sulfation, enhanced susceptibility to experimental DSS colitis and systemic infection by *C. jejuni* (Dawson *et al.*, 2009). In addition, mice with a deletion of the sulfo-transferase GlcNAc6ST2 enzyme adding sulfate to GlcNAC residues on *O*-mucin glycan chains exhibited an increased susceptibility to DSS-induced colitis (Tobisawa *et al.*, 2010). Mice deleted for Sat-1 (sulphate anion transporter-1) were more susceptible to chronic infection by parasite *T. muris* (Hasnain *et al.*, 2017). Collectively, these findings indicate that mucin abnormalities can initiate the onset of inflammatory related diseases in the gut.

In addition to mice harbouring a deletion in genes encoding proteins directly involved in mucin expression or glycosylation, several transgenic mouse models have been shown to display alterations in mucus properties. These include the Winnie and Eeyore mice which carry single missense mutations in two different D-domains of Muc2 (Heazlewood *et al.*, 2008). These mice display fewer goblet cells and a reduction in secreted mucus with *O*-glycosylated and non-*O*-glycosylated Muc2. The misfolding results in endoplasmic reticulum stress, goblet cell apoptosis, depletion of the secreted mucus layer and development of

chronic intestinal inflammation (Heazlewood *et al.*, 2008). In combination with mucus, a large population of intraepithelial lymphocytes (IELs) bearing the $\gamma\delta$ T cell receptor is mediating immune protection against invading bacteria. In $\gamma\delta$ T-cell-deficient ($TCR\delta^{-/-}$) mice, mucin expression and glycosylation is altered, mucus-secreting goblet cells are significantly reduced in number and those animals are more prone to DSS-induced colitis (Kober *et al.*, 2014). Mouse models deficient in TLR5, IL-10 and Sodium hydrogen antiporter 3 (Slc9a3 or Nhe3) revealed bacteria in contact with the epithelium. Additional analysis of the less inflamed $IL-10^{-/-}$ mice revealed a thicker mucus layer but a more penetrable inner mucus allowing bacteria to penetrate and reach the epithelium (Johansson *et al.*, 2014).

Non-rodent models. Differences in mucus thickness and composition have been observed between rats, pigs and rabbits, and suggests that the pig mucus pattern resembles more closely that of humans (Varum *et al.*, 2012). The zebrafish larva is an emerging model system for investigating components of the innate immune system, including mucus physiology. It has been shown that five gel-forming secreted mucin genes are found in zebrafish with a high degree of homology to other vertebrate mucins regarding their genomic and protein domain organisation, as well as their tissue specific expression (Jevtov *et al.*, 2014).

5. Limitations of current experimental models involving mucus and future challenges

Given the importance of the gut microbiota as a modulator of health and disease, increasing attention has been devoted to the role played by mucus in the interaction with gut bacteria (Juge, 2019). As described above (section 4), various experimental models increasing in complexity from simple *in vitro* assays to cell lines, organ-on-chips, *in vitro* colon fermentation systems or animal models have been developed and successfully applied to the

study of gut microbe-mucus interactions. However, one of the limitations common to most *in vitro* models is the origin of mucins used to assess the interactions with bacteria doubled by the inability to reproduce a colonic mucus gel recapitulating the *in vivo* situation. This is important as the nature and origin of purified mucins used in these assays greatly influence the outcome of binding as demonstrated using microtitre plate (Owen *et al.*, 2017), dot-blot (Ringot-Destrez *et al.*, 2018) or mucin microarrays (Clyne *et al.*, 2017). Mucin glycosylation plays a critical role in the interaction between gut bacteria and mucus and significant glycosylation differences occur between purified mucins used in *in vitro* assays from different sites of the murine GI tract or from goblet cells (e.g. LS174T), as analysed by mass spectrometry (Leclaire *et al.*, 2018, Ringot-Destrez *et al.*, 2018). In addition, the purification steps alter the properties of native glycoproteins and purified mucins used in these assays lack the ability to form viscoelastic hydrogels (Kocevar-Nared *et al.*, 1997). A similar situation occurs with mucus secreting cell lines where the type of mucins and structure of mucus differ from the colonic environment. For example, the HT29 cell line secretes mostly MUC5AC whereas MUC2 is the main mucin secreted in the small and large intestines. These differences are due to the use of cancer cells which show an alteration in the expression and glycosylation of mucins. In addition, the production of mucus by epithelial cell lines can be influenced by culture conditions. For example, growing cells on Transwell filters with a small amount of apical medium (semi-wet interface culture) in combination with mechanical stimulation (on a rocking platform) and addition of the Notch γ -secretase inhibitor DAPT resulted in polarisation and secretion of MUC2 and MUC5AC by HT29 MTX-P8, HT29 MTX-E12 and LS513 cells (Navabi *et al.*, 2013). Additionally, the mucus produced by goblet cells in *in vitro* co-culture cell models is not continuous nor homogenate which is not fully representative of the *in vivo* situation. Lastly, the formation of the bi-layered mucus found in the colon remains a challenge in these models. Novel strategies such as multiple cell layers, 2D-organoid

techniques or Organ-on-a-Chip devices are currently being developed to better mimic the human intestinal epithelial microenvironment. Such multiple cell models exhibit intestinal villus morphogenesis associated with mucus production. These models are also needed to recapitulate antimicrobial defense and inflammatory reactions normally occurring in mucosal tissues. Another advantage of these systems is that, unlike cell lines, organoids can be used to evaluate long-term interactions between mucus and gut microbes. However, these more advanced biopsy-based models remain low throughput and expensive as compared to *in vitro* assays and are limited by the availability and variability of clinical specimens.

In addition, to the host side, several microbial factors must be taken into consideration when assaying the interactions between the gut bacteria and mucus. These include the handling and labelling microbial cells which may affect the surface molecular determinants potentially involved in mucus/mucin interactions (e.g. cell-surface adhesins, pili or flagella) (Chagnot *et al.*, 2014). The growth conditions (e.g. growth media with different nutrient compositions; temperature, pH, osmolality or redox potential) can also influence the expression of the bacterial receptors mediating the interactions with mucins. To date, most studies have focused on the interactions between mucus and probiotic or pathogenic strains and assessing strictly anaerobe gut symbionts or complex microbial communities remain a challenge in this field of research.

An alternative to the systems described above is the use of dynamic *in vitro* fermentation models of the human gut, such as the M-SHIME (Marzorati *et al.*, 2014) or DP-M-SHIME (De Paepe *et al.*, 2018) models. In these *in vitro* colonic models, the introduction of mucin-covered beads allows to study the long-term *in vitro* microbial colonisation of mucin, in the presence of a complex anaerobic intestinal microbiota (Marzorati *et al.*, 2014, Shah *et al.*, 2016). These models provide a mean to study gut microbiota functionality and niche differentiation, during treatments with xenobiotics (for example antibiotics, synthetic

chemicals such as food additives, environmental pollutants like persistent organic pollutants (POPs)), pathogens or functional foods. Future developments in this field will be the introduction of mucus secretion and/or a mucus surface layer in dynamic *in vitro* models of the upper GI tract, such as in the gastric and small intestinal TNO Gastro-Intestinal model (TIM) (Guerra *et al.*, 2012). This is important so to take into account the successive stressful events (e.g. acidic gastric pH, bile salts) that commensal or pathogenic microbes undergo in the human GI tract before reaching the intestinal epithelium and that may greatly influence their physiological stage, virulence and/or activity.

However, as mentioned above, a limitation of these *in vitro* GI models is that they rely on commercially available mucins used for the mucin bead technology. These secretory mucins, usually MUC5AC and MUC6 porcine gut gastric mucin, differ in terms of structure and glycosylation from intestinal MUC2 and cannot form a bi-layered mucus gel. It has been proposed that in the future, *in vitro* engineered mucus may be used to mimic human-derived mucus in a more reproducible manner. The colonic *in vitro* models could also be improved by including immunoglobulins, specific antimicrobial peptides, or secreted phosphatidylcholine, which have been shown to modulate mucus surface properties, thereby influencing bacterial adhesion (Martens *et al.*, 2018). Future *in vitro* colon models should also better mimic the *in vivo* transit, and particularly retrograde movements (Hiroz *et al.*, 2009), as back-flow was recently suggested to be crucial for the persistence of gut microbes in the GI tract (Cremer *et al.*, 2016). Current technological advances include the coupling of these fermentation models to intestinal epithelial cells or more complex units such as the HMI module. A next step will be to couple the digestive/fermentation models with enteroids/colonoids or HIO. However, despite their increased complexity, most of these approaches remain limited by the absence of important host functions, such as variable peristalsis-like motions. This is a critical limitation because mechanical deformations resulting from peristalsis both influence normal epithelial

cell differentiation and control microbial overgrowth in the living intestine (Gayer & Basson, 2009, Benam *et al.*, 2015). The development of microfluidic systems and organ-on-chips is currently addressing this important technological gap (Kim & Ingber, 2013, Kim *et al.*, 2016).

The development of these advanced *in vitro* systems is essential to help reduce dependence on animal studies. Due to the invasive nature of the experiments, the mechanisms underpinning microbe-mucus interactions *in vivo* have mainly been investigated in animal models, mostly rodents. Genetically engineered mice impaired in mucin secretion or glycosylation have been instrumental to decipher the role of mucins and mucus in the protection of the intestinal epithelium and the interactions between pathogenic bacteria, commensal microbiota and the mucus barrier. However, although the domain organisation and expression pattern of mucins appear largely conserved between human and mouse (Joshi *et al.*, 2015), mucin glycosylation (Thomsson *et al.*, 2012) and gut microbiota (Nguyen *et al.*, 2015) differ between these two species. It has been speculated that differences in mucin glycosylation between mammalian species may underlie some of the differences in infectivity and/or pathogenicity for individual microbial pathogens (Linden *et al.*, 2008) or the different commensal microbiota (Thomsson *et al.*, 2012). Therefore, caution should be applied when translating data obtained in mouse models to humans. Lastly, unlike *in vitro* assays, *in vivo* studies are restricted to end-point measurements.

Recent years have witnessed unprecedented technological advances in the development of *in vitro* GI models that more closely resemble the gut mucosal interface. Our next challenge will be to simulate these models at different stages of development or disease conditions (e.g. IBD, obesity or CF). Special attention should be paid to inter-individual differences and intra-individual variability in gut microbiota composition and intestinal biopsies from different donors or patients. This is important to better understand the role of gut microbe-mucus interactions in the aetiology of a particular disease or condition and

1472 determine the microbial and biochemical signature that could differentiate between diseased
1473 or healthy status. In particular, more research is warranted to determine how the
1474 physicochemical properties and/or thickness of the mucus layer and mucin glycosylation are
1475 altered during a specific disease. In the future, these pre-clinical models will help screen novel
1476 therapeutic strategies aimed at restoring gut barrier function and tailored to the individual
1477 patient as a step towards personalised medicine.

1478

1479 **Conflicts of interest.** None declared.

1480

1481 REFERENCES

- 1482 Abreu AG & Barbosa AS (2017) How Escherichia coli Circumvent Complement-Mediated Killing. *Front*
1483 *Immunol* **8**: 452.
- 1484 Abyzov A, Mariani J, Palejev D, *et al.* (2012) Somatic copy number mosaicism in human skin revealed by
1485 induced pluripotent stem cells. *Nature* **492**: 438-442.
- 1486 Albenberg L, Esipova TV, Judge CP, *et al.* (2014) Correlation between intraluminal oxygen gradient and radial
1487 partitioning of intestinal microbiota. *Gastroenterology* **147**: 1055-1063 e1058.
- 1488 Aleksandrak-Piekarczyk T, Koryszewska-Baginska A, Grynberg M, Nowak A, Cukrowska B, Kozakova H &
1489 Bardowski J (2015) Genomic and Functional Characterization of the Unusual pLOCK 0919 Plasmid Harboring
1490 the spaCBA Pili Cluster in Lactobacillus casei LOCK 0919. *Genome Biol Evol* **8**: 202-217.
- 1491 Alemka A, Clyne M, Shanahan F, Tompkins T, Corcionivoschi N & Bourke B (2010) Probiotic colonization of
1492 the adherent mucus layer of HT29MTXE12 cells attenuates Campylobacter jejuni virulence properties. *Infect*
1493 *Immunol* **78**: 2812-2822.
- 1494 Allais L, Kerckhof FM, Verschuere S, *et al.* (2016) Chronic cigarette smoke exposure induces microbial and
1495 inflammatory shifts and mucin changes in the murine gut. *Environ Microbiol* **18**: 1352-1363.
- 1496 Allison C, McFarlan C & MacFarlane GT (1989) Studies on mixed populations of human intestinal bacteria
1497 grown in single-stage and multistage continuous culture systems. *Appl Environ Microbiol* **55**: 672-678.
- 1498 Alvarez RA, Blaylock MW & Baseman JB (2003) Surface localized glyceraldehyde-3-phosphate dehydrogenase
1499 of Mycoplasma genitalium binds mucin. *Mol Microbiol* **48**: 1417-1425.
- 1500 An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, Braun J & Xia L (2007) Increased susceptibility to
1501 colitis and colorectal tumors in mice lacking core 3-derived O-glycans. *J Exp Med* **204**: 1417-1429.
- 1502 Andrade JA, Freymuller E & Fagundes-Neto U (2011) Adherence of enteroaggregative Escherichia coli to the
1503 ileal and colonic mucosa: an in vitro study utilizing the scanning electron microscopy. *Arquivos de*
1504 *gastroenterologia* **48**: 199-204.
- 1505 Arabyan N, Park D, Foutouhi S, *et al.* (2016) Salmonella Degrades the Host Glycocalyx Leading to Altered
1506 Infection and Glycan Remodeling. *Sci Rep* **6**: 29525.
- 1507 Arike L & Hansson GC (2016) The Densely O-Glycosylated MUC2 Mucin Protects the Intestine and Provides
1508 Food for the Commensal Bacteria. *J Mol Biol* **428**: 3221-3229.
- 1509 Arike L, Holmen-Larsson J & Hansson GC (2017) Intestinal Muc2 mucin O-glycosylation is affected by
1510 microbiota and regulated by differential expression of glycosyltransferases. *Glycobiology* **27**: 318-328.
- 1511 Artis D & Grencis RK (2008) The intestinal epithelium: sensors to effectors in nematode infection. *Mucosal*
1512 *Immunol* **1**: 252-264.
- 1513 Atuma C, Strugala V, Allen A & Holm L (2001) The adherent gastrointestinal mucus gel layer: thickness and
1514 physical state in vivo. *Am J Physiol Gastrointest Liver Physiol* **280**: G922-929.
- 1515 Azeredo J, Azevedo NF, Briandet R, *et al.* (2017) Critical review on biofilm methods. *Crit Rev Microbiol* **43**:
1516 313-351.
- 1517 Bahrami B, Child MW, Macfarlane S & Macfarlane GT (2011) Adherence and cytokine induction in Caco-2
1518 cells by bacterial populations from a three-stage continuous-culture model of the large intestine. *Appl Environ*
1519 *Microbiol* **77**: 2934-2942.
- 1520 Baker DR, Moxley RA & Francis DH (1997) Variation in virulence in the gnotobiotic pig model of O157:H7
1521 Escherichia coli strains of bovine and human origin. *AdvExpMedBiol* **412**: 53-58.
- 1522 Bansil R & Turner BS (2018) The biology of mucus: Composition, synthesis and organization. *Adv Drug Deliv*
1523 *Rev* **124**: 3-15.
- 1524 Barketi-Klai A, Hoys S, Lambert-Bordes S, Collignon A & Kansau I (2011) Role of fibronectin-binding protein
1525 A in Clostridium difficile intestinal colonization. *J Med Microbiol* **60**: 1155-1161.
- 1526 Beduneau A, Tempesta C, Fimbel S, Pellequer Y, Jannin V, Demarne F & Lamprecht A (2014) A tunable Caco-
1527 2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original
1528 seeding procedure. *European journal of pharmaceuticals and biopharmaceutics : official journal of*
1529 *Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik eV* **87**: 290-298.
- 1530 Behrens I, Stenberg P, Artursson P & Kissel T (2001) Transport of lipophilic drug molecules in a new mucus-
1531 secreting cell culture model based on HT29-MTX cells. *Pharm Res* **18**.
- 1532 Bellu R, Gagliardi L, Tagliabue P, Corchia C, Vendettuoli V, Mosca F, Zanini R & Italian Neonatal N (2013)
1533 Survey of neonatal respiratory care and surfactant administration in very preterm infants in the Italian Neonatal
1534 Network. *Acta Biomed* **84 Suppl 1**: 7-11.
- 1535 Belzer C, Chia LW, Aalvink S, Chamlagain B, Piironen V, Knol J & de Vos WM (2017) Microbial Metabolic
1536 Networks at the Mucus Layer Lead to Diet-Independent Butyrate and Vitamin B12 Production by Intestinal
1537 Symbionts. *MBio* **8**.
- 1538 Benam KH, Dauth S, Hassell B, *et al.* (2015) Engineered in vitro disease models. *Annu Rev Pathol* **10**: 195-262.

1539 Bene KP, Kavanaugh DW, Leclaire C, Gunning AP, MacKenzie DA, Wittmann A, Young ID, Kawasaki N,
1540 Rajnavolgyi E & Juge N (2017) Lactobacillus reuteri Surface Mucus Adhesins Upregulate Inflammatory
1541 Responses Through Interactions With Innate C-Type Lectin Receptors. *Front Microbiol* **8**: 321.
1542 Benjdia A, Martens EC, Gordon JI & Berteau O (2011) Sulfatases and a radical S-adenosyl-L-methionine
1543 (AdoMet) enzyme are key for mucosal foraging and fitness of the prominent human gut symbiont, Bacteroides
1544 thetaiotaomicron. *J Biol Chem* **286**: 25973-25982.
1545 Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA & Tabak LA (2012) Control of mucin-type O-
1546 glycosylation: a classification of the polypeptide GalNAc-transferase gene family. *Glycobiology* **22**: 736-756.
1547 Bergstrom K, Fu J, Johansson ME, *et al.* (2017) Core 1- and 3-derived O-glycans collectively maintain the
1548 colonic mucus barrier and protect against spontaneous colitis in mice. *Mucosal Immunol* **10**: 91-103.
1549 Bergstrom K, Liu X, Zhao Y, *et al.* (2016) Defective Intestinal Mucin-Type O-Glycosylation Causes
1550 Spontaneous Colitis-Associated Cancer in Mice. *Gastroenterology* **151**: 152-164 e111.
1551 Bergstrom KS & Xia L (2013) Mucin-type O-glycans and their roles in intestinal homeostasis. *Glycobiology* **23**:
1552 1026-1037.
1553 Bergstrom KS, Kisson-Singh V, Gibson DL, *et al.* (2010) Muc2 protects against lethal infectious colitis by
1554 disassociating pathogenic and commensal bacteria from the colonic mucosa. *PLoS Pathog* **6**: e1000902.
1555 Bernet MF, Brassart D, Neeser JR & Servin AL (1993) Adhesion of human bifidobacterial strains to cultured
1556 human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. *Appl Environ Microbiol* **59**:
1557 4121-4128.
1558 Bernet MF, Brassart D, Neeser JR & Servin AL (1994) Lactobacillus acidophilus LA 1 binds to cultured human
1559 intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. *Gut* **35**: 483-489.
1560 Berteau O, Guillot A, Benjdia A & Rabot S (2006) A new type of bacterial sulfatase reveals a novel maturation
1561 pathway in prokaryotes. *J Biol Chem* **281**: 22464-22470.
1562 Bhinder G, Stahl M, Sham HP, Crowley SM, Morampudi V, Dalwadi U, Ma C, Jacobson K & Vallance BA
1563 (2014) Intestinal epithelium-specific MyD88 signaling impacts host susceptibility to infectious colitis by
1564 promoting protective goblet cell and antimicrobial responses. *Infect Immun* **82**: 3753-3763.
1565 Bhowmick R, Ghosal A, Das B, Koley H, Saha DR, Ganguly S, Nandy RK, Bhadra RK & Chatterjee NS (2008)
1566 Intestinal adherence of Vibrio cholerae involves a coordinated interaction between colonization factor GbpA and
1567 mucin. *Infect Immun* **76**: 4968-4977.
1568 Birchenough GM, Nystrom EE, Johansson ME & Hansson GC (2016) A sentinel goblet cell guards the colonic
1569 crypt by triggering Nlrp6-dependent Muc2 secretion. *Science* **352**: 1535-1542.
1570 Blanquet-Diot S, Denis S, Chalancon S, Chaira F, Cardot JM & Alric M (2012) Use of artificial digestive
1571 systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during
1572 gastrointestinal transit in humans. *Pharm Res* **29**: 1444-1453.
1573 Bolonkin VP (1990) [The rationale for the choice of the method of surgical intervention in patients with
1574 mandibular prognathism]. *Stomatologiia (Mosk)* **69**: 46-48.
1575 Bretin A, Gewirtz AT & Chassaing B (2018) Microbiota and metabolism: what's new in 2018? *Am J Physiol*
1576 *Endocrinol Metab* **315**: E1-E6.
1577 Brockhausen I, Schachter H & Stanley P (2009) O-GalNAc Glycans. *Essentials of Glycobiology*, (nd, Varki A,
1578 Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW & Etzler ME, eds.), p. ^pp. Cold Spring
1579 Harbor (NY).
1580 Browning TH & Trier JS (1969) Organ culture of mucosal biopsies of human small intestine. *J Clin Invest* **48**:
1581 1423-1432.
1582 Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, van Goudoever JB, van
1583 Seuningen I & Renes IB (2009) The regulation of intestinal mucin MUC2 expression by short-chain fatty acids:
1584 implications for epithelial protection. *Biochem J* **420**: 211-219.
1585 Burger-van Paassen N, Vincent A, Puiman Patrycja J, van der Sluis M, Bouma J, Boehm G, van Goudoever
1586 Johannes B, van Seuningen I & Renes Ingrid B (2009) The regulation of intestinal mucin MUC2 expression by
1587 short-chain fatty acids: implications for epithelial protection. *Biochemical Journal* **420**: 211-219.
1588 Cameron EA, Curtis MM, Kumar A, Dunne GM & Sperandio V (2018) Microbiota and Pathogen Proteases
1589 Modulate Type III Secretion Activity in Enterohemorrhagic Escherichia coli. *MBio* **9**.
1590 Carvalho FA, Koren O, Goodrich JK, *et al.* (2012) Transient inability to manage proteobacteria promotes
1591 chronic gut inflammation in TLR5-deficient mice. *Cell Host Microbe* **12**: 139-152.
1592 Chagnot C, Listrat A, Astruc T & Desvaux M (2012) Bacterial adhesion to animal tissues: protein determinants
1593 for recognition of extracellular matrix components. *Cell Microbiol* **14**: 1687-1696.
1594 Chagnot C, Agus A, Renier S, Peyrin F, Talon R, Astruc T & Desvaux M (2013) In vitro colonization of the
1595 muscle extracellular matrix components by Escherichia coli O157:H7: the influence of growth medium,
1596 temperature and pH on initial adhesion and induction of biofilm formation by collagens I and III. *PLoS One* **8**:
1597 e59386.

Chagnot C, Caccia N, Loukiadis E, Ganet S, Durand A, Bertin Y, Talon R, Astruc T & Desvaux M (2014) Colonization of the meat extracellular matrix proteins by O157 and non-O157 enterohemorrhagic *Escherichia coli*. *Int J Food Microbiol* **188**: 92-98.

Chassaing B & Gewirtz AT (2019) Identification of Inner Mucus-Associated Bacteria by Laser Capture Microdissection. *Cell Mol Gastroenterol Hepatol* **7**: 157-160.

Chassaing B, Ley RE & Gewirtz AT (2014) Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice. *Gastroenterology* **147**: 1363-1377 e1317.

Chassaing B, Raja SM, Lewis JD, Srinivasan S & Gewirtz AT (2017) Colonic Microbiota Encroachment Correlates With Dysglycemia in Humans. *Cell Mol Gastroenterol Hepatol* **4**: 205-221.

Chassaing B, Van de Wiele T, De Bodt J, Marzorati M & Gewirtz AT (2017) Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. *Gut* **66**: 1414-1427.

Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE & Gewirtz AT (2015) Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. *Nature* **519**: 92-96.

Chassaing B, Miles-Brown J, Pellizzon M, Ulman E, Ricci M, Zhang L, Patterson AD, Vijay-Kumar M & Gewirtz AT (2015) Lack of soluble fiber drives diet-induced adiposity in mice. *Am J Physiol Gastrointest Liver Physiol* **309**: G528-541.

Chatzidaki-Livanis M & Comstock LE (2015) Friend turned foe: a role for bacterial sulfatases in colitis. *Cell Host Microbe* **17**: 540-541.

Chen Y, Zhou W, Roh T, Estes MK & Kaplan DL (2017) In vitro enteroid-derived three-dimensional tissue model of human small intestinal epithelium with innate immune responses. *PLoS One* **12**: e0187880.

Chen Y, Lin Y, Davis KM, Wang Q, Rnjak-Kovacina J, Li C, Isberg RR, Kumamoto CA, Meccas J & Kaplan DL (2015) Robust bioengineered 3D functional human intestinal epithelium. *Scientific Reports* **5**: 13708.

Clyne M, Duggan G, Naughton J & Bourke B (2017) Methods to Assess the Direct Interaction of *C. jejuni* with Mucins. *Methods Mol Biol* **1512**: 107-115.

Coconnier MH, Lievin V, Hemery E & Servin AL (1998) Antagonistic activity against *Helicobacter* infection in vitro and in vivo by the human *Lactobacillus acidophilus* strain LB. *Appl Environ Microbiol* **64**: 4573-4580.

Coconnier MH, Klaenhammer TR, Kerneis S, Bernet MF & Servin AL (1992) Protein-mediated adhesion of *Lactobacillus acidophilus* BG2FO4 on human enterocyte and mucus-secreting cell lines in culture. *Appl Environ Microbiol* **58**: 2034-2039.

Coconnier MH, Dliissi E, Robard M, Laboisie CL, Gaillard JL & Servin AL (1998) *Listeria monocytogenes* stimulates mucus exocytosis in cultured human polarized mucosecreting intestinal cells through action of listeriolysin O. *Infect Immun* **66**: 3673-3681.

Corcionivoschi N, Alvarez LA, Sharp TH, Strengert M, Alemka A, Mantell J, Verkade P, Knaus UG & Bourke B (2012) Mucosal reactive oxygen species decrease virulence by disrupting *Campylobacter jejuni* phosphotyrosine signaling. *Cell Host Microbe* **12**: 47-59.

Cordonnier C, Thevenot J, Etienne-Mesmin L, Denis S, Alric M, Livrelli V & Blanquet-Diot S (2015) Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota. *Microorganisms* **3**: 725-745.

Cornick S, Moreau F, Gaisano HY & Chadee K (2017) *Entamoeba histolytica*-Induced Mucin Exocytosis Is Mediated by VAMP8 and Is Critical in Mucosal Innate Host Defense. *MBio* **8**.

Cremer J, Segota I, Yang CY, Arnoldini M, Sauls JT, Zhang ZG, Gutierrez E, Groisman A & Hwa T (2016) Effect of flow and peristaltic mixing on bacterial growth in a gut-like channel. *P Natl Acad Sci USA* **113**: 11414-11419.

Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M & Finlay BB (2013) Recent advances in understanding enteric pathogenic *Escherichia coli*. *Clinical microbiology reviews* **26**: 822-880.

Da Silva S, Robbe-Masselot C, Ait-Belgnaoui A, et al. (2014) Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment. *Am J Physiol Gastrointest Liver Physiol* **307**: G420-429.

Dague E, Le DT, Zanna S, Marcus P, Loubiere P & Mercier-Bonin M (2010) Probing in vitro interactions between *Lactococcus lactis* and mucins using AFM. *Langmuir* **26**: 11010-11017.

Dawson PA, Huxley S, Gardiner B, Tran T, McAuley JL, Grimmond S, McGuckin MA & Markovich D (2009) Reduced mucin sulfonation and impaired intestinal barrier function in the hyposulfataemic NaS1 null mouse. *Gut* **58**: 910-919.

De Paepe K, Verspreet J, Verbeke K, Raes J, Courtin CM & Van de Wiele T (2018) Introducing insoluble wheat bran as a gut microbiota niche in an in vitro dynamic gut model stimulates propionate and butyrate production and induces colon region specific shifts in the luminal and mucosal microbial community. *Environ Microbiol.*

de Repentigny L, Aumont F, Bernard K & Belhumeur P (2000) Characterization of binding of *Candida albicans* to small intestinal mucin and its role in adherence to mucosal epithelial cells. *Infect Immun* **68**: 3172-3179.

De Weirdt R & Van de Wiele T (2015) Micromanagement in the gut: microenvironmental factors govern colon mucosal biofilm structure and functionality. *NPJ Biofilms Microbiomes* **1**: 15026.

De Weirdt R, Coenen E, Vlaeminck B, Fievez V, Van den Abbeele P & Van de Wiele T (2013) A simulated mucus layer protects *Lactobacillus reuteri* from the inhibitory effects of linoleic acid. *Benef Microbes* **4**: 299-312.

Defois C, Ratel J, Garrait G, Denis S, Le Goff O, Talvas J, Mosoni P, Engel E & Peyret P (2018) Food Chemicals Disrupt Human Gut Microbiota Activity And Impact Intestinal Homeostasis As Revealed By In Vitro Systems. *Sci Rep* **8**: 11006.

Deplancke B & Gaskins HR (2001) Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. *The American journal of clinical nutrition* **73**: 1131s-1141s.

Derrien M, Vaughan EE, Plugge CM & de Vos WM (2004) *Akkermansia muciniphila* gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. *Int J Syst Evol Microbiol* **54**: 1469-1476.

Desai MS, Seekatz AM, Koropatkin NM, et al. (2016) A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* **167**: 1339-1353 e1321.

Desvaux M, Candela T & Serrero P (2018) Surfaceome and Proteosurfaceome in Parietal Monoderm Bacteria: Focus on Protein Cell-Surface Display. *Front Microbiol* **9**: 100.

Dolan B, Naughton J, Tegtmeyer N, May FE & Clyne M (2012) The interaction of *Helicobacter pylori* with the adherent mucus gel layer secreted by polarized HT29-MTX-E12 cells. *PLoS One* **7**: e47300.

Donaldson GP, Lee SM & Mazmanian SK (2016) Gut biogeography of the bacterial microbiota. *Nat Rev Microbiol* **14**: 20-32.

Douillard FP, Ribbera A, Kant R, et al. (2013) Comparative genomic and functional analysis of 100 *Lactobacillus rhamnosus* strains and their comparison with strain GG. *PLoS Genet* **9**: e1003683.

Dunne C, Naughton J, Duggan G, et al. (2018) Binding of *Helicobacter pylori* to Human Gastric Mucins Correlates with Binding of TFF1. *Microorganisms* **6**.

Dutta PR, Cappello R, Navarro-Garcia F & Nataro JP (2002) Functional comparison of serine protease autotransporters of enterobacteriaceae. *Infect Immun* **70**: 7105-7113.

Earle KA, Billings G, Sigal M, Lichtman JS, Hansson GC, Elias JE, Amieva MR, Huang KC & Sonnenburg JL (2015) Quantitative Imaging of Gut Microbiota Spatial Organization. *Cell Host Microbe* **18**: 478-488.

Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE & Relman DA (2005) Diversity of the human intestinal microbial flora. *Science* **308**: 1635-1638.

Egan M, Jiang H, O'Connell Motherway M, Oscarson S & van Sinderen D (2016) Glycosulfatase-Encoding Gene Cluster in *Bifidobacterium breve* UCC2003. *Appl Environ Microbiol* **82**: 6611-6623.

Elderman M, Sovran B, Hugenholtz F, et al. (2017) The effect of age on the intestinal mucus thickness, microbiota composition and immunity in relation to sex in mice. *PLoS One* **12**: e0184274.

Engevik MA, Yacyshyn MB, Engevik KA, Wang J, Darien B, Hassett DJ, Yacyshyn BR & Worrell RT (2015) Human *Clostridium difficile* infection: altered mucus production and composition. *Am J Physiol Gastrointest Liver Physiol* **308**: G510-524.

Erdem AL, Avelino F, Xicohtencatl-Cortes J & Giron JA (2007) Host protein binding and adhesive properties of H6 and H7 flagella of attaching and effacing *Escherichia coli*. *J Bacteriol* **189**: 7426-7435.

Etzold S, MacKenzie DA, Jeffers F, Walshaw J, Roos S, Hemmings AM & Juge N (2014) Structural and molecular insights into novel surface-exposed mucus adhesins from *Lactobacillus reuteri* human strains. *Mol Microbiol* **92**: 543-556.

Etzold S, Kober OI, Mackenzie DA, Tailford LE, Gunning AP, Walshaw J, Hemmings AM & Juge N (2014) Structural basis for adaptation of lactobacilli to gastrointestinal mucus. *Environ Microbiol* **16**: 888-903.

Eveillard M, Fourel V, Barc MC, Kerneis S, Coconnier MH, Karjalainen T, Bourlioux P & Servin AL (1993) Identification and characterization of adhesive factors of *Clostridium difficile* involved in adhesion to human colonic enterocyte-like Caco-2 and mucus-secreting HT29 cells in culture. *Mol Microbiol* **7**: 371-381.

Everard A, Belzer C, Geurts L, et al. (2013) Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* **110**: 9066-9071.

Fabich AJ, Jones SA, Chowdhury FZ, et al. (2008) Comparison of carbon nutrition for pathogenic and commensal *Escherichia coli* strains in the mouse intestine. *Infect Immun* **76**: 1143-1152.

Favre-Bonte S, Joly B & Forestier C (1999) Consequences of reduction of *Klebsiella pneumoniae* capsule expression on interactions of this bacterium with epithelial cells. *Infect Immun* **67**: 554-561.

Fernandez N, Wrzosek L, Radziwill-Bienkowska JM, et al. (2018) Characterization of Mucus-Related Properties of *Streptococcus thermophilus*: From Adhesion to Induction. *Front Physiol* **9**: 980.

Fitzhenry RJ, Pickard DJ, Hartland EL, Reece S, Dougan G, Phillips AD & Frankel G (2002) Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic *Escherichia coli* O157:H7. *Gut* **50**: 180-185.

Flannery A, Gerlach JQ, Joshi L & Kilcoyne M (2015) Assessing Bacterial Interactions Using Carbohydrate-Based Microarrays. *Microarrays (Basel)* **4**: 690-713.

1718 Flint HJ, Scott KP, Louis P & Duncan SH (2012) The role of the gut microbiota in nutrition and health. *Nat Rev*
1719 *Gastro Hepat* **9**: 577-589.

1720 Frese SA, Benson AK, Tannock GW, *et al.* (2011) The evolution of host specialization in the vertebrate gut
1721 symbiont *Lactobacillus reuteri*. *PLoS Genet* **7**: e1001314.

1722 Fu J, Wei B, Wen T, *et al.* (2011) Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice.
1723 *J Clin Invest* **121**: 1657-1666.

1724 Gagnon M, Zihler Berner A, Chervet N, Chassard C & Lacroix C (2013) Comparison of the Caco-2, HT-29 and
1725 the mucus-secreting HT29-MTX intestinal cell models to investigate *Salmonella* adhesion and invasion. *J*
1726 *Microbiol Methods* **94**: 274-279.

1727 Ganguli K, Collado MC, Rautava J, *et al.* (2015) *Lactobacillus rhamnosus* GG and its SpaC pilus adhesin
1728 modulate inflammatory responsiveness and TLR-related gene expression in the fetal human gut. *Pediatr Res* **77**:
1729 528-535.

1730 Gaudier E, Jarry A, Blottiere HM, de Coppet P, Buisine MP, Aubert JP, Laboisie C, Cherbut C & Hoebler C
1731 (2004) Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of
1732 glucose. *Am J Physiol Gastrointest Liver Physiol* **287**: G1168-1174.

1733 Gayer CP & Basson MD (2009) The effects of mechanical forces on intestinal physiology and pathology. *Cell*
1734 *Signal* **21**: 1237-1244.

1735 Geirnaert A, Calatayud M, Grootaert C, Laukens D, Devriese S, Smagghe G, De Vos M, Boon N & Van de
1736 Wiele T (2017) Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota
1737 increased butyrate production and enhanced intestinal epithelial barrier integrity. *Sci Rep-Uk* **7**.

1738 Gerhardt E, Masso M, Paton AW, Paton JC, Zotta E & Ibarra C (2013) Inhibition of water absorption and
1739 selective damage to human colonic mucosa are induced by subtilase cytotoxin produced by *Escherichia coli*
1740 O113:H21. *Infect Immun* **81**: 2931-2937.

1741 Gibold L, Garenaux E, Dalmasso G, *et al.* (2016) The Vat-AIEC protease promotes crossing of the intestinal
1742 mucus layer by Crohn's disease-associated *Escherichia coli*. *Cell Microbiol* **18**: 617-631.

1743 Gibson GR, Cummings JH & Macfarlane GT (1988) Use of a three-stage continuous culture system to study the
1744 effect of mucin on dissimilatory sulfate reduction and methanogenesis by mixed populations of human gut
1745 bacteria. *Appl Environ Microbiol* **54**: 2750-2755.

1746 Gillois K, Leveque M, Theodorou V, Robert H & Mercier-Bonin M (2018) Mucus: An Underestimated Gut
1747 Target for Environmental Pollutants and Food Additives. *Microorganisms* **6**.

1748 Gonzalez-Rodriguez I, Sanchez B, Ruiz L, Turrone F, Ventura M, Ruas-Madiedo P, Gueimonde M & Margolles
1749 A (2012) Role of extracellular transaldolase from *Bifidobacterium bifidum* in mucin adhesion and aggregation.
1750 *Appl Environ Microbiol* **78**: 3992-3998.

1751 Gopal PK, Prasad J, Smart J & Gill HS (2001) In vitro adherence properties of *Lactobacillus rhamnosus* DR20
1752 and *Bifidobacterium lactis* DR10 strains and their antagonistic activity against an enterotoxigenic *Escherichia*
1753 *coli*. *Int J Food Microbiol* **67**: 207-216.

1754 Grant AJ, Woodward J & Maskell DJ (2006) Development of an ex vivo organ culture model using human
1755 gastro-intestinal tissue and *Campylobacter jejuni*. *FEMS Microbiology Letters* **263**: 240-243.

1756 Graziani F, Pujol A, Nicoletti C, Dou S, Maresca M, Giardina T, Fons M & Perrier J (2016) *Ruminococcus*
1757 *gnavus* E1 modulates mucin expression and intestinal glycosylation. *Journal of applied microbiology* **120**: 1403-
1758 1417.

1759 Grys TE, Walters LL & Welch RA (2006) Characterization of the StcE protease activity of *Escherichia coli*
1760 O157:H7. *J Bacteriol* **188**: 4646-4653.

1761 Grys TE, Siegel MB, Latham WW & Welch RA (2005) The StcE protease contributes to intimate adherence of
1762 enterohemorrhagic *Escherichia coli* O157:H7 to host cells. *Infect Immun* **73**: 1295-1303.

1763 Guerra A, Etienne-Mesmin L, Livrelli V, Denis S, Blanquet-Diot S & Alric M (2012) Relevance and challenges
1764 in modeling human gastric and small intestinal digestion. *Trends Biotechnol* **30**: 591-600.

1765 Gunning AP, Kavanaugh D, Thursby E, Etzold S, MacKenzie DA & Juge N (2016) Use of Atomic Force
1766 Microscopy to Study the Multi-Modular Interaction of Bacterial Adhesins to Mucins. *Int J Mol Sci* **17**.

1767 Gusils C, Morata V & Gonzalez S (2004) Determination of bacterial adhesion to intestinal mucus. *Methods Mol*
1768 *Biol* **268**: 411-415.

1769 Haque A, Bowe F, Fitzhenry RJ, *et al.* (2004) Early interactions of *Salmonella enterica* serovar typhimurium
1770 with human small intestinal epithelial explants. *Gut* **53**: 1424-1430.

1771 Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB &
1772 Schnabl B (2016) Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and
1773 obesity. *Am J Physiol Gastrointest Liver Physiol* **310**: G310-322.

1774 Hartmann P, Chen P, Wang HJ, *et al.* (2013) Deficiency of intestinal mucin-2 ameliorates experimental alcoholic
1775 liver disease in mice. *Hepatology* **58**: 108-119.

1776 Hasnain SZ, Dawson PA, Lourie R, Hutson P, Tong H, Grecis RK, McGuckin MA & Thornton DJ (2017)
 1777 Immune-driven alterations in mucin sulphation is an important mediator of *Trichuris muris* helminth expulsion.
 1778 *PLoS Pathog* **13**: e1006218.
 1779 Hasnain SZ, Wang H, Ghia JE, Haq N, Deng Y, Velcich A, Grecis RK, Thornton DJ & Khan WI (2010) Mucin
 1780 gene deficiency in mice impairs host resistance to an enteric parasitic infection. *Gastroenterology* **138**: 1763-
 1781 1771.
 1782 Hay ID, Belousoff MJ, Dunstan RA, Bamert RS & Lithgow T (2018) Structure and Membrane Topography of
 1783 the Vibrio-Type Secretin Complex from the Type 2 Secretion System of Enteropathogenic *Escherichia coli*. *J*
 1784 *Bacteriol* **200**.
 1785 Hayes CL, Dong J, Galipeau HJ, *et al.* (2018) Commensal microbiota induces colonic barrier structure and
 1786 functions that contribute to homeostasis. *Sci Rep* **8**: 14184.
 1787 Heazlewood CK, Cook MC, Eri R, *et al.* (2008) Aberrant mucin assembly in mice causes endoplasmic reticulum
 1788 stress and spontaneous inflammation resembling ulcerative colitis. *PLoS Med* **5**: e54.
 1789 Hecht AL, Casterline BW, Choi VM & Bubeck Wardenburg J (2017) A Two-Component System Regulates
 1790 *Bacteroides fragilis* Toxin to Maintain Intestinal Homeostasis and Prevent Lethal Disease. *Cell Host Microbe* **22**:
 1791 443-448 e445.
 1792 Hedblom GA, Reiland HA, Sylte MJ, Johnson TJ & Baumler DJ (2018) Segmented Filamentous Bacteria -
 1793 Metabolism Meets Immunity. *Front Microbiol* **9**: 1991.
 1794 Henderson B (2014) An overview of protein moonlighting in bacterial infection. *Biochem Soc Trans* **42**: 1720-
 1795 1727.
 1796 Henderson B & Martin A (2011) Bacterial virulence in the moonlight: multitasking bacterial moonlighting
 1797 proteins are virulence determinants in infectious disease. *Infect Immun* **79**: 3476-3491.
 1798 Henderson B & Martin A (2013) Bacterial moonlighting proteins and bacterial virulence. *Curr Top Microbiol*
 1799 *Immunol* **358**: 155-213.
 1800 Henderson IR, Czczulin J, Eslava C, Noriega F & Nataro JP (1999) Characterization of pic, a secreted protease
 1801 of *Shigella flexneri* and enteroaggregative *Escherichia coli*. *Infect Immun* **67**: 5587-5596.
 1802 Henderson IR, Hicks S, Navarro-Garcia F, Elias WP, Phillips AD & Nataro JP (1999) Involvement of the
 1803 enteroaggregative *Escherichia coli* plasmid-encoded toxin in causing human intestinal damage. *Infect Immun* **67**:
 1804 5338-5344.
 1805 Hews CL, Tran SL, Wegmann U, Brett B, Walsham ADS, Kavanaugh D, Ward NJ, Juge N & Schuller S (2017)
 1806 The StcE metalloprotease of enterohaemorrhagic *Escherichia coli* reduces the inner mucus layer and promotes
 1807 adherence to human colonic epithelium ex vivo. *Cell Microbiol* **19**.
 1808 Hicks S, Candy DC & Phillips AD (1996) Adhesion of enteroaggregative *Escherichia coli* to pediatric
 1809 intestinal mucosa *in vitro*. *Infection and Immunity* **64**: 4751-4760.
 1810 Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL & Langguth P (2000) Caco-2 versus caco-
 1811 2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated
 1812 transport. *Journal of Pharmaceutical Sciences* **89**: 63-75.
 1813 Hill DR, Huang S, Nagy MS, *et al.* (2017) Bacterial colonization stimulates a complex physiological response in
 1814 the immature human intestinal epithelium. *eLife* **6**.
 1815 Hirno S, Artursson E, Puu G, Wadstrom T & Nilsson B (1999) *Helicobacter pylori* interactions with human
 1816 gastric mucin studied with a resonant mirror biosensor. *J Microbiol Methods* **37**: 177-182.
 1817 Hiroz P, Schlageter V, Givel JC & Kucera P (2009) Colonic movements in healthy subjects as monitored by a
 1818 Magnet Tracking System. *Neurogastroenterol Motil* **21**: 838-e857.
 1819 Hollingsworth MA & Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. *Nat Rev*
 1820 *Cancer* **4**: 45-60.
 1821 Holmen Larsson JM, Thomsson KA, Rodriguez-Pineiro AM, Karlsson H & Hansson GC (2013) Studies of
 1822 mucus in mouse stomach, small intestine, and colon. III. Gastrointestinal Muc5ac and Muc2 mucin O-glycan
 1823 patterns reveal a regiospecific distribution. *Am J Physiol Gastrointest Liver Physiol* **305**: G357-363.
 1824 Huang EY, Inoue T, Leone VA, *et al.* (2015) Using corticosteroids to reshape the gut microbiome: implications
 1825 for inflammatory bowel diseases. *Inflamm Bowel Dis* **21**: 963-972.
 1826 Huang IN, Okawara T, Watanabe M, *et al.* (2013) New screening methods for probiotics with adhesion
 1827 properties to sialic acid and sulphate residues in human colonic mucin using the Biacore assay. *Journal of*
 1828 *applied microbiology* **114**: 854-860.
 1829 Ijssennagger N, van der Meer R & van Mil SWC (2016) Sulfide as a Mucus Barrier-Breaker in Inflammatory
 1830 Bowel Disease? *Trends Mol Med* **22**: 190-199.
 1831 In J, Foulke-Abel J, Zachos NC, *et al.* (2016) Enterohemorrhagic *Escherichia coli* reduces mucus and
 1832 intermicrovillar bridges in human stem cell-derived colonoids. *Cell Mol Gastroenterol Hepatol* **2**: 48-62.e43.
 1833 Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, Ermund A, Boysen P, Bemark M, Sommer F, Backhed F,
 1834 Hansson GC & Johansson ME (2015) The composition of the gut microbiota shapes the colon mucus barrier.
 1835 *EMBO Rep* **16**: 164-177.

1836 Jensen H, Roos S, Jonsson H, Rud I, Grimmer S, van Pijkeren JP, Britton RA & Axelsson L (2014) Role of
1837 Lactobacillus reuteri cell and mucus-binding protein A (CmbA) in adhesion to intestinal epithelial cells and
1838 mucus in vitro. *Microbiology* **160**: 671-681.

1839 Jeong GN, Jo UB, Ryu HY, Kim YS, Song KS & Yu IJ (2010) Histochemical study of intestinal mucins after
1840 administration of silver nanoparticles in Sprague-Dawley rats. *Arch Toxicol* **84**: 63-69.

1841 Jevtov I, Samuelsson T, Yao G, Amsterdam A & Ribbeck K (2014) Zebrafish as a model to study live mucus
1842 physiology. *Sci Rep* **4**: 6653.

1843 Johansson ME (2012) Fast renewal of the distal colonic mucus layers by the surface goblet cells as measured by
1844 in vivo labeling of mucin glycoproteins. *PLoS One* **7**: e41009.

1845 Johansson ME & Hansson GC (2013) Mucus and the goblet cell. *Dig Dis* **31**: 305-309.

1846 Johansson ME & Hansson GC (2016) Immunological aspects of intestinal mucus and mucins. *Nat Rev Immunol*
1847 **16**: 639-649.

1848 Johansson ME, Larsson JM & Hansson GC (2011) The two mucus layers of colon are organized by the MUC2
1849 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc Natl Acad Sci U S A* **108 Suppl**
1850 **1**: 4659-4665.

1851 Johansson ME, Sjövall H & Hansson GC (2013) The gastrointestinal mucus system in health and disease. *Nat*
1852 *Rev Gastroenterol Hepatol* **10**: 352-361.

1853 Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L & Hansson GC (2008) The inner of the two Muc2
1854 mucin-dependent mucus layers in colon is devoid of bacteria. *Proc Natl Acad Sci U S A* **105**: 15064-15069.

1855 Johansson ME, Gustafsson JK, Sjöberg KE, Petersson J, Holm L, Sjövall H & Hansson GC (2010) Bacteria
1856 penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. *PLoS One* **5**: e12238.

1857 Johansson ME, Gustafsson JK, Holmen-Larsson J, *et al.* (2014) Bacteria penetrate the normally impenetrable
1858 inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. *Gut* **63**: 281-291.

1859 Johansson ME, Jakobsson HE, Holmen-Larsson J, *et al.* (2015) Normalization of Host Intestinal Mucus Layers
1860 Requires Long-Term Microbial Colonization. *Cell Host Microbe* **18**: 582-592.

1861 Juge N (2012) Microbial adhesins to gastrointestinal mucus. *Trends Microbiol* **20**: 30-39.

1862 Juge N (2019) Special Issue: Gut Bacteria-Mucus Interaction. *Microorganisms* **7**.

1863 Jung P, Sato T, Merlos-Suarez A, *et al.* (2011) Isolation and in vitro expansion of human colonic stem cells. *Nat*
1864 *Med* **17**: 1225-1227.

1865 Jung TH, Park JH, Jeon WM & Han KS (2015) Butyrate modulates bacterial adherence on LS174T human
1866 colorectal cells by stimulating mucin secretion and MAPK signaling pathway. *Nutrition research and practice* **9**:
1867 343-349.

1868 Kamphuis JBJ, Mercier-Bonin M, Eutamene H & Theodorou V (2017) Mucus organisation is shaped by colonic
1869 content; a new view. *Sci Rep* **7**: 8527.

1870 Kandori H, Hirayama K, Takeda M & Doi K (1996) Histochemical, lectin-histochemical and morphometrical
1871 characteristics of intestinal goblet cells of germfree and conventional mice. *Exp Anim* **45**: 155-160.

1872 Kankainen M, Paulin L, Tynkkynen S, *et al.* (2009) Comparative genomic analysis of Lactobacillus rhamnosus
1873 GG reveals pili containing a human- mucus binding protein. *Proc Natl Acad Sci U S A* **106**: 17193-17198.

1874 Karve SS, Pradhan S, Ward DV & Weiss AA (2017) Intestinal organoids model human responses to infection by
1875 commensal and Shiga toxin producing Escherichia coli. *PLoS One* **12**: e0178966.

1876 Kasendra M, Tovaglieri A, Sontheimer-Phelps A, *et al.* (2018) Development of a primary human Small
1877 Intestine-on-a-Chip using biopsy-derived organoids. *Sci Rep* **8**: 2871.

1878 Kerneis S, Bernet MF, Coconnier MH & Servin AL (1994) Adhesion of human enterotoxigenic Escherichia coli
1879 to human mucus secreting HT-29 cell subpopulations in culture. *Gut* **35**: 1449-1454.

1880 Khodzhakuliev GK & Ovezova GK (1986) [Archman health resort factors in the rehabilitative treatment
1881 following cholecystectomy]. *Vopr Kurortol Fizioter Lech Fiz Kult* 55-56.

1882 Kim HJ & Ingber DE (2013) Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus
1883 differentiation. *Integrative biology : quantitative biosciences from nano to macro* **5**: 1130-1140.

1884 Kim HJ, Huh D, Hamilton G & Ingber DE (2012) Human gut-on-a-chip inhabited by microbial flora that
1885 experiences intestinal peristalsis-like motions and flow. *Lab Chip* **12**.

1886 Kim HJ, Li H, Collins JJ & Ingber DE (2016) Contributions of microbiome and mechanical deformation to
1887 intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. *Proc Natl Acad Sci U S A* **113**: E7-
1888 15.

1889 Kinoshita H, Uchida H, Kawai Y, Kitazawa H, Miura K, Shiiba K, Horii A & Saito T (2007) Quantitative
1890 evaluation of adhesion of lactobacilli isolated from human intestinal tissues to human colonic mucin using
1891 surface plasmon resonance (BIACORE assay). *Journal of applied microbiology* **102**: 116-123.

1892 Kinoshita H, Imoto S, Suda Y, Ishida M, Watanabe M, Kawai Y, Kitazawa H, Miura K, Horii A & Saito T
1893 (2013) Proposal of screening method for intestinal mucus adhesive lactobacilli using the enzymatic activity of
1894 glyceraldehyde-3-phosphate dehydrogenase (GAPDH). *Anim Sci J* **84**: 150-158.

1895 Kinoshita H, Uchida H, Kawai Y, *et al.* (2008) Cell surface *Lactobacillus plantarum* LA 318 glyceraldehyde-3-
1896 phosphate dehydrogenase (GAPDH) adheres to human colonic mucin. *Journal of applied microbiology* **104**:
1897 1667-1674.

1898 Kissoon-Singh V, Moreau F, Trusevych E & Chadee K (2013) *Entamoeba histolytica* exacerbates epithelial tight
1899 junction permeability and proinflammatory responses in Muc2(-/-) mice. *Am J Pathol* **182**: 852-865.

1900 Kleessen B, Hartmann L & Blaut M (2003) Fructans in the diet cause alterations of intestinal mucosal
1901 architecture, released mucins and mucosa-associated bifidobacteria in gnotobiotic rats. *Br J Nutr* **89**: 597-606.

1902 Knutton S, Lloyd DR & McNeish AS (1987) Adhesion of enteropathogenic *Escherichia coli* to human
1903 intestinal enterocytes and cultured human intestinal mucosa. *Infection and Immunity* **55**: 69-77.

1904 Knutton S, McConnell MM, Rowe B & McNeish AS (1989) Adhesion and ultrastructural properties of human
1905 enterotoxigenic *Escherichia coli* producing colonization factor antigens III and IV. *Infect Immun* **57**: 3364-3371.

1906 Kober OI, Ahl D, Pin C, Holm L, Carding SR & Juge N (2014) γ T-cell-deficient mice show
1907 alterations in mucin expression, glycosylation, and goblet cells but maintain an intact mucus layer. *Am J Physiol*
1908 *Gastrointest Liver Physiol* **306**: G582-593.

1909 Kocevar-Nared J, Kristl J & Smid-Korbar J (1997) Comparative rheological investigation of crude gastric mucin
1910 and natural gastric mucus. *Biomaterials* **18**: 677-681.

1911 Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. *Nat Rev Cancer* **9**: 874-885.

1912 Kumar M, Kissoon-Singh V, Coria AL, Moreau F & Chadee K (2017) Probiotic mixture VSL#3 reduces colonic
1913 inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. *Am J Physiol Gastrointest*
1914 *Liver Physiol* **312**: G34-G45.

1915 Kuznetsova ZA (1990) [Ways of reducing the recurrences of respiratory tuberculosis and their therapeutic and
1916 economic effects]. *Probl Tuberk* 64-65.

1917 Ladinsky MS, Araujo LP, Zhang X, *et al.* (2019) Endocytosis of commensal antigens by intestinal epithelial
1918 cells regulates mucosal T cell homeostasis. *Science* **363**.

1919 Laparra JM & Sanz Y (2009) Comparison of in vitro models to study bacterial adhesion to the intestinal
1920 epithelium. *Lett Appl Microbiol* **49**: 695-701.

1921 Larsson JM, Karlsson H, Crespo JG, Johansson ME, Eklund L, Sjövall H & Hansson GC (2011) Altered O-
1922 glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased
1923 inflammation. *Inflamm Bowel Dis* **17**: 2299-2307.

1924 Lathem WW, Grys TE, Witowski SE, Torres AG, Kaper JB, Tarr PI & Welch RA (2002) StcE, a
1925 metalloprotease secreted by *Escherichia coli* O157:H7, specifically cleaves C1 esterase inhibitor. *Mol Microbiol*
1926 **45**: 277-288.

1927 Laudisi F, Di Fusco D, Dinallo V, *et al.* (2018) The food additive Maltodextrin promotes Endoplasmic
1928 Reticulum stress-driven mucus depletion and exacerbates intestinal inflammation. *Cellular and Molecular*
1929 *Gastroenterology and Hepatology*.

1930 Le DT, Zanna S, Frateur I, Marcus P, Loubiere P, Dague E & Mercier-Bonin M (2012) Real-time investigation
1931 of the muco-adhesive properties of *Lactococcus lactis* using a quartz crystal microbalance with dissipation
1932 monitoring. *Biofouling* **28**: 479-490.

1933 Le DT, Tran TL, Duviau MP, Meyrand M, Guerardel Y, Castelain M, Loubiere P, Chapot-Chartier MP, Dague E
1934 & Mercier-Bonin M (2013) Unraveling the role of surface mucus-binding protein and pili in muco-adhesion of
1935 *Lactococcus lactis*. *PLoS One* **8**: e79850.

1936 Lebeer S, Claes I, Tytgat HL, *et al.* (2012) Functional analysis of *Lactobacillus rhamnosus* GG pili in relation to
1937 adhesion and immunomodulatory interactions with intestinal epithelial cells. *Appl Environ Microbiol* **78**: 185-
1938 193.

1939 Leclaire C, Lecoite K, Gunning PA, Tribolo S, Kavanaugh DW, Wittmann A, Latousakis D, MacKenzie DA,
1940 Kawasaki N & Juge N (2018) Molecular basis for intestinal mucin recognition by galectin-3 and C-type lectins.
1941 *FASEB J* fj201700619R.

1942 Leon-Coria A, Kumar M, Moreau F & Chadee K (2018) Defining cooperative roles for colonic microbiota and
1943 Muc2 mucin in mediating innate host defense against *Entamoeba histolytica*. *PLoS Pathog* **14**: e1007466.

1944 Leslie JL & Young VB (2016) A Whole New Ball Game: Stem Cell-Derived Epithelia in the Study of Host-
1945 Microbe Interactions. *Anaerobe* **37**: 25-28.

1946 Lesuffleur T, Barbat A, Dussaulx E & Zweibaum A (1990) Growth adaptation to methotrexate of HT-29 human
1947 colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-
1948 secreting cells. *Cancer Res* **50**: 6334-6343.

1949 Lesuffleur T, Kornowski A, Luccioni C, Muleris M, Barbat A, Beaumatin J, Dussaulx E, Dutrillaux B &
1950 Zweibaum A (1991) Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29
1951 results in the selection of cells committed to differentiation. *Int J Cancer* **49**: 721-730.

1952 Lewis SB, Cook V, Tighe R & Schüller S (2015) Enterohemorrhagic *Escherichia coli* colonization of human
1953 colonic epithelium *in vitro* and *ex vivo*. *Infect Immun* **83**: 942-949.

1954 Leyton DL, Sloan J, Hill RE, Doughty S & Hartland EL (2003) Transfer region of pO113 from
1955 enterohemorrhagic *Escherichia coli*: similarity with R64 and identification of a novel plasmid-encoded
1956 autotransporter, EpeA. *Infect Immun* **71**: 6307-6319.

1957 Li H, Limenitakis JP, Fuhrer T, *et al.* (2015) The outer mucus layer hosts a distinct intestinal microbial niche.
1958 *Nat Commun* **6**: 8292.

1959 Lidell ME, Moncada DM, Chadee K & Hansson GC (2006) *Entamoeba histolytica* cysteine proteases cleave the
1960 MUC2 mucin in its C-terminal domain and dissolve the protective colonic mucus gel. *Proc Natl Acad Sci U S A*
1961 **103**: 9298-9303.

1962 Lievin-Le Moal V & Servin AL (2013) Pathogenesis of human enterovirulent bacteria: lessons from cultured,
1963 fully differentiated human colon cancer cell lines. *Microbiology and molecular biology reviews : MMBR* **77**:
1964 380-439.

1965 Lievin-Le Moal V, Servin AL & Coconnier-Polter MH (2005) The increase in mucin exocytosis and the
1966 upregulation of MUC genes encoding for membrane-bound mucins induced by the thiol-activated exotoxin
1967 listeriolysin O is a host cell defence response that inhibits the cell-entry of *Listeria monocytogenes*. *Cell*
1968 *Microbiol* **7**: 1035-1048.

1969 Linden SK, Driessen KM & McGuckin MA (2007) Improved in vitro model systems for gastrointestinal
1970 infection by choice of cell line, pH, microaerobic conditions, and optimization of culture conditions.
1971 *Helicobacter* **12**: 341-353.

1972 Linden SK, Wickstrom C, Lindell G, Gilshenan K & Carlstedt I (2008) Four modes of adhesion are used during
1973 *Helicobacter pylori* binding to human mucins in the oral and gastric niches. *Helicobacter* **13**: 81-93.

1974 Linden SK, Sutton P, Karlsson NG, Korolik V & McGuckin MA (2008) Mucins in the mucosal barrier to
1975 infection. *Mucosal Immunol* **1**: 183-197.

1976 Linden SK, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, Sutton P & McGuckin MA (2009) MUC1
1977 limits *Helicobacter pylori* infection both by steric hindrance and by acting as a releasable decoy. *PLoS Pathog* **5**:
1978 e1000617.

1979 Lozoya-Agullo I, Araujo F, Gonzalez-Alvarez I, Merino-Sanjuan M, Gonzalez-Alvarez M, Bermejo M &
1980 Sarmiento B (2017) Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B Coculture Models To
1981 Predict Intestinal and Colonic Permeability Compared to Caco-2 Monoculture. *Molecular pharmaceutics* **14**:
1982 1264-1270.

1983 Lukic J, Strahinic I, Jovcic B, Filipic B, Topisirovic L, Kojic M & Begovic J (2012) Different roles for
1984 lactococcal aggregation factor and mucin binding protein in adhesion to gastrointestinal mucosa. *Appl Environ*
1985 *Microbiol* **78**: 7993-8000.

1986 Lukic J, Strahinic I, Milenkovic M, Nikolic M, Tolinacki M, Kojic M & Begovic J (2014) Aggregation factor as
1987 an inhibitor of bacterial binding to gut mucosa. *Microb Ecol* **68**: 633-644.

1988 Luo Q, Kumar P, Vickers TJ, Sheikh A, Lewis WG, Rasko DA, Sistrunk J & Fleckenstein JM (2014)
1989 Enterotoxigenic *Escherichia coli* secretes a highly conserved mucin-degrading metalloprotease to effectively
1990 engage intestinal epithelial cells. *Infect Immun* **82**: 509-521.

1991 Macfarlane GT, Hay S & Gibson GR (1989) Influence of Mucin on Glycosidase, Protease and Arylamidase
1992 Activities of Human Gut Bacteria Grown in a 3-Stage Continuous Culture System. *J Appl Bacteriol* **66**: 407-417.

1993 Macfarlane S, McBain AJ & Macfarlane GT (1997) Consequences of biofilm and sessile growth in the large
1994 intestine. *Advances in Dental Research* **11**: 59-68.

1995 Macfarlane S, Woodmansey EJ & Macfarlane GT (2005) Colonization of mucin by human intestinal bacteria
1996 and establishment of biofilm communities in a two-stage continuous culture system. *Appl Environ Microb* **71**:
1997 7483-7492.

1998 Macfarlane S, Woodmansey EJ & Macfarlane GT (2005) Colonization of mucin by human intestinal bacteria
1999 and establishment of biofilm communities in a two-stage continuous culture system. *Appl Environ Microbiol* **71**:
2000 7483-7492.

2001 Macias-Rodriguez ME, Zagorec M, Ascencio F, Vazquez-Juarez R & Rojas M (2009) *Lactobacillus fermentum*
2002 BCS87 expresses mucus- and mucin-binding proteins on the cell surface. *Journal of applied microbiology* **107**:
2003 1866-1874.

2004 Mack DR, Ahrne S, Hyde L, Wei S & Hollingsworth MA (2003) Extracellular MUC3 mucin secretion follows
2005 adherence of *Lactobacillus* strains to intestinal epithelial cells in vitro. *Gut* **52**: 827-833.

2006 MacKenzie DA, Tailford LE, Hemmings AM & Juge N (2009) Crystal structure of a mucus-binding protein
2007 repeat reveals an unexpected functional immunoglobulin binding activity. *J Biol Chem* **284**: 32444-32453.

2008 Mackenzie DA, Jeffers F, Parker ML, Vibert-Vallet A, Bongaerts RJ, Roos S, Walter J & Juge N (2010) Strain-
2009 specific diversity of mucus-binding proteins in the adhesion and aggregation properties of *Lactobacillus reuteri*.
2010 *Microbiology* **156**: 3368-3378.

2011 Magalhaes A, Marcos-Pinto R, Nairn AV, *et al.* (2015) *Helicobacter pylori* chronic infection and mucosal
2012 inflammation switches the human gastric glycosylation pathways. *Biochim Biophys Acta* **1852**: 1928-1939.

2013 Mahida YR, Makh S, Hyde S, Gray T & Borriello SP (1996) Effect of *Clostridium difficile* toxin A on human
2014 intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. *Gut* **38**: 337-
2015 347.

2016 Martens EC, Neumann M & Desai MS (2018) Interactions of commensal and pathogenic microorganisms with
2017 the intestinal mucosal barrier. *Nat Rev Microbiol*.

2018 Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, Bonnet R, Darfeuille-Michaud A & Barnich N
2019 (2014) Western diet induces dysbiosis with increased *E. coli* in CEABAC10 mice, alters host barrier function
2020 favouring AIEC colonisation. *Gut* **63**: 116-124.

2021 Martins M, Porrini C, du Merle L, Danne C, Robbe-Masselot C, Trieu-Cuot P & Dramsi S (2016) The Pil3 pilus
2022 of *Streptococcus gallolyticus* binds to intestinal mucins and to fibrinogen. *Gut Microbes* **7**: 526-532.

2023 Martins M, Aymeric L, du Merle L, Danne C, Robbe-Masselot C, Trieu-Cuot P, Sansonetti P & Dramsi S (2015)
2024 *Streptococcus gallolyticus* Pil3 Pilus Is Required for Adhesion to Colonic Mucus and for Colonization of Mouse
2025 Distal Colon. *The Journal of infectious diseases* **212**: 1646-1655.

2026 Marzorati M, Vanhoecke B, De Ryck T, *et al.* (2014) The HMI module: a new tool to study the Host-Microbiota
2027 Interaction in the human gastrointestinal tract in vitro. *BMC microbiology* **14**: 133.

2028 McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ, Florin TH, Hill GR, Korolik V &
2029 McGuckin MA (2007) MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. *J Clin*
2030 *Invest* **117**: 2313-2324.

2031 McDonald JAK, Schroeter K, Fuentes S, Heikamp-deJong I, Khursigara CM, de Vos WM & Allen-Vercoe E
2032 (2013) Evaluation of microbial community reproducibility, stability and composition in a human distal gut
2033 chemostat model. *J Microbiol Meth* **95**: 167-174.

2034 McGuckin MA, Every AL, Skene CD, *et al.* (2007) Muc1 mucin limits both *Helicobacter pylori* colonization of
2035 the murine gastric mucosa and associated gastritis. *Gastroenterology* **133**: 1210-1218.

2036 McNamara N & Basbaum C (2001) Signaling networks controlling mucin production in response to Gram-
2037 positive and Gram-negative bacteria. *Glycoconj J* **18**: 715-722.

2038 McNamara NA, Sack RA & Fleiszig SM (2000) Mucin-bacterial binding assays. *Methods Mol Biol* **125**: 429-
2039 437.

2040 Mercier-Bonin M & Chapot-Chartier MP (2017) Surface Proteins of *Lactococcus lactis*: Bacterial Resources for
2041 Muco-adhesion in the Gastrointestinal Tract. *Front Microbiol* **8**: 2247.

2042 Mercier-Bonin M, Despax B, Raynaud P, Houdeau E & Thomas M (2018) Mucus and microbiota as emerging
2043 players in gut nanotoxicology: The example of dietary silver and titanium dioxide nanoparticles. *Crit Rev Food*
2044 *Sci Nutr* **58**: 1023-1032.

2045 Miguel F, Chantal C, Jean-Michel A, Friedrich P, Catherine S & Germain T (2001) A heat labile soluble factor
2046 from *Bacteroides thetaiotaomicron* VPI-5482 specifically increases the galactosylation pattern of HT29-MTX
2047 cells. *Cellular Microbiology* **3**: 289-300.

2048 Miller TL & Wolin MJ (1981) Fermentation by the human large intestine microbial community in an *in vitro*
2049 semicontinuous culture system. *Appl Environ Microbiol* **42**: 400-407.

2050 Mondal M, Nag D, Koley H, Saha DR & Chatterjee NS (2014) The *Vibrio cholerae* extracellular chitinase
2051 ChiA2 is important for survival and pathogenesis in the host intestine. *PLoS One* **9**: e103119.

2052 Monteiro R, Ageorges V, Rojas-Lopez M, *et al.* (2016) A secretome view of colonisation factors in Shiga toxin-
2053 encoding *Escherichia coli* (STEC): from enterohaemorrhagic *E. coli* (EHEC) to related enteropathotypes. *FEMS*
2054 *Microbiol Lett* **363**.

2055 Moore ME, Boren T & Solnick JV (2011) Life at the margins: modulation of attachment proteins in *Helicobacter*
2056 *pylori*. *Gut Microbes* **2**: 42-46.

2057 Morampudi V, Dalwadi U, Bhinder G, *et al.* (2016) The goblet cell-derived mediator RELM-beta drives
2058 spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. *Mucosal Immunol* **9**:
2059 1218-1233.

2060 Naili I, Baudner BC, Bernalier-Donadille A, Pizza M, Desvaux M, Jubelin G & Buonsanti C (2017) *In*
2061 *vivo* characterization of the immune response towards the pathogenic *Escherichia coli* antigen
2062 SslE and modulation of the intestinal microbiota. *The Journal of Immunology* **198**: 147.123-147.123.

2063 Naili I, Buonsanti C, Soriani M, Desvaux M, Jubelin G, Vieru M, Baudner BC & D'Oro U (2016) *In*
2064 *vivo* characterization of the immune response towards the pathogenic *Escherichia coli* antigen
2065 SslE and modulation of the intestinal microbiota. *The Journal of Immunology* **196**: 215.219-215.219.

2066 Naughton JA, Marino K, Dolan B, *et al.* (2013) Divergent mechanisms of interaction of *Helicobacter pylori* and
2067 *Campylobacter jejuni* with mucus and mucins. *Infect Immun* **81**: 2838-2850.

2068 Navabi N, McGuckin MA & Lindén SK (2013) Gastrointestinal cell lines form polarized epithelia with an
2069 adherent mucus layer when cultured in semi-wet interfaces with mechanical stimulation. *PLoS One* **8**: e68761.

2070 Navabi N, McGuckin MA & Linden SK (2013) Gastrointestinal cell lines form polarized epithelia with an
2071 adherent mucus layer when cultured in semi-wet interfaces with mechanical stimulation. *PLoS One* **8**: e68761.

2072 Ndeh D & Gilbert HJ (2018) Biochemistry of complex glycan depolymerisation by the human gut microbiota.
2073 *FEMS Microbiol Rev* **42**: 146-164.

2074 Nesta B, Valeri M, Spagnuolo A, *et al.* (2014) SslE elicits functional antibodies that impair in vitro mucinase
2075 activity and in vivo colonization by both intestinal and extraintestinal *Escherichia coli* strains. *PLoS Pathog* **10**:
2076 e1004124.

2077 Ng GZ, Menheniott TR, Every AL, *et al.* (2016) The MUC1 mucin protects against *Helicobacter pylori*
2078 pathogenesis in mice by regulation of the NLRP3 inflammasome. *Gut* **65**: 1087-1099.

2079 Ng KM, Ferreyra JA, Higginbottom SK, *et al.* (2013) Microbiota-liberated host sugars facilitate post-antibiotic
2080 expansion of enteric pathogens. *Nature* **502**: 96-99.

2081 Nguyen TL, Vieira-Silva S, Liston A & Raes J (2015) How informative is the mouse for human gut microbiota
2082 research? *Dis Model Mech* **8**: 1-16.

2083 Nishiyama K, Sugiyama M & Mukai T (2016) Adhesion Properties of Lactic Acid Bacteria on Intestinal Mucin.
2084 *Microorganisms* **4**.

2085 Nishiyama K, Ochiai A, Tsubokawa D, Ishihara K, Yamamoto Y & Mukai T (2013) Identification and
2086 characterization of sulfated carbohydrate-binding protein from *Lactobacillus reuteri*. *PLoS One* **8**: e83703.

2087 Nishiyama K, Nakamata K, Ueno S, Terao A, Aryantini NP, Sujaya IN, Fukuda K, Urashima T, Yamamoto Y &
2088 Mukai T (2015) Adhesion properties of *Lactobacillus rhamnosus* mucus-binding factor to mucin and
2089 extracellular matrix proteins. *Biosci Biotechnol Biochem* **79**: 271-279.

2090 Nissila E, Douillard FP, Ritari J, Paulin L, Jarvinen HM, Rasinkangas P, Haapasalo K, Meri S, Jarva H & de Vos
2091 WM (2017) Genotypic and phenotypic diversity of *Lactobacillus rhamnosus* clinical isolates, their comparison
2092 with strain GG and their recognition by complement system. *PLoS One* **12**: e0176739.

2093 Noel G, Baetz NW, Staab JF, Donowitz M, Kovbasnjuk O, Pasetti MF & Zachos NC (2017) A primary human
2094 macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. *Sci*
2095 *Rep* **7**: 45270.

2096 Owen CD, Tailford LE, Monaco S, *et al.* (2017) Unravelling the specificity and mechanism of sialic acid
2097 recognition by the gut symbiont *Ruminococcus gnavus*. *Nat Commun* **8**: 2196.

2098 Pacheco AR, Curtis MM, Ritchie JM, Munera D, Waldor MK, Moreira CG & Sperandio V (2012) Fucose
2099 sensing regulates bacterial intestinal colonization. *Nature* **492**: 113-117.

2100 Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, Barnich N, Ng SC & Colombel JF (2018) Adherent-
2101 invasive *Escherichia coli* in inflammatory bowel disease. *Gut* **67**: 574-587.

2102 Parham NJ, Srinivasan U, Desvaux M, Foxman B, Marrs CF & Henderson IR (2004) PicU, a second serine
2103 protease autotransporter of uropathogenic *Escherichia coli*. *FEMS Microbiol Lett* **230**: 73-83.

2104 Patel DK, Shah KR, Pappachan A, Gupta S & Singh DD (2016) Cloning, expression and characterization of a
2105 mucin-binding GAPDH from *Lactobacillus acidophilus*. *Int J Biol Macromol* **91**: 338-346.

2106 Paton AW, Beddoe T, Thorpe CM, Whisstock JC, Wilce MC, Rossjohn J, Talbot UM & Paton JC (2006) AB5
2107 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. *Nature* **443**: 548-552.

2108 Pedron T, Mulet C, Dauga C, Frangeul L, Chervaux C, Grompone G & Sansonetti PJ (2012) A crypt-specific
2109 core microbiota resides in the mouse colon. *MBio* **3**.

2110 Pelaseyed T, Bergstrom JH, Gustafsson JK, *et al.* (2014) The mucus and mucins of the goblet cells and
2111 enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system.
2112 *Immunol Rev* **260**: 8-20.

2113 Pereira FC & Berry D (2017) Microbial nutrient niches in the gut. *Environ Microbiol* **19**: 1366-1378.

2114 Peterson KM & Mekalanos JJ (1988) Characterization of the *Vibrio cholerae* ToxR regulon: identification of
2115 novel genes involved in intestinal colonization. *Infect Immun* **56**: 2822-2829.

2116 Peterson LW & Artis D (2014) Intestinal epithelial cells: regulators of barrier function and immune homeostasis.
2117 *Nat Rev Immunol* **14**: 141-153.

2118 Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO, Roos S, Holm L & Phillipson M
2119 (2011) Importance and regulation of the colonic mucus barrier in a mouse model of colitis. *Am J Physiol*
2120 *Gastrointest Liver Physiol* **300**: G327-333.

2121 Phillips AD, Navabpour S, Hicks S, Dougan G, Wallis T & Frankel G (2000) Enterohaemorrhagic *Escherichia*
2122 *coli* O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine
2123 intestine. *Gut* **47**: 377-381.

2124 Phillips TE, Huet C, Bilbo PR, Podolsky DK, Louvard D & Neutra MR (1988) Human intestinal goblet cells in
2125 monolayer culture: characterization of a mucus-secreting subclone derived from the HT29 colon
2126 adenocarcinoma cell line. *Gastroenterology* **94**: 1390-1403.

2127 Pickard JM, Zeng MY, Caruso R & Nunez G (2017) Gut microbiota: Role in pathogen colonization, immune
2128 responses, and inflammatory disease. *Immunol Rev* **279**: 70-89.

2129 Plovier H, Everard A, Druart C, *et al.* (2017) A purified membrane protein from *Akkermansia muciniphila* or the
2130 pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med* **23**: 107-113.

2131 Poole J, Day CJ, von Itzstein M, Paton JC & Jennings MP (2018) Glycointeractions in bacterial pathogenesis.
2132 *Nat Rev Microbiol* **16**: 440-452.

2133 Poquet L, Clifford MN & Williamson G (2008) Transport and metabolism of ferulic acid through the colonic
2134 epithelium. *Drug metabolism and disposition: the biological fate of chemicals* **36**: 190-197.

2135 Praharaj AB, Dehury B, Mahapatra N, Kar SK & Behera SK (2018) Molecular dynamics insights into the
2136 structure, function, and substrate binding mechanism of mucin desulfating sulfatase of gut microbe *Bacteroides*
2137 *fragilis*. *J Cell Biochem* **119**: 3618-3631.

2138 Pretzer G, Snel J, Molenaar D, Wiersma A, Bron PA, Lambert J, de Vos WM, van der Meer R, Smits MA &
2139 Kleerebezem M (2005) Biodiversity-based identification and functional characterization of the mannose-specific
2140 adhesin of *Lactobacillus plantarum*. *J Bacteriol* **187**: 6128-6136.

2141 Raffatellu M, Chessa D, Wilson RP, Dusold R, Rubino S & Baumler AJ (2005) The Vi capsular antigen of
2142 *Salmonella enterica* serotype Typhi reduces Toll-like receptor-dependent interleukin-8 expression in the
2143 intestinal mucosa. *Infect Immun* **73**: 3367-3374.

2144 Reeves EP, Ali T, Leonard P, *et al.* (2008) *Helicobacter pylori* lipopolysaccharide interacts with TFF1 in a pH-
2145 dependent manner. *Gastroenterology* **135**: 2043-2054, 2054 e2041-2042.

2146 Rey FE, Gonzalez MD, Cheng J, Wu M, Ahern PP & Gordon JI (2013) Metabolic niche of a prominent sulfate-
2147 reducing human gut bacterium. *Proc Natl Acad Sci U S A* **110**: 13582-13587.

2148 Ribiere C, Peyret P, Parisot N, Darcha C, Dechelotte PJ, Barnich N, Peyretailade E & Boucher D (2016) Oral
2149 exposure to environmental pollutant benzo[a]pyrene impacts the intestinal epithelium and induces gut microbial
2150 shifts in murine model. *Sci Rep* **6**: 31027.

2151 Ringot-Destrez B, D'Alessandro Z, Lacroix JM, Mercier-Bonin M, Leonard R & Robbe-Masselot C (2018) A
2152 Sensitive and Rapid Method to Determin the Adhesion Capacity of Probiotics and Pathogenic Microorganisms
2153 to Human Gastrointestinal Mucins. *Microorganisms* **6**.

2154 Robbe C, Capon C, Coddeville B & Michalski JC (2004) Structural diversity and specific distribution of O-
2155 glycans in normal human mucins along the intestinal tract. *Biochem J* **384**: 307-316.

2156 Robbe C, Capon C, Maes E, Rousset M, Zweibaum A, Zanetta JP & Michalski JC (2003) Evidence of regio-
2157 specific glycosylation in human intestinal mucins: presence of an acidic gradient along the intestinal tract. *J Biol*
2158 *Chem* **278**: 46337-46348.

2159 Rodriguez-Pineiro AM & Johansson ME (2015) The colonic mucus protection depends on the microbiota. *Gut*
2160 *Microbes* **6**: 326-330.

2161 Rojas M, Ascencio F & Conway PL (2002) Purification and characterization of a surface protein from
2162 *Lactobacillus fermentum* 104R that binds to porcine small intestinal mucus and gastric mucin. *Appl Environ*
2163 *Microbiol* **68**: 2330-2336.

2164 Rolhion N & Chassaing B (2016) When pathogenic bacteria meet the intestinal microbiota. *Philos Trans R Soc*
2165 *Lond B Biol Sci* **371**.

2166 Rooks MG & Garrett WS (2016) Gut microbiota, metabolites and host immunity. *Nat Rev Immunol* **16**: 341-352.

2167 Rossez Y, Maes E, Lefebvre Darroman T, Gosset P, Ecobichon C, Joncquel Chevalier Curt M, Boneca IG,
2168 Michalski JC & Robbe-Masselot C (2012) Almost all human gastric mucin O-glycans harbor blood group A, B
2169 or H antigens and are potential binding sites for *Helicobacter pylori*. *Glycobiology* **22**: 1193-1206.

2170 Rossez Y, Gosset P, Boneca IG, *et al.* (2014) The lacdiNAc-specific adhesin LabA mediates adhesion of
2171 *Helicobacter pylori* to human gastric mucosa. *The Journal of infectious diseases* **210**: 1286-1295.

2172 Salyers AA, Vercellotti JR, West SE & Wilkins TD (1977) Fermentation of mucin and plant polysaccharides by
2173 strains of *Bacteroides* from the human colon. *Appl Environ Microbiol* **33**: 319-322.

2174 Sato T, Stange DE, Ferrante M, *et al.* (2011) Long-term expansion of epithelial organoids from human colon,
2175 adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* **141**: 1762-1772.

2176 Schild S, Lamprecht AK, Fourestier C, Lauriano CM, Klose KE & Reidl J (2005) Characterizing
2177 lipopolysaccharide and core lipid A mutant O1 and O139 *Vibrio cholerae* strains for adherence properties on
2178 mucus-producing cell line HT29-Rev MTX and virulence in mice. *Int J Med Microbiol* **295**: 243-251.

2179 Schroeder BO, Birchenough GMH, Stahlman M, Arike L, Johansson MEV, Hansson GC & Backhed F (2018)
2180 *Bifidobacteria* or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration. *Cell*
2181 *Host Microbe* **23**: 27-40 e27.

2182 Schüller S, Frankel G & Phillips AD (2004) Interaction of Shiga toxin from *Escherichia coli* with human
2183 intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. *Cell Microbiol* **6**:
2184 289-301.

2185 Schüller S, Lucas M, Kaper JB, Girón JA & Phillips AD (2009) The *ex vivo* response of human intestinal
2186 mucosa to enteropathogenic *Escherichia coli* infection. *Cell Microbiol* **11**: 521-530.

2187 Schüller S, Chong Y, Lewin J, Kenny B, Frankel G & Phillips AD (2007) Tir phosphorylation and Nck/N-
2188 WASP recruitment by enteropathogenic and enterohaemorrhagic *Escherichia coli* during *ex vivo* colonization of
2189 human intestinal mucosa is different to cell culture models. *Cell Microbiol* **9**: 1352-1364.

2190 Sender R, Fuchs S & Milo R (2016) Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to
2191 Host Cells in Humans. *Cell* **164**: 337-340.

2192 Sequeira S, Kavanaugh D, MacKenzie DA, *et al.* (2018) Structural basis for the role of serine-rich repeat
2193 proteins from *Lactobacillus reuteri* in gut microbe-host interactions. *Proc Natl Acad Sci U S A* **115**: E2706-
2194 E2715.

2195 Shah P, Fritz JV, Glaab E, *et al.* (2016) A microfluidics-based in vitro model of the gastrointestinal human-
2196 microbe interface. *Nat Commun* **7**: 11535.

2197 Sheng YH, Hasnain SZ, Png CW, McGuckin MA & Linden SK (2012) Techniques for assessment of
2198 interactions of mucins with microbes and parasites in vitro and in vivo. *Methods Mol Biol* **842**: 297-312.

2199 Sheng YH, Lourie R, Linden SK, *et al.* (2011) The MUC13 cell-surface mucin protects against intestinal
2200 inflammation by inhibiting epithelial cell apoptosis. *Gut* **60**: 1661-1670.

2201 Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS & Bae JW (2014) An increase in the *Akkermansia* spp.
2202 population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* **63**:
2203 727-735.

2204 Shin W & Kim HJ (2018) Intestinal barrier dysfunction orchestrates the onset of inflammatory host-microbiome
2205 cross-talk in a human gut inflammation-on-a-chip. *Proc Natl Acad Sci U S A* **115**: E10539-E10547.

2206 Shin W, Wu A, Massidda MW, Foster C, Thomas N, Lee DW, Koh H, Ju Y, Kim J & Kim HJ (2019) A Robust
2207 Longitudinal Co-culture of Obligate Anaerobic Gut Microbiome With Human Intestinal Epithelium in an
2208 Anoxic-Oxic Interface-on-a-Chip. *Front Bioeng Biotechnol* **7**: 13.

2209 Sicard JF, Le Bihan G, Vogeeler P, Jacques M & Harel J (2017) Interactions of Intestinal Bacteria with
2210 Components of the Intestinal Mucus. *Front Cell Infect Microbiol* **7**: 387.

2211 Sinagoga KL & Wells JM (2015) Generating human intestinal tissues from pluripotent stem cells to study
2212 development and disease. *The EMBO Journal* **34**: 1149-1163.

2213 Singh KS, Kumar S, Mohanty AK, Grover S & Kaushik JK (2018) Mechanistic insights into the host-microbe
2214 interaction and pathogen exclusion mediated by the Mucus-binding protein of *Lactobacillus plantarum*. *Sci Rep*
2215 **8**: 14198.

2216 Singh KS, Choudhary R, Bisht S, Grover S, Kumar S, Mohanty AK & Kaushik JK (2017) Expression of
2217 recombinant truncated domains of mucus-binding (Mub) protein of *Lactobacillus plantarum* in soluble and
2218 biologically active form. *Protein Expr Purif* **135**: 54-60.

2219 Skoog EC, Sjoling A, Navabi N, Holgersson J, Lundin SB & Linden SK (2012) Human gastric mucins
2220 differently regulate *Helicobacter pylori* proliferation, gene expression and interactions with host cells. *PLoS One*
2221 **7**: e36378.

2222 Skoog EC, Padra M, Aberg A, Gideonsson P, Obi I, Quintana-Hayashi MP, Arnqvist A & Linden SK (2017)
2223 BabA dependent binding of *Helicobacter pylori* to human gastric mucins cause aggregation that inhibits
2224 proliferation and is regulated via ArsS. *Sci Rep* **7**: 40656.

2225 Smirnova MG, Guo L, Birchall JP & Pearson JP (2003) LPS up-regulates mucin and cytokine mRNA expression
2226 and stimulates mucin and cytokine secretion in goblet cells. *Cell Immunol* **221**: 42-49.

2227 Sonnenburg ED & Sonnenburg JL (2014) Starving our microbial self: the deleterious consequences of a diet
2228 deficient in microbiota-accessible carbohydrates. *Cell Metab* **20**: 779-786.

2229 Sovran B, Loonen LM, Lu P, *et al.* (2015) IL-22-STAT3 pathway plays a key role in the maintenance of ileal
2230 homeostasis in mice lacking secreted mucus barrier. *Inflamm Bowel Dis* **21**: 531-542.

2231 Spence JR, Mayhew CN, Rankin SA, *et al.* (2011) Directed differentiation of human pluripotent stem cells into
2232 intestinal tissue in vitro. *Nature* **470**: 105-109.

2233 Sperandio B, Fischer N, Joncquel Chevalier-Curt M, Rossez Y, Roux P, Robbe Masselot C & Sansonetti PJ
2234 (2013) Virulent *Shigella flexneri* affects secretion, expression, and glycosylation of gel-forming mucins in
2235 mucus-producing cells. *Infect Immun* **81**: 3632-3643.

2236 Stone EL, Ismail MN, Lee SH, Luu Y, Ramirez K, Haslam SM, Ho SB, Dell A, Fukuda M & Marth JD (2009)
2237 Glycosyltransferase function in core 2-type protein O glycosylation. *Mol Cell Biol* **29**: 3770-3782.

2238 Sullan RM, Beaussart A, Tripathi P, Derclaye S, El-Kirat-Chatel S, Li JK, Schneider YJ, Vanderleyden J, Lebeer
2239 S & Dufrene YF (2014) Single-cell force spectroscopy of pili-mediated adhesion. *Nanoscale* **6**: 1134-1143.

2240 Suo C, Fan Z, Zhou L & Qiu J (2017) Perfluorooctane sulfonate affects intestinal immunity against bacterial
2241 infection. *Sci Rep* **7**: 5166.

2242 Swidsinski A, Weber J, Loening-Baucke V, Hale LP & Lochs H (2005) Spatial organization and composition of
2243 the mucosal flora in patients with inflammatory bowel disease. *J Clin Microbiol* **43**: 3380-3389.

2244 Szabady RL, Yanta JH, Halladin DK, Schofield MJ & Welch RA (2011) TagA is a secreted protease of *Vibrio*
2245 *cholerae* that specifically cleaves mucin glycoproteins. *Microbiology* **157**: 516-525.




2246 Tailford LE, Crost EH, Kavanaugh D & Juge N (2015) Mucin glycan foraging in the human gut microbiome.
2247 *Front Genet* **6**: 81.

2248 Talbot P, Radziwill-Bienkowska JM, Kamphuis JBJ, *et al.* (2018) Food-grade TiO₂ is trapped by intestinal
 2249 mucus in vitro but does not impair mucin O-glycosylation and short-chain fatty acid synthesis in vivo:
 2250 implications for gut barrier protection. *J Nanobiotechnology* **16**: 53.
 2251 Tapader R, Bose D & Pal A (2017) YghJ, the secreted metalloprotease of pathogenic *E. coli* induces
 2252 hemorrhagic fluid accumulation in mouse ileal loop. *Microb Pathog* **105**: 96-99.
 2253 Tasteyre A, Barc MC, Collignon A, Boureau H & Karjalainen T (2001) Role of FliC and FliD flagellar proteins
 2254 of *Clostridium difficile* in adherence and gut colonization. *Infect Immun* **69**: 7937-7940.
 2255 Thaïss CA, Levy M, Korem T, *et al.* (2016) Microbiota Diurnal Rhythmicity Programs Host Transcriptome
 2256 Oscillations. *Cell* **167**: 1495-1510 e1412.
 2257 Theodoratou E, Campbell H, Ventham NT, *et al.* (2014) The role of glycosylation in IBD. *Nat Rev*
 2258 *Gastroenterol Hepatol* **11**: 588-600.
 2259 Thevenot J, Cordonnier C, Rougeron A, Le Goff O, Nguyen HT, Denis S, Alric M, Livrelli V & Blanquet-Diot S
 2260 (2015) Enterohemorrhagic *Escherichia coli* infection has donor-dependent effect on human gut microbiota and
 2261 may be antagonized by probiotic yeast during interaction with Peyer's patches. *Appl Microbiol Biotechnol* **99**:
 2262 9097-9110.
 2263 Thomsson KA, Holmen-Larsson JM, Angstrom J, Johansson ME, Xia L & Hansson GC (2012) Detailed O-
 2264 glycomics of the Muc2 mucin from colon of wild-type, core 1- and core 3-transferase-deficient mice highlights
 2265 differences compared with human MUC2. *Glycobiology* **22**: 1128-1139.
 2266 Tobisawa Y, Imai Y, Fukuda M & Kawashima H (2010) Sulfation of colonic mucins by N-acetylglucosamine 6-
 2267 O-sulfotransferase-2 and its protective function in experimental colitis in mice. *J Biol Chem* **285**: 6750-6760.
 2268 Tomas J, Mulet C, Saffarian A, *et al.* (2016) High-fat diet modifies the PPAR-gamma pathway leading to
 2269 disruption of microbial and physiological ecosystem in murine small intestine. *Proc Natl Acad Sci U S A* **113**:
 2270 E5934-E5943.
 2271 Troge A, Scheppach W, Schroeder BO, Rund SA, Heuner K, Wehkamp J, Stange EF & Oelschlaeger TA (2012)
 2272 More than a marine propeller--the flagellum of the probiotic *Escherichia coli* strain Nissle 1917 is the major
 2273 adhesin mediating binding to human mucus. *Int J Med Microbiol* **302**: 304-314.
 2274 Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, Viale G & Rescigno M (2012) Probiotic and
 2275 postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. *Gut* **61**:
 2276 1007-1015.
 2277 Turner JR (2009) Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol* **9**: 799-809.
 2278 Tytgat HL, Douillard FP, Reunanen J, Rasinkangas P, Hendrickx AP, Laine PK, Paulin L, Satokari R & de Vos
 2279 WM (2016) *Lactobacillus rhamnosus* GG Outcompetes *Enterococcus faecium* via Mucus-Binding Pili: Evidence
 2280 for a Novel and Heterospecific Probiotic Mechanism. *Appl Environ Microbiol* **82**: 5756-5762.
 2281 Uchida H, Fujitani K, Kawai Y, Kitazawa H, Horii A, Shiiba K, Saito K & Saito T (2004) A new assay using
 2282 surface plasmon resonance (SPR) to determine binding of the *Lactobacillus acidophilus* group to human colonic
 2283 mucin. *Biosci Biotechnol Biochem* **68**: 1004-1010.
 2284 Valeri M, Rossi Paccani S, Kasendra M, Nesta B, Serino L, Pizza M & Soriani M (2015) Pathogenic *E. coli*
 2285 exploits SslE mucinase activity to translocate through the mucosal barrier and get access to host cells. *PLoS One*
 2286 **10**: e0117486.
 2287 Van den Abbeele P, Grootaert C, Possemiers S, Verstraete W, Verbeken K & Van de Wiele T (2009) *In vitro*
 2288 model to study the modulation of the mucin-adhered bacterial community. *Appl Microbiol Biot* **83**: 349-359.
 2289 Van den Abbeele P, Marzorati M, Derde M, De Weirtdt R, Joan V, Possemiers S & Van de Wiele T (2016)
 2290 Arabinoxylans, inulin and *Lactobacillus reuteri* 1063 repress the adherent-invasive *Escherichia coli* from mucus
 2291 in a mucosa-comprising gut model. *NPJ Biofilms Microbiomes* **2**: 16016.
 2292 Van den Abbeele P, Belzer C, Goossens M, Kleerebezem M, De Vos WM, Thas O, De Weirtdt R, Kerckhof FM
 2293 & Van de Wiele T (2013) Butyrate-producing *Clostridium* cluster XIVa species specifically colonize mucins in
 2294 an in vitro gut model. *ISME J* **7**: 949-961.
 2295 Van den Abbeele P, Roos S, Eeckhaut V, *et al.* (2012) Incorporating a mucosal environment in a dynamic gut
 2296 model results in a more representative colonization by lactobacilli. *Microb Biotechnol* **5**: 106-115.
 2297 Van der Sluis M, De Koning BA, De Bruijn AC, *et al.* (2006) Muc2-deficient mice spontaneously develop
 2298 colitis, indicating that MUC2 is critical for colonic protection. *Gastroenterology* **131**: 117-129.
 2299 Van Herreweghen F, Van den Abbeele P, De Mulder T, *et al.* (2017) *In vitro* colonisation of the distal colon by
 2300 *Akkermansia muciniphila* is largely mucin and pH dependent. *Beneficial Microbes* **8**: 81-96.
 2301 van Klinken BJ, Oussoren E, Weenink JJ, Strous GJ, Buller HA, Dekker J & Einerhand AW (1996) The human
 2302 intestinal cell lines Caco-2 and LS174T as models to study cell-type specific mucin expression. *Glycoconj J* **13**:
 2303 757-768.
 2304 Van Tassell ML & Miller MJ (2011) *Lactobacillus* adhesion to mucus. *Nutrients* **3**: 613-636.
 2305 VanDussen KL, Marinshaw JM, Shaikh N, Miyoshi H, Moon C, Tarr PI, Ciorba MA & Stappenbeck TS (2015)
 2306 Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays.
 2307 *Gut* **64**: 911-920.

2308 Vargas Garcia CE, Petrova M, Claes IJ, *et al.* (2015) Piliation of *Lactobacillus rhamnosus* GG promotes
 2309 adhesion, phagocytosis, and cytokine modulation in macrophages. *Appl Environ Microbiol* **81**: 2050-2062.
 2310 Varum FJ, Veiga F, Sousa JS & Basit AW (2012) Mucus thickness in the gastrointestinal tract of laboratory
 2311 animals. *J Pharm Pharmacol* **64**: 218-227.
 2312 Vazquez-Gutierrez P, de Wouters T, Werder J, Chassard C & Lacroix C (2016) High Iron-Sequestering
 2313 Bifidobacteria Inhibit Enteropathogen Growth and Adhesion to Intestinal Epithelial Cells In vitro. *Front*
 2314 *Microbiol* **7**: 1480.
 2315 Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K & Augenlicht
 2316 L (2002) Colorectal cancer in mice genetically deficient in the mucin Muc2. *Science* **295**: 1726-1729.
 2317 Vermeiren J, Van den Abbeele P, Laukens D, Vigsnaes LK, De Vos M, Boon N & Van de Wiele T (2012)
 2318 Decreased colonization of fecal *Clostridium coccoides*/Eubacterium rectale species from ulcerative colitis
 2319 patients in an in vitro dynamic gut model with mucin environment. *Fems Microbiol Ecol* **79**: 685-696.
 2320 Vieira MA, Gomes TA, Ferreira AJ, Knöbl T, Servin AL & Liévin-Le Moal V (2010) Two atypical
 2321 enteropathogenic *Escherichia coli* strains induce the production of secreted and membrane-bound mucins to
 2322 benefit their own growth at the apical surface of human mucin-secreting intestinal HT29-MTX cells. *Infect*
 2323 *Immun* **78**: 927-938.
 2324 von Ossowski I, Satokari R, Reunanen J, Lebeer S, De Keersmaecker SC, Vanderleyden J, de Vos WM & Palva
 2325 A (2011) Functional characterization of a mucus-specific LPXTG surface adhesin from probiotic *Lactobacillus*
 2326 *rhamnosus* GG. *Appl Environ Microbiol* **77**: 4465-4472.
 2327 von Ossowski I, Pietila TE, Rintahaka J, Nummenmaa E, Makinen VM, Reunanen J, Satokari R, de Vos WM,
 2328 Palva I & Palva A (2013) Using recombinant Lactococci as an approach to dissect the immunomodulating
 2329 capacity of surface piliation in probiotic *Lactobacillus rhamnosus* GG. *PLoS One* **8**: e64416.
 2330 Walsham AD, MacKenzie DA, Cook V, Wemyss-Holden S, Hews CL, Juge N & Schüller S (2016)
 2331 *Lactobacillus reuteri* inhibition of enteropathogenic *Escherichia coli* adherence to human intestinal epithelium.
 2332 *Front Microbiol* **7**: 244.
 2333 Wang H, Paton JC & Paton AW (2007) Pathologic changes in mice induced by subtilase cytotoxin, a potent new
 2334 *Escherichia coli* AB5 toxin that targets the endoplasmic reticulum. *The Journal of infectious diseases* **196**: 1093-
 2335 1101.
 2336 Wang L, Cao H, Liu L, Wang B, Walker WA, Acra SA & Yan F (2014) Activation of Epidermal Growth Factor
 2337 Receptor Mediates Mucin Production Stimulated by p40, a *Lactobacillus rhamnosus* GG-derived Protein.
 2338 *Journal of Biological Chemistry* **289**: 20234-20244.
 2339 Wang Y, Antonopoulos DA, Zhu X, Harrell L, Hanan I, Alverdy JC, Meyer F, Musch MW, Young VB & Chang
 2340 EB (2010) Laser capture microdissection and metagenomic analysis of intact mucosa-associated microbial
 2341 communities of human colon. *Appl Microbiol Biotechnol* **88**: 1333-1342.
 2342 Watanabe M, Kinoshita H, Nitta M, *et al.* (2010) Identification of a new adhesin-like protein from *Lactobacillus*
 2343 *mucosae* ME-340 with specific affinity to the human blood group A and B antigens. *Journal of applied*
 2344 *microbiology* **109**: 927-935.
 2345 Willemsen LE, Koetsier MA, van Deventer SJ & van Tol EA (2003) Short chain fatty acids stimulate epithelial
 2346 mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal
 2347 myofibroblasts. *Gut* **52**: 1442-1447.
 2348 Wlodarska M, Willing B, Keeney KM, Menendez A, Bergstrom KS, Gill N, Russell SL, Vallance BA & Finlay
 2349 BB (2011) Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated
 2350 *Citrobacter rodentium*-induced colitis. *Infect Immun* **79**: 1536-1545.
 2351 Wong E, Vaaje-Kolstad G, Ghosh A, Hurtado-Guerrero R, Konarev PV, Ibrahim AF, Svergun DI, Eijssink VG,
 2352 Chatterjee NS & van Aalten DM (2012) The *Vibrio cholerae* colonization factor GbpA possesses a modular
 2353 structure that governs binding to different host surfaces. *PLoS Pathog* **8**: e1002373.
 2354 Wrzosek L, Miquel S, Noordine ML, *et al.* (2013) Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii
 2355 influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a
 2356 gnotobiotic model rodent. *BMC Biol* **11**: 61.
 2357 Wu M, Wu Y, Li J, Bao Y, Guo Y & Yang W (2018) The Dynamic Changes of Gut Microbiota in Muc2
 2358 Deficient Mice. *Int J Mol Sci* **19**.
 2359 Ye J, Pan Q, Shang Y, Wei X, Peng Z, Chen W, Chen L & Wang R (2015) Core 2 mucin-type O-glycan inhibits
 2360 EPEC or EHEC O157:H7 invasion into HT-29 epithelial cells. *Gut Pathog* **7**: 31.
 2361 Ye J, Song L, Liu Y, *et al.* (2015) Core 2 Mucin-Type O-Glycan Is Related to EPEC and EHEC O157:H7
 2362 Adherence to Human Colon Carcinoma HT-29 Epithelial Cells. *Dig Dis Sci* **60**: 1977-1990.
 2363 Yissachar N, Zhou Y, Ung L, *et al.* (2017) An Intestinal Organ Culture System Uncovers a Role for the Nervous
 2364 System in Microbe-Immune Crosstalk. *Cell* **168**: 1135-1148 e1112.
 2365 Yu AC, Worrall LJ & Strynadka NC (2012) Structural insight into the bacterial mucinase StcE essential to
 2366 adhesion and immune evasion during enterohemorrhagic *E. coli* infection. *Structure* **20**: 707-717.




2367 Zarepour M, Bhullar K, Montero M, Ma C, Huang T, Velcich A, Xia L & Vallance BA (2013) The mucin Muc2
 2368 limits pathogen burdens and epithelial barrier dysfunction during *Salmonella enterica* serovar Typhimurium
 2369 colitis. *Infect Immun* **81**: 3672-3683.
 2370 Zihler A, Gagnon M, Chassard C & Lacroix C (2011) Protective effect of probiotics on *Salmonella* infectivity
 2371 assessed with combined in vitro gut fermentation-cellular models. *BMC microbiology* **11**: 264.
 2372 Zivkovic M, Hidalgo-Cantabrana C, Kojic M, Gueimonde M, Golic N & Ruas-Madiedo P (2015) Capability of
 2373 exopolysaccharide-producing *Lactobacillus paraplantarum* BGCG11 and its non-producing isogenic strain NB1,
 2374 to counteract the effect of enteropathogens upon the epithelial cell line HT29-MTX. *Food research international*
 2375 (*Ottawa, Ont*) **74**: 199-207.
 2376 Zou J, Chassaing B, Singh V, Pellizzon M, Ricci M, Fythe MD, Kumar MV & Gewirtz AT (2018) Fiber-
 2377 Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated
 2378 Colonic Health. *Cell Host Microbe* **23**: 41-53 e44.

2379

Types of models	Description	Applications	Advantages	Limitations	References
<i>In vitro</i> mucus/mucin binding assays					
<i>Microplates - Flow chambers</i>					
	<ul style="list-style-type: none"> * Immobilization of mucus/mucin on the microtiter plate * Microtiter plate : adhesion in static conditions * Flow chambers : adhesion under dynamic conditions (fluid shear) 	<ul style="list-style-type: none"> * Evaluation of bacterial adhesion (commensals and pathogens) to mucins and molecular mechanisms associated 	<ul style="list-style-type: none"> * Fast, quantitative and high throughput method to study mucus-microbe interactions independently from other <i>in vivo</i> conditions * Identification of molecular determinants involved in adhesion of microbes * Coupling with biophysical techniques (Surface Plasmon Resonance, Atomic Force Microscopy) 	<ul style="list-style-type: none"> * Influence of experimental conditions (antibiotics, mechanical treatments, growth conditions, hydrophobic interactions) * Limited availability of purified mucins (mainly use of pig gastric mucin) * Absence of gut microbiota 	McNamara <i>et al.</i> , 2000, Gusils <i>et al.</i> , 2004 ; Ringot-Clyne <i>et al.</i> , 2017 Dunne <i>et al.</i> 2018
<i>In vitro</i> cell models					
<i>Monoculture models</i>					
	<ul style="list-style-type: none"> * Gut-derived epithelial cells resembling intestinal tissue consisting mainly of mature goblet cells that secrete an adherent 	<ul style="list-style-type: none"> * Adherence of commensal and pathogenic bacteria to host cells * Effect of commensals/pathogens on host cell mucin synthesis and/or composition of the mucus layer 	<ul style="list-style-type: none"> * Reproducible and easily handled in laboratories * Identification of molecular determinants involved in adhesion of microbes and host cell mucin synthesis * Good platform for screening and characterizing probiotic activity 	<ul style="list-style-type: none"> * Derived from cancer cells, different from healthy tissue * Not representative of various cell types recovered in mucosal epithelial tissues * Not representative of appropriate <i>MUC</i> gene expression * Modulation of mucus production by culture conditions * Absence of gut microbiota * Difficulty to maintain for long-term experiments (>1 month) * Requirement of high oxygen levels (difficulty to study oxygen-sensitive microbes) 	Linden <i>et al.</i> , 2007, Navabi <i>et al.</i> , 2013, Hews <i>et al.</i> , 2017
<i>Co-culture models</i>					
	<ul style="list-style-type: none"> * Mixed culture of enterocytes and mucin secreting cells 	<ul style="list-style-type: none"> * Adherence of commensal and pathogenic bacteria to host cells * Effect of commensals/pathogens on host cell mucin synthesis and / or composition of the 	<ul style="list-style-type: none"> * Better representation of cell-type ratio recovered in mucosal epithelial tissues * Simple model, well described in literature 	<ul style="list-style-type: none"> * Absence of M-cells (development of triple co-culture Caco-2/HT29-MTX/Raji B) * Variations in seeding ratios of HT29 MTX/Caco-2 can impede results interpretation * Modulation of mucus production by culture conditions * Absence of gut microbiota * Difficulty to maintain for 	Hilgendorf <i>et al.</i> , 2000, Lozoya-Agullo <i>et al.</i> , 2017


mucus layer

long-term experiments (>1
month)
* Requirement of high oxygen
levels (difficulty to study
oxygen-sensitive microbes)

Ex-vivo organ cultures					
Intestinal organoids					
	<ul style="list-style-type: none"> * Generation of self-propagating spheres of primary intestinal epithelial cells * Enteroids = derived from adult stem cells isolated from the crypts of human small intestinal * Colonoids = derived from adult stem cells isolated from the crypts of human colonic tissue 	<ul style="list-style-type: none"> * Study of advanced aspects of mucus development in a more complex scenario * Study of host–commensals and pathogens interactions 	<ul style="list-style-type: none"> * Often collected from mice tissues, possible use of patient-derived tissues * Assay that more accurately mimics <i>in vivo</i> conditions * Amenable to long-term culture 	<ul style="list-style-type: none"> * Highly expensive and requires specialized expertise * Requires access to biopsies/tissues * Donor-to-donor variability * Requirement of injection to infect organoids with bacteria * Absence of gut microbiota * No reproduction of peristalsis motions and GI stressful events * Requirement of high oxygen levels (difficulty to study oxygen-sensitive microbes) 	Jung <i>et al.</i> , 2011, Sato <i>et al.</i> , 2011
In vitro organ culture (IVOC)					
	<ul style="list-style-type: none"> * Whole organs maintained <i>in vitro</i> 	<ul style="list-style-type: none"> * Study of host–commensals and pathogens interactions 	<ul style="list-style-type: none"> * Better maintenance of tissue architecture * Presence of non-transformed cells including all major cell types (enterocytes, goblet cells, Paneth cells and endocrine cells) * Often collected from animal tissues, possible use of patient-derived tissues * Possible use of biopsies from disease patients (e.g. IBD) 	<ul style="list-style-type: none"> * Requires access to biopsies/tissues * Expensive and requires expertise * Donor-to-donor variability * Difficulty to maintain for long-term experiments * No reproduction of peristalsis motions and GI stressful events * Requirement of high oxygen levels (difficulty to study oxygen-sensitive microbes) 	Browning & Trier, 1969, Schüller <i>et al.</i> , 2007
Gut- on-a chip					
	<ul style="list-style-type: none"> * Reproduction of the multicellular structures, cell–cell and tissue–tissue interactions, and the native microenvironment * Closely reproduction of the <i>in vivo</i> situation 	<ul style="list-style-type: none"> * Study of the complex physiological and pathophysiological responses of tissues at an organ level * Study of host–commensals and pathogens interactions 	<ul style="list-style-type: none"> * Presence of non-transformed cells including all major cell types (enterocytes, goblet cells, Paneth cells and endocrine cells) * Reproduction of peristalsis like motions * Possible use of biopsies from disease patients (e.g. IBD) 	<ul style="list-style-type: none"> * Expensive and requires dedicated expertise and instrumentation * Stem cell differentiation is difficult to achieve * Flow rate of the medium can influence cell metabolism * Absence of gut microbiota * No input from immune and nervous system * Requirement of high oxygen levels (difficulty to study oxygen-sensitive microbes) * No reproduction of the full 	Kasendra <i>et al.</i> , 2018

***In vitro* human colonic models involving a mucosal phase**

M-SHIME



- * Series of bioreactor modeling the different parts of the human gut
- * Introduction of mucus-coated carriers (Mucus SHIME)

- * Study the fine-scale spatial organization of the gut microbial ecosystem
- * Investigation of the interactions between commensals, pathogens, probiotics and luminal/mucosal gut microbiota

- * Integration of human GI - related parameters and possibility to modulate them depending on diet, age and diseases (e.g. ulcerative colitis)
- * Capture dynamics by time-resolved analyses
- * Capture inter-individual variability of human gut microbiota
- * Possible long term experiments
- * Possible coupling with cell culture models and Host-Microbe Interactions (HMI) module

- * Expensive and requires expertise and specialized instrumentation
- * Use of pig gastric mucin
- * No reproduction of immune and nervous system
- * No reproduction of the full complexity of the human gut microbiota
- * Donor-to-donor variability

Van den Abbeele *et al.*, 2012
Van den Abbeele *et al.*, 2013
De Paepe *et al.*, 2018

***In vivo* animal models**

- * Whole organism models
- * Development of genetically modified mice with impaired mucin production (comparison with wild type animals)

- * Study of the functional roles of mucin and mucus under physiological or pathological conditions at the level of entire organism
- * Investigation of downstream consequences of mucin modulation in mucosal barrier defense
- * Investigation of the interactions between commensals, pathogens, probiotics and luminal/mucosal gut microbiota

- * Physiological model
- * Allow targeting of a specific gene/pathway in the complex gut-microbiota – host interactions
- * Amenable to diet or microbiome-based interventions
- * Possible long-term experiments



- * Requires housing facility and adequate agreements
- * Expensive to maintain colonies
- * Housing husbandries and diets can modulate mouse microbiota
- * Murine gut microbiota different from the human gut microbiota
- * Mucin glycosylation profile of mice different from human intestinal mucins
- * No reproduction of the full complexity of the human gut microbiota
- * Limited translational capacity to human situation
- * Mice generally inbred so no reproduction of the genetic variations found in the human population

Van der Sluis *et al.*, 2006
Velcich *et al.*, 2002



Table 1. Experimental models available to study mucus-bacteria interactions.

GI : Gastro-Intestinal, HMI : Host-Microbe Interactions, IBD : Inflammatory Bowel Diseases, IVOC : *In vitro* organ culture, M-SHIME : Mucus Simulator of the Human Intestinal Microbial Ecosystem.






FIGURE LEGENDS

Fig. 1. Mucin-bacterial interactions in the digestive tract

Left panel: Mucins display various and diverse oligosaccharide structures representing potential binding sites for microbial adhesion. Commensal and pathogenic microbes can use cell-surface appendages, such as pili, flagella or fimbriae or adhesins to bind to mucus.

Right panel: Mucin glycans are an important energy source for microbes inhabiting the mucus niche that further confer them with an ecological advantage over other members of the gut microbiota. Commensal and pathogenic microorganisms can degrade mucin glycan chains leading to the release of mono- or oligosaccharides from that can be subsequently metabolized by other gut microbes in the mucosal environment.

Fig.2. Perturbations of the mucus barrier in response to environmental and microbial stimuli.

This figure represents an overview of the various factors (diets, nanomaterials, pollutants, antibiotics or invading pathogens) affecting the gut microbiota composition and/or the thickness, structure and composition of the mucus barrier. Disruption of the mucus layer promotes bacterial encroachment leading to the subsequent development of low-grade inflammation, associated with inflammatory bowel diseases and metabolic disorders.